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64Cu-Diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM) is a hypoxia-
selective positron emission tomography (PET) tracer and has potential imaging 
applications in cardiology. To fully exploit and develop 64Cu-ATSM, it is 
essential to understand its mode of action. It has been suggested that 
intracellular reductants, such as thiols, reduce the uncharged Cu(II)-ATSM 
complex to Cu(I)-ATSM- which dissociates to deposit its radiocopper in hypoxic 
tissue.  It is also possible that this process may be accelerated by intracellular 
acidosis, which is a hallmark of ischaemic tissue.  The sensitivity of Cu-ATSM to 
intracellular thiol status or pH would impact upon its hypoxia specificity and 
potentially restrict its diagnostic utility.  
An isolated perfused rat heart model and cultured bovine aortic endothelial cells 
(BAEC) were therefore utilised to investigate the importance of intracellular thiol 
status and intracellular acidosis on the hypoxia selectivity and pharmacokinetics 
of 64Cu-ATSM.   
During these studies the hypoxia selective retention of 64Cu from 64Cu-ATSM 
was confirmed in isolated perfused rat hearts. It was also demonstrated that 
intracellular thiol concentration has no effect on 64Cu retention from 64Cu-ATSM 
in normoxic or hypoxic hearts. Conversely, hypoxic BAEC incubated with high 
concentrations of thiols displayed significantly higher 64Cu retention from 64Cu-
ATSM, while thiol depletion had no effect.  It was therefore concluded that while 
thiols may be necessary for the initial reduction of Cu-ATSM, physiological 
changes in thiol concentration do not affect Cu-ATSM pharmacokinetics, or 
underlie its hypoxia selectivity. 
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It was also demonstrated that the hypoxic myocardium is not acidotic, and that 
acidosis cannot be a prime determinant of Cu-ATSM retention during hypoxia. 
Subsequent experiments suggest that acidosis may suppress 64Cu retention 
from 64Cu-ATSM during normoxia and hypoxia; but that this may be secondary 
to the oxygen-sparing effect that acidosis has on the hypoxic heart, by impairing 
cardiac contractility. These findings provide further insight into the mechanisms 



























I Fiona Shaughnessy confirm that no part of this thesis has been submitted in 
support of any other application for a degree or qualification of King’s College, 
or any other university or institute of learning. I confirm that this work is my own. 
Where information has been derived from other sources it has been indicated in 


























I begin by thanking my supervisor, Dr Rick Southworth, for all his support and 
guidance throughout my Ph.D. In particular I thank him for his help and 
comments during writing this thesis: by leaving no stone unturned I got there in 
the end!  I also appreciate that he trusted me to work with very expensive, 
delicate pieces of equipment and remained calm and in good spirits when they 
(accidently) got broken.    
From the cardiovascular group I would like to thank my 2nd supervisor, Dr 
Richard Siow, for supervising the in vitro project in this thesis and  for allowing 
me to work in his lab and freeing up important equipment when necessary. I 
would also like to thank Prof. Giovanni Mann for his help and support in this. I 
thank Dr Tabasum Mughal, Dr Sarah Chapple, Bijal Patel and Salil Srivastava 
for being so accommodating and making my life as easy as possible when I had 
experiments on.  In particular I owe a special thanks to Shane McSweeny for 
providing me with cells for that project and working weekends to do so.  I owe a 
special mention to undergraduate, Martin Davies, for his hard work in helping 
me with the extensive in vitro studies at the beginning of that project.  
I would like to thank Prof. Philip Blower for his support, advice and for sharing 
his extensive knowledge of the Cu-BTSC complexes whenever I asked for it.  
I owe a big thank-you to Dr Thomas Eykyn for teaching me the ropes of NMR 
spectroscopy and enthusing over the results, and again, for remaining as calm 
as possible when certain pieces of equipment broke. 
I would like to thank my partner in crime Dr Maxwell Handley, and also Dr 
Jennifer Williams and Julia Blower for keeping my morale up throughout 
particularly testing periods of my Ph.D.  Also a big thank-you to Dr Erika 
6 
 
Mariotti, not only for her friendship but also for sharing her kinetic modelling 
wisdom with me. Thanks also to the lovely Zaitul Saffee for kindly helping me 
out in the lab in times of need. 
I would also like to thank David Thakor and Barry Crook for helping me acquire 
equipment, often at short notice, without which these experiments would not 
have been possible.  
I owe a big thank-you to Dr Karen Shaw for helping me with pretty much 
everything: providing 64Cu-ATSM, letting me down gently when 64Cu production 
failed, helping me with NMR spectroscopy and talking to me in the lab when 
everybody else had gone home.   
Finally, I would like to thank my family and friends: my father Gordon 
Shaughnessy for putting up with me being a student for so many years, my 
lovely sister Aleanna Shaughnessy for taking my fair share of family 
responsibilities and my dearest friends Charlene Constantine and Lucy Esmond 
for understanding my lack of sociability, particularly over the last few years. I 
owe an extra-special thanks to my superhero nephew, Christopher, for his love 
and for trying to “help” me work by watching Adventure Time on my laptop and 
drawing dinosaurs in my note books: if anything it helped me smile when I 
needed it the most. 
Most importantly I would like to thank my wonderful boyfriend, Jason Smith, and 
my mother, Philomena Shaughnessy for their fantastic support emotionally and 
financially over the years. In particular I thank my mother for pushing me in the 
right direction and making sure I had everything I needed to be where I am 
today. I also thank her in advance for not crying when she reads this. It is to her 
I would like to dedicate this thesis. 
7 
 




Table of contents.............................................................................7 
List of figures.................................................................................16 
List of tables...................................................................................21 
List of equations............................................................................22 
List of abbreviations......................................................................23 
Chapter 1. Introduction.................................................................28 
1.1 Ischaemic heart disease..............................................................................29 
1.2 The pathogenesis of myocardial ischaemia.................................................30 
1.2.1 Atherosclerosis.....................................................................................30 
1.2.2 Coronary artery disease.......................................................................31 
1.2.3 Coronary microvascular disease..........................................................32 
1.2.4 Myocardial hibernation..........................................................................32 
1.2.5 Myocardial hypertrophy........................................................................33 
1.3 Myocardial aerobic metabolism...................................................................34 
1.3.1 Fatty acid β-oxidation...........................................................................34 
1.3.2 Glycolysis..............................................................................................37 
1.3.3 The tricarboxylic acid cycle...................................................................39 
1.3.4 Mitochondrial respiration (oxidative phosphorylation)...........................40 
1.3.5 Myocardial anaerobic metabolism........................................................41 
1.3.6 Energy metabolism in the vascular endothelium..................................45 
1.4 Changes to cardiovascular redox status......................................................45 
1.4.1 Reactive oxygen species......................................................................46 
8 
 
1.4.2 Myocardial ROS generation..................................................................48 
1.4.3 Endothelial nitric oxide generation........................................................50 
1.4.4 Lipid, protein and damage....................................................................50 
1.4.5 The effects of ROS upon Ca2+ and Na+ homeostasis...........................52 
1.4.6 The effect of ROS upon endothelial dysfunction..................................52 
1.4.7 Antioxidants..........................................................................................53 
1.5 Current techniques for the detection of cardiac redox status.......................54 
1.5.1 Electron paramagnetic spin resonance spectroscopy..........................55 
1.5.2 Fluorescent ROS probes......................................................................56 
1.5.3 Luminescence.......................................................................................56 
1.5.4 Ascorbyl radicals...................................................................................57 
1.6 Current techniques for the detection of myocardial hypoxia........................58 
1.6.1 Invasive probes.....................................................................................58 
1.6.2 Non-invasive imaging...........................................................................59 
1.6.2.1 Magnetic resonance imaging......................................................59 
1.6.2.2 Cardiac nuclear medicine............................................................60 
1.7 Nitroimidazoles for imaging tissue hypoxia..................................................62 
1.8 Copper bis (thiosemicarbazone) (Cu-BTSC) complexes.............................64 
1.8.1 The proposed trapping mechanism of Cu-BTSC complexes................66 
1.8.2 Cu-BTSC redox potential and hypoxia selectivity.................................67 
1.8.3 Tuning Cu-BTSC redox potential..........................................................68 
1.8.4 Potential Cu-BTSC reductants: NADH dependent enzymes................71 
1.8.5 Potential Cu-BTSC reductants: thiols...................................................72 
1.8.6 The effect of ROS on Cu-BTSC dissociation........................................73 
1.8.7 The effect of intracellular pH on Cu-BTSC dissociation........................74 





Chapter 2. Materials and methods...............................................77 
2.1 Introduction..................................................................................................78 
2.2 The isolated perfused heart model..............................................................78 
2.2.1 Coronary perfusion in vivo.............................................................78 
2.2.2 Langendorff isolated heart perfusion..............................................79 
2.2.3 Why use the Langendorff isolated heart perfusion technique?....79 
2.2.4 Basic perfusion apparatus..............................................................81 
2.2.5 Krebs-Henseleit buffer...................................................................81 
2.2.6 Gas mixtures..................................................................................82 
2.2.7 Temperature, flow rate and pressure measurements....................83 
2.2.8 Preparation of heart for perfusion..................................................84 
2.2.9 Exclusion criteria studies................................................................85 
 2.2.10 Perfusate analysis for lactate, glucose and protein content.......86 
  2.2.10.1 Lactate and glucose analysis.........................................86 
  2.2.10.2 Protein and creatine kinase (CK) analysis....................86 
   2.2.10.2.1 The CK assay...................................................87 
   2.2.10.2.2 The BCA assay.................................................88 
2.2.10.2.3 Comparison of CK and BCA assays for  
cardiac viability..................................................................89 
2.3 Isolated bovine aortic endothelial cells........................................................90 
 2.3.1 Culture of BAEC.............................................................................91 
 2.3.2 MTT viability assay.........................................................................92 
2.4 Thiol measurement assays..........................................................................93 
 2.4.1 Thiol concentration modification.....................................................93 
 2.4.2 The DTNB assay............................................................................94 
 2.4.3 The OPA assay..............................................................................95 
 2.4.4 Comparison of the DTNB assay and OPA assays.........................94 
2.5 31P NMR spectroscopy................................................................................98 
10 
 
2.6 64Protocols for investigating Cu-ATSM hypoxia selectivity........................100 
 2.6.1 64Cu production............................................................................100 
2.6.2 Radiolabeling ATSM with 64Cu.....................................................101 
2.6.3 Measurement of 64Cu from 64Cu-ATSM in isolated  
perfused rat hearts................................................................................101 
2.6.4 Time activity curve retention and clearance rate analysis...........102 
2.6.5 64Cu retention in BAEC incubated with 64Cu-ATSM.....................104 
 2.6.5.1 Gamma counter calibration............................................104 
 2.6.5.2 Incubation time optimisation of 64Cu-ATSM...................105 
 
Chapter 3. Is the hypoxia selectivity of 64Cu-ATSM dependent 
upon cardiac thiol status?..........................................................106 
3.1 Introduction................................................................................................107 
 3.1.1 GSH changes during myocardial hypoxia and ischaemia............107 
 3.1.2 Experimental approach................................................................109 
3.2 Materials and methods..............................................................................110 
3.2.1 Chemicals and reagents..............................................................110 
3.2.2 Animals........................................................................................110 
3.2.3 Thiol concentration modification protocols...................................110 
3.2.4 Perfusion protocols......................................................................111 
3.2.5 Thiol concentration analysis.........................................................111 
3.2.6 64Cu-ATSM pharmacokinetic analysis.........................................112 
3.2.7 Statistical analysis........................................................................112 
3.3 Results.......................................................................................................113 
 3.3.1 Cardiac thiol concentration..........................................................113 
 3.3.2 Effect of cardiac thiol concentration on contractile function.........114 
  3.3.2.1 Heart rate.......................................................................114 
  3.2.2.2 Coronary perfusion pressure..........................................116 
11 
 
  3.2.2.3 Left ventricular developed pressure (LVDP)..................118 
  3.2.2.4 Left ventricular end diastolic pressure (LVEDP).............120 
3.3.3 Cardiac lactate release, glucose consumption and  
protein release......................................................................................122 
  3.3.3.1 Lactate release...............................................................122 
  3.3.3.2 Glucose consumption.....................................................124 
  3.3.3.3 Cardiac protein release..................................................126 
3.3.4 Myocardial 64Cu retention from Cu-ATSM in  
thiol-modified hearts..............................................................................128 
 3.3.5 Pharmacokinetic analysis of time-activity  
curve data.............................................................................................131 
3.4 Discussion and conclusions.......................................................................137 
 3.4.1 Effect of thiol concentration on 64Cu-ATSM  
hypoxia selectivity……………………………………………………..…..137 
  3.4.1.1 Cardiac 64Cu retention from 64Cu-ATSM........................137 
  3.4.1.2 Cardiac 64Cu-ATSM pharmacokinetics..........................138 
3.4.2 Thiol concentration modification.............................................................139 
3.4.3 Cardiac function......................................................................................141 
 3.4.3.1 Contractile function...................................................................141 
 3.4.3.2 Lactate production, glucose consumption and viability............143 
 
Chapter 4. Effect of thiol concentration on the hypoxia 




 4.1.1 Hypoxia induced ROS generation in the endothelium.................146 
 4.1.2 Changes in endothelial GSH........................................................146 
12 
 
 4.1.3 Experimental approach................................................................147 
4.2 Materials and methods...............................................................................149 
 4.2.1 Chemicals and reagents..............................................................149 
 4.2.2 Cell culture...................................................................................149 
 4.2.3 Thiol concentration modification...................................................149 
  4.2.3.1 MTT viability assay.........................................................149 
4.2.3.2 Effect of DEM, BSO and NAC on BAEC thiol  
concentration: time and dose optimisation studies.....................150 
  4.2.3.3 Thiol and protein extraction and analysis.......................150 
4.2.4 Determination of hypoxia protocol................................................150 
 4.2.5 64Cu-ATSM hypoxia selectivity in BAEC......................................151 
 4.2.6 Statistical analysis........................................................................151 
4.3 Results.......................................................................................................152 
 4.3.1 Preliminary dose response findings.............................................152 
  4.3.1.1 Effect of modifying thiol concentration on  
BAEC viability.............................................................................152 
4.3.1.2 Effect of DEM, BSO and NAC on BAEC  
thiol concentration......................................................................153 
  4.3.1.3 Effect of low oxygen and thiol concentration on  
BAEC viability.............................................................................161 
4.3.2 Effect of BAEC thiol concentration on 64Cu retention from  
64Cu-ATSM............................................................................................165 
 4.3.2.1 BAEC thiol concentration...............................................165 
 4.3.2.2 BAEC 64Cu retention from 64Cu-ATSM……...................168 
4.4 Discussion and 
conclusions...............................................................................173 
4.4.1 Effect of thiol concentration and low oxygen on BAEC 64Cu  
retention from 64Cu-ATSM....................................................................173 
13 
 
 4.4.2 Modification of BAEC thiol concentration.....................................174 




Chapter 5. Effect of acidosis on 64Cu-ATSM hypoxia selectivity 
.......................................................................................................179 
5.1 Introduction................................................................................................180 
5.2 Materials and methods..............................................................................182 
 5.2.1 Chemicals and reagents..............................................................182 
 5.2.2 Animals........................................................................................182 
 5.2.3 Perfusion protocols......................................................................182 
 5.2.4 Measurement of cardiac acidosis via 31P  
NMR spectroscopy……........................................................................183 
 5.2.5 64Cu-ATSM pharmacokinetic analysis..........................................184 
 5.2.6 Statistical analysis........................................................................184 
5.3 
Results.............................................................................................................185 
 5.3.1 Effect of hypoxia and NH4Cl prepulse protocols on  
cardiac pHi............................................................................................185 
  5.3.1.1 Myocardial pHi during hypoxia.......................................185 
  5.3.1.2 Effect of NH4Cl prepulse and NHE inhibition on  
myocardial pHi............................................................................185 
5.3.1.3 Myocardial metabolite concentration..............................190 
 5.3.1.3.1 Phosphorous metabolite concentration  
during normoxia and hypoxia..........................................190 
 5.3.1.3.2 Metabolite concentration during acidosis........190 
5.3.1.4 Cardiac function.............................................................196 
14 
 
 5.3.1.4.1 Heart rate.........................................................196 
 5.3.1.4.2 Coronary perfusion pressure............................198 
 5.3. 1.4.3 Left ventricular developed pressure ...............200 
 5.3. 1.4.4 Left ventricular end diastolic pressure.............202 
 5.3. 1.4.5 Lactate release................................................204 
 5.3. 1.4.6 Glucose consumption......................................205 
 5.3.1.4.7 Protein release.................................................206 
 5.3.2 Effect of hypoxia with 20% O2 saturated buffers and NH4Cl  
prepulse protocols on cardiac pHi.........................................................207 
  5.3.2.1 Myocardial pHi during hypoxia with 20% O2...................207 
  5.3.2.2 Effect of hypoxia with 20% O2, NH4Cl prepulse and  
NHE inhibition on myocardial pHi...............................................207 
5.3.2.3 Myocardial metabolite concentration..............................210 
5.3.2.3.1 Phosphorous metabolite concentration  
during normoxia and hypoxia with 20% O2….……………..…...210 
5.3.2.3.2 Metabolite concentration during acidosis.........210 
5.3.2.4 Cardiac Function.................................................213 
5.3.2.4.1 Heart Rate........................................................213 
5.3.2.4.2 Coronary Perfusion Pressure...........................214 
5.3.2.4.3 Left ventricular developed pressure (LVDP).....215 
5.3.2.4.4 Left ventricular end diastolic  
Pressure (LVEDP)….……………………………………...216 
5.3.2.4.5 Lactate release.................................................217 
5.3.2.4.6 Glucose Consumption......................................218 
5.3.2.4.7 Protein release.................................................219 
5.3.3 Effect of acidosis on 64Cu-ATSM hypoxia selectivity  
and pharmacokinetics……………………………………………………...220 
5.3.3.1 64Cu retention from 64Cu-ATSM in acidic hearts............220 
15 
 
5.3.3.2 Pharmacokinetic analysis of time-activity curve data.....224 
5.3.4 Effect of perfusion with zoniporide in the absence of NH4Cl
 .......229 
5.3.4.1 Cardiac contractile function…........................................230 
5.3.4.2 64Cu retention from 64Cu-ATSM during zoniporide  
infusion alone.............................................................................232 
5.3.4.3 Pharmacokinetic analysis of time-activity curve data….233 
5.4 Discussion and conclusions.......................................................................240 
 5.4.1 Effect of hypoxia on myocardial pHi and 
64Cu retention  
from 64Cu-ATSM....................................................................................240 
 5.4.2 Effect of acidosis on 64Cu retention from 64Cu-ATSM..................241 
 5.4.3 Effect of hypoxia and acidosis on contractile function..................242 
 5.4.4 Effect of hypoxia and acidosis on lactate release, glucose  
consumption and viability......................................................................243 
 5.4.5 Effect of hypoxia on myocardial metabolism................................244 
 
Chapter 6. Summary and further work......................................247 
6.1 Summary of main conclusions...................................................................248 











List of figures 
Chapter 1 
Figure 1.1. Fatty acid translocation and subsequent β-oxidation.......................36 
Figure 1.2. Glucose metabolism........................................................................38 
Figure 1.3. The tricarboxylic acid cycle..............................................................39 
Figure 1.4. The mitochondrial ETC....................................................................41 
Figure 1.5. Trapping mechanism of nitroimidazole compounds........................63 
Figure 1.6. Proposed uptake and trapping mechanism of copper from  
hypoxia selective Cu-BTSC...............................................................................67 
Figure 1.7. Structure of general Cu-BTSC, Cu-PTSM and Cu-ATSM...............70 
 
Chapter 2 
Figure 2.1. Schematic diagram of basic Langendorff  
Preparation apparatus…………….……………………………………………...…81 
Figure 2.2. pO2 of KHB gassed with 95% N2/5% CO2.......................................83 
Figure 2.3. Exclusion criteria established from isolated perfused rat hearts.....85 
Figure 2.4. Calibration of standard solutions of CK and protein plotted  
against absorbance…........................................................................................89 
Figure 2.5. Perfusate CK activity and protein content from ischaemia  
reperfused hearts and time-matched controls...................................................90 
Figure 2.6. BAEC in culture...............................................................................92 
Figure 2.7. Standard GSH calibration curves from DTNB OPA assays.............96 
Figure 2.8. Thiol content of TCA extracts from BSO treated BAEC...................98 
Figure 2.9. Example 31P-NMR spectra from healthy heart...............................100 
Figure 2.10. The triple γ-detector system for measurement of 64Cu retention  




 Figure 2.11. Example time activity curves of a heart administered three  
bolus injections of 64Cu-ATSM.........................................................................103 
Figure  2.12 Gamma counter linearity. Decay (CPS) was plotted against  
the radioactivity of 64CuCl2 aliquots..................................................................104 
Figure 2.13  64Cu retention in BAEC incubated with 64Cu-ATSM over time….105 
 
Chapter 3 
Figure 3.1. Perfusion protocols........................................................................111 
Figure 3.2. Effect of BSO pre-treatment and NAC perfusion on myocardial  
thiol content......................................................................................................113 
Figure 3.3. Heart rate.......................................................................................115 
Figure 3.4. Coronary perfusion pressure ........................................................117 
Figure. 3.5. LVDP............................................................................................119 
Figure. 3.6. LVEDP..........................................................................................121 
Figure 3.7. Lactate concentration of perfusate samples..................................123 
Figure 3.8. Glucose concentration of perfusate samples.................................125 
Figure 3.9. Protein concentration of perfusate samples…...............................127 
Figure 3.10. Representative time-activity curves.............................................128 
Figure 3.11. Effect of thiol depletion and augmentation on 64Cu retention in  
normoxic and  hypoxic hearts……...................................................................130 
Figure 3.12. FCR of each 64Cu-ATSM injection...............................................132 
Figure 3.13. SCR of each 64Cu-ATSM.............................................................133 
Figure 3.14. Amplitude of the FCR and SCR for all injections.........................134 
 
Chapter 4 
Figure 4.1. BAEC viability................................................................................152 




Figure 4.3. Thiol concentrations of BAEC treated with DEM...........................155 
Figure 4.4. Thiol concentrations in BAEC treated with BSO............................156 
Figure 4.5. Thiol concentrations of BAEC treated with NAC............................158 
Figure 4.6. Effect of BSO and NAC on BAEC thiol concentration...................161 
Figure 4.7. Effect of low oxygen on BAEC viability……...................................163 
Figure 4.8. BAEC protein concentration..........................................................164 
Figure 4.9. Thiol concentrations in BAEC incubated with BSO/NAC and  
64Cu-ATSM.......................................................................................................167 
Figure 4.10. 64Cu in medium and PBS wash (combined) from BAEC.............169 
Figure 4.11. 64Cu retention in BAEC incubated with BSO/NAC and  
64Cu-ATSM.......................................................................................................171 




Figure 5.1. Perfusion protocols........................................................................183 
Figure 5.2. Representative stacked plot of 31P NMR spectra,  
corresponding single spectra and average myocardial pHi of normoxic  
control hearts………………………………….…………………………………….186 
Figure 5.3. Representative stacked plot of 31P NMR spectra,  
corresponding single spectra and average myocardial pHi of hypoxic  
(0% O2) hearts.................................................................................................187 
Figure 5.4. Representative stacked plot of 31P NMR spectra,  
corresponding single spectra and average myocardial pHi of normoxic  
acidotic hearts..................................................................................................188 
Figure 5.5. Representative stacked plot of 31P NMR spectra,  
corresponding single spectra and average myocardial pHi of hypoxic  
(0% O2) acidotic hearts……….........................................................................189 
19 
 
Figure 5.6. PCr levels......................................................................................192 
Figure 5.7. Pi levels..........................................................................................193 
Figure 5.8. ATP levels......................................................................................194 
Figure 5.9. Sugar phosphate levels.................................................................195 
Figure 5.10. Heart rate.....................................................................................197 
Figure 5.11. Coronary perfusion pressure.......................................................199 
Figure 5.12. LVDP...........................................................................................201 
Figure 5.13. LVEDP.........................................................................................203 
Figure 5.14. Lactate concentration of perfusate samples................................204 
Figure 5.15. Glucose concentration of perfusate samples...............................205 
Figure 5.16. Protein concentration of perfusate samples................................206 
Figure 5.17 Representative stacked plot of 31P NMR spectra,  
corresponding single spectra and average myocardial pHi of hypoxic  
(20% O2) hearts...............................................................................................208 
Figure 5.18. Representative stacked plot of 31P NMR spectra,  
corresponding single spectra and average myocardial pHi of  
acidotic hearts..................................................................................................209 
Figure 5.19. PCr levels....................................................................................211 
Figure 5.20. Pi levels........................................................................................211 
Figure 5.21. ATP levels....................................................................................212 
Figure 5.22. Sugar phosphate levels...............................................................212 
Figure 5.23. Heart rate.....................................................................................213 
Figure 5.24. Coronary perfusion pressure.......................................................214 
Figure 5.25. LVDP...........................................................................................215 
Figure 5.26. LVEDP.........................................................................................216 
Figure 5.27. Lactate concentration of perfusate samples................................217 
Figure 5.28. Glucose concentration of perfusate samples...............................218 
Figure 5.29. Protein concentration of perfusate samples…….........................219 
20 
 
Figure 5.30. Representative time-activity curves.............................................221 
Figure 5.31. Effect of acidosis on 64Cu retention from 64Cu-ATSM in normoxic  
and hypoxic hearts...........................................................................................223 
Figure 5.32. FCR for each Cu –ATSM injection...............................................225 
Figure 5.33. SCR for each Cu –ATSM injection..............................................226 
Figure 5.34 Amplitudes of the FCR and SCR for all injections........................227 
Figure 5.35. Heart rates of hearts infused with zoniporide only.......................230 
Figure 5.36. Coronary perfusion pressures of hearts infused with zoniporide 
only..................................................................................................................231 
Figure 5.37. LVDP of hearts infused with zoniporide only...............................231 
Figure 5.38. LVEDP of hearts infused with zoniporide only.............................226 
Figure 5.39 Effect of zoniporide alone on 64Cu retention in normoxic and  
hypoxic hearts..................................................................................................234 
Figure 5.40 FCR for each Cu–ATSM injection.................................................235 
Figure 5.41.  FCR for each Cu–ATSM injection...............................................236 













List of tables  
 
Chapter 2 
Table 2.1 List of reagents required for the CK assay.........................................88 
 
Chapter 3 
Table 3.1. FCR and SCR values from figures 3.12-3.13.................................135 
Table 3.2. Amplitudes of FCR and SCR from figure 3.14................................136 
 
Chapter 4 
Table 4.1. Thiol concentrations of BAEC incubated with DEM........................156 
Table 4.2. Thiol concentrations of BAEC incubated with BSO........................157 
Table 4.3A. Thiol concentrations of BAEC incubated with NAC  
(as displayed in figure 4.5A)……………………………………………………….159 
Table 4.3B. Thiol concentrations of BAEC incubated with NAC  
(as displayed in  
figure 4.5B)…………………………………………………………….…...……….159 
Table 4.4. BAEC viability and protein levels....................................................164 
 
Chapter 5 
Table 5.1. FCR and SCR values from figures 5.33 and 5.34...........................228 
Table 5.2. Amplitudes of FCR and SCR from figure 5.34................................229 
Table 5.3. FCR and SCR values from figures 5.40-5.41.................................238 





List of equations 
 
Chapter 1 
Equation 1.1. Generation of ∙O2
-, ∙OH and H2O2................................................46 
Equation 1.2. Further generation of 
∙O2
- and ∙OH through the Haber-Weiss  
and Fenton reactions.........................................................................................47 
Equation 1.3. Generation of singlet oxygen.......................................................48 
Equation 1.4. Reaction of NO with ∙O2
- generates nitrogen radicals and ∙OH..50 
Equation 1.5. Lipid peroxidation cascade..........................................................51 
 
Chapter 2 
Equation 2.1. Measurement of pHi using δPi acquired from 
31P NMR spectra....99 


















List of Abbreviations 
 
3-KAT: 3-keotacyl CoA thiolase 
3-OH-ACAD: 3-OH acyl coenzyme A dehydrogenase  
ACAD: Acyl coenzyme A dehydrogenase 
ADP: Adenosine diphosphate 
ATP: Adenosine triphosphate 
ATSM: Diacetyl-bis(N4-methyl-3-thiosemicarbazone) 
BAEC: Bovine aortic endothelial cells 
BPM: Beats per minute 
Bq: Becquerel 
BSO: Buthionine sulphoximine 
BTSC: Bis (thiosemicarbazone) 
CAD: Coronary artery disease 
CAS: Coronary artery spasm 
CAT: Carnitine: acylcarnitine translocase 
CHO: Chinese hamster ovary 
CK: Creatine kinase 
MVD: Microvascular disease 
Co A: Coenzyme A 
CPT: Carnitine palmitoyltransferase 
CT: Computed tomography 
24 
 
DEM: Diethyl maleate 
DMEM: Dulbecco’s modified Eagle’s medium  
ECAH:  Enoyl coenzyme A hydratase 
EDTA: Ethylenediaminetetraacetic acid 
EMT6: Murine mammary tumour cell line 
eNOS: Endothelial NOS 
EPR: Electron paramagnetic resonance  
ETC: Electron transport chain 
FABPpm: Plasma membrane fatty acid binding protein 
FACS: Fatty acyl Co A synthase 
FADH2: Flavin adenine dinucleotide 
FAT: Fatty acid translocase 
FATP: Fatty acid transport protein 
GAPDH: Glyceraldehyde phosphate dehydrogenase 
GDP: Guanosine diphosphate 
GLUT: Glucose transporter 
GS: Glycogen synthase 
GSH: Reduced glutathione (γ-gluatamyl-cysteinyl-glycine) 
GSH-Px: Glutathione peroxidase 
GSNO: S-nitrosoglutathione 
GSSG: Oxidised glutathione 
GTP: Guanosine triphosphate 
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HIF: Hypoxia-inducible factor 
HK: Hexokinase 
H2O2: Hydrogen peroxide 
∙HO2
: Hydroperoxyl radical 
LAD: Left anterior descending artery 
LDL: Low density lipoprotein 
LPC: Lactate/proton co-transporter 
LVDP: Left ventricular developed pressure 
LVEDP: Left ventricular end diastolic pressure 
MCT: Monocarboxylase transporter 
MPT: Mitochondrial permeability transition 
MRI: Magnetic resonance imaging 
MTT: Dimethylthiazol diphenyltetrazolium 
NAC: N-acetylcysteine 
NADH: Nicotinamide adenine dinucleotide 
NADPH: Nicotinamide adenine dinucleotide phosphate 
NCX: Na+/Ca2+ exchanger 
NHE: Na+/H+ exchanger 
NH2Cl: Chloramine 
NMR: Nuclear magnetic resonance 
NO: Nitric oxide 
∙NO2: Nitrite radical 
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NOS: Nitric oxide synthase 
∙O2
-: Superoxide anion 
∙OH: Hydroxyl anion 
ONOO-: Peroxynitrite anion 
PAEC: Pulmonary artery endothelial cells 
PBS: Phosphate buffered saline 
PCr: Phosphocreatine 
PDH: Pyruvate dehydrogenase kinase 
PET: Positron emission tomography 
PFK: Phosphofructokinase 
PGI: Phosphoglucose isomerase  
PGK: Phosphoglycerate kinase 
PGM: Phosphoglycerate mutase 
Ph: Glycogen phosphorylase 
pHi: Intracellular pH 
Pi: Inorganic phosphate  
PK: Pyruvate kinase 
pO2: Oxygen partial pressure 
ppm: Parts per million 
PTSM: Pyruvaldehyde-bis-(N4-methyl-3-thiosemicarbazone) 




SPECT: Single photon emission computed tomography 
SOD: Superoxide dismutase 
TCA (in chapter 1): Tricarboxylic acid  
TCA (in chapters 2-4): Trichloroacetate 
TNF-α: Tumour necrosis factor α 
TPI: Triosephosphate isomerase 
TTFA: Thenoyltrifluoroacetone 


































1.1 Ischaemic heart disease 
Ischaemic heart disease is currently the leading cause of global mortality with 
an increase in incidence expected over the next 20 years1,2. Ischaemia is 
characterised as a condition in which there is inadequate blood supply to satisfy 
the metabolic demands of a tissue3, resulting in limited delivery of nutrients, 
energy substrates, oxygen and the accumulation of waste products within 
affected tissues.  Without surgical or pharmacological intervention, the heart is 
increasingly prone to myocardial infarction in the acute setting, while in the less 
severe chronic setting, it progresses along a path of hypertrophy, adverse 
remodelling, and ultimately, heart failure4.  
Many current imaging techniques aimed at diagnosing and characterising 
ischaemically compromised myocardium rely on changes in physical properties 
such as contractility and perfusion5. Although these techniques can be used to 
assess the degree of ischaemia and provide an index of the appropriateness of 
intervention, they detect abnormalities in physical parameters which occur 
further down the ischaemic cascade and may be associated with cell injury and 
remodelling. There is therefore a need for more sensitive techniques to detect 
earlier signs of the progression of ischaemia before these physical changes 
manifest. As a key early feature of impending cardiac injury, the ability to detect 
myocardial hypoxia or changes in redox status would provide new insights into 
ischaemia related pathologies, and help guide therapies in patients with 





1.2 The pathogenesis of myocardial ischaemia  
The ultimate fate of an ischaemic cell without intervention is death. In the heart 
this may lead to myocardial infarction or heart failure and is frequently fatal. Cell 
death occurs as a consequence of a cascade of events which progress with 
increasing ischaemic severity or time. Discussed here are some of the 
pathologies associated with ischaemic heart disease and the relevance of 
hypoxia and redox status. 
 
1.2.1 Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease of the arteries. The formation 
of atherosclerotic plaque in the arterial intima results in wall thickening and 
narrowing of the lumen6. Changes in arterial redox status and oxygen tension 
have been implicated in atherogenesis. Common risk factors for atherosclerosis 
include hypercholesterolaemia, diabetes, hypertension, smoking and age; each 
of which increase the likelihood of reactive oxygen species (ROS) generation in 
the endothelial, smooth muscle and adventitial cells of arteries7. ROS initiate 
endothelial activation which can lead to endothelial dysfunction, oxidation of low 
density lipoprotein (LDL), plaque formation and plaque rupture8. Atherosclerosis 
is initiated upon ROS induced endothelial activation which increases uptake of 
LDL into the vessel wall, migration of monocytes and their differentiation into 
macrophages. Macrophages then accumulate the oxidised-LDL to form foam 
cells. These lesions progress into plaques as a result of foam cell accumulation, 
smooth muscle cell migration from the arterial media to the site of the lesion and 
collagen deposition. As plaque formation progresses, the arterial lumen 
becomes narrowed limiting blood flow downstream and potentially resulting in 
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ischaemia. Plaques may also rupture and occlude the coronary vessels leading 
to acute coronary syndromes such as myocardial infarction9. Atherosclerosis is 
a complex pathophysiological process which may also give rise to coronary 
vasospasm, further inflammation, microvascular disease and endothelial 
dysfunction, all of which may result in myocardial ischaemia10.  Although ROS 
play a key role in atherogenesis and plaque formation, plaques may also be 
hypoxic due to increased plaque size and/or elevated oxygen demand induced 
by inflammation11. 
 
1.2.2 Coronary artery disease 
Coronary artery disease (CAD) is the progressive narrowing of coronary blood 
vessels due to atherosclerotic plaque formation. It is a chronic disease, which is 
generally asymptomatic for many years before any clinical manifestation. As 
CAD results from vessel narrowing rather than complete occlusion, blood flow is 
frequently restricted but may still be sufficient to prevent ischaemia at rest. 
Increased myocardial demand for blood, such as during exercise, can induce 
demand ischaemia resulting in chest pain (angina pectoris). In the long term, 
these frequent bouts of ischaemia may cause myocardial damage, tissue 
fibrosis and depressed cardiac function12.  While the effects of CAD on the 
myocardium are commonly slow and progressive in combination with coronary 
artery spasm (CAS), they can be fatal. CAS is the sudden vasoconstriction of 
an epicardial coronary artery. CAS combined with CAD can result in complete 
vessel occlusion and severe myocardial ischaemia. While the pathogenesis of 




1.2.3 Coronary microvascular disease 
Coronary microvascular disease (MVD) is a cardiovascular pathology affecting 
the microvessels which branch from myocardial coronary arteries. The 
microcirculation is responsible for matching blood flow with oxygen demand by 
regulating vascular resistance. Microvascular dysfunction can therefore cause a 
disparity between blood delivery and oxygen supply leading to hypoxia in the 
affected tissue. MVD can result from a wide variety of microvascular 
dysfunctions including vessel obstruction, vascular remodelling and endothelial 
and smooth muscle cell dysfunction. MVD can manifest in the presence or 
absence of CAD and the main symptom is chronic angina14. MVD has been 
suggested as the primary cause of angina in patients without any other cardiac 
or systemic diseases; however, currently there are no techniques available for 
the direct visualisation of coronary microvessels or the diagnosis of patients 
with MVD13,15. Coronary arteries can be imaged via angioplasty; however, this 
only detects gross cardiac perfusion and cannot detect areas affected by MVD 
where local perfusion is poor even when gross perfusion is normal.  As MVD 
compromises myocardial blood flow and results in local myocardial ischaemia 
and hypoxia, a hypoxia tracer may be useful in identifying regions of the 
myocardium affected by MVD. 
 
1.2.4 Myocardial hibernation 
Myocardial hibernation is a term used to describe the downregulation of cardiac 
myocardial contractility in response to an impaired perfusion reserve16. It is 
currently unclear whether this low perfusion is constant, or periodic, and as 
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such causes low level chronic ischaemia or intermittent acute ischaemia, either 
of which could explain the chronic depression of cardiac contractility 17,18.  
Myocardial hibernation can manifest for years after onset. As hibernating tissue 
is viable, it is potentially reversible by revascularisation surgery, but left 
untreated may lead to heart failure19. As the hibernating myocardium may be 
hypoxic, hypoxia specific imaging agents could provide new insights into this 
pathology and help guide revascularisation therapy in the future5. 
 
1.2.5 Myocardial hypertrophy 
Various cardiac pathologies such as myocardial hibernation, ischaemia-
reperfusion and myocardial infarction result in impaired contractile function. 
Myocardial hypertrophy is the enlargement of cardiac myocytes, a protective 
mechanism designed to overcome losses in contractile force20. Without 
compensatory angiogenesis, however, hypertrophic cells may become hypoxic 
due to an increase in the diffusion distance from blood vessels across the 
enlarged cells21. Although this adaptive mechanism serves to maintain cardiac 
contractile function and cardiac output, hypertrophy increases synthesis of 
extracellular matrix components such as collagen which induces myocardial 
fibrosis22. Fibrosis increases myocardial stiffness, therefore impairing cardiac 
function and can lead to heart failure23. Ischemia increases circulating levels of 
angiotensin II and tumour necrosis factor α (TNF-α), which increase hydrogen 
peroxide and superoxide generation by NADPH oxidases in cardiac myocytes 
and vascular smooth muscle cells24. ROS signalling has therefore been 
implicated as the origin of myocardial hypertrophy and may stimulate myocyte 
apoptosis by direct genotoxicity or by activating apoptotic pathways8. Hypoxia 
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and/or redox sensitive imaging modalities may therefore be beneficial in 
identifying hypertrophic myocardium. 
 
1.3 Myocardial aerobic metabolism 
The contracting myocardium needs a constant supply of adenosine 
triphosphate (ATP) to meet its high energy demands. Over 95% of ATP utilised 
by the heart is generated through mitochondrial respiration, and the remainder 
through glycolysis or guanosine triphosphate (GTP) synthesis from the 
tricarboxylic acid (TCA) cycle25. The mitochondria utilises substrates from the 
metabolism of a range of substrates including fatty acids, glucose, lactate, 
ketones and amino acids in order to generate ATP26. The main pathways 
involved in myocardial ATP production are described below. 
 
1.3.1 Fatty acid β-oxidation 
Fatty acid metabolism accounts for the majority (up to 70%) of ATP generation 
in the healthy adult heart 25. The complete β-oxidation of an oleic acid molecule, 
for example, yields 146 ATP molecules. Fatty acids enter the myocardium via 
transport proteins in the sarcolemmal membrane and are converted into long-
chain acyl coenzyme A (CoA) esters by fatty acyl CoA synthase (FACS) in the 
cytosol (figure 1.1 A). Carnitine palmitoyltransferase 1 (CPT1), situated on the 
outer mitochondrial membrane, converts these long-chain CoA esters to 
acylcarnitine, which enters the mitochondrial matrix via carnitine: acylcarnitine 
translocase (CAT) in exchange for carnitine. In the matrix, acylcarnitine is 
converted back to a long-chain acyl CoA via CPT2 and enters the β-oxidation 
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spiral (figure 1.1 B). At each cycle of the β-oxidation spiral, the long chain acyl 
CoA is shortened by two carbon atoms, producing flavin adenine dinucleotide 
(FADH2), nicotinamide adenine dinucleotide (NADH), and acetyl CoA. The 
mitochondrial electron transport chain (ETC) utilises this FADH2 and NADH to 
pump protons across the inner mitochondrial membrane to generate the proton 














Figure 1.1. Fatty acid translocation (A) and subsequent β-oxidation  (B).  Adapted from 



















































1.3.2 Glycolysis  
In addition to fatty acid β-oxidation, glycolysis generates ATP directly, as well as 
providing further energy substrates for oxidation in the mitochondrion. One 
glucose molecule is converted to two molecules of pyruvate,  generating two 
ATP and two NADH molecules (figure 1.2.)29. During aerobic glucose 
metabolism, pyruvate enters the mitochondria via monocarboxylase transporter 
(MCT), and is oxidised by pyruvate dehydrogenase (PDH) to acetyl CoA which 
then enters the TCA cycle30.  A net of 31 ATP molecules are produced from the 





Figure 1.2. Glucose metabolism. Red bar represents inhibition of PDH. Adapted from Katz 
























































1.3.3 The tricarboxylic acid cycle 
Acetyl CoA produced from fatty acid β-oxidation and glycolysis is oxidised by 
the mitochondrial enzymes of the TCA cycle (figure 1.3). This process takes 
place in the mitochondrial matrix and generates further NADH and FADH2 
molecules for ATP production via the electron transport chain29. In addition, the 
hydrolysis of succinyl CoA results in the transfer of a high energy phosphate 
bond to guanosine diphosphate (GDP), generating a GTP molecule, which in 
turn transfers this bond to ADP to form an ATP molecule27.  
 
 

































1.3.4 Mitochondrial respiration (oxidative phosphorylation) 
The respiratory substrates NADH and FADH2 are utilised by the mitochondria to 
generate ATP by a series of enzymatic complexes which form the ETC (figure 
1.4). Complexes I-IV, ubiquinone (located in the inner mitochondrial membrane) 
and cytochrome c (in the intermembrane space) transfer electrons down a 
redox-potential gradient to oxygen at the end of the chain29,32,33. The oxidation 
of NADH at complex I and FADH2 at complex II releases electrons which 
reduce ubiquinone to the mobile intramembrane electron carrier ubiquinol. 
Ubiquinol transfers these electrons to complex III, which reduces the haem 
group of the small mobile protein cytochrome c, which in turn reduces complex 
IV.  Complex IV finally reduces molecular oxygen form water34.  The passage of 
electrons through each of these proteins leads to the pumping of protons across 
the inner mitochondrial membrane from the matrix to the intermembrane space 
to generate a proton gradient. These protons re-enter the matrix down this 
gradient, by driving the rotation of the F1 unit of ATP synthase, which catalyses 
the phosphorylation of ADP to generate ATP.  As the terminal electron acceptor 
in this entire process, the reduction of oxygen is the fundamental rate limiting 










1.3.5 Myocardial anaerobic metabolism 
Ischaemic heart disease is associated with a range of pathologies, including 
MVD, CVD, myocardial hibernation and hypertrophy, which are characterised 
as hypoxic due to disparities between blood flow and oxygen demand of the 
affected tissue27.  
As oxygen demand supersedes oxygen supply, less oxygen is available to 
accept electrons from complex IV of the mitochondrial ETC. This prevents the 
reduction of each complex and thus electrons are no longer transferred down 
the chain.  As a result proton flux into the intermembrane space by complex I, III 
and IV ceases, the proton gradient becomes insufficient to drive ATP synthase, 
and ATP production stops4,35. As NADH and FADH2 can no longer be recycled 
to their oxidised forms, the TCA cycle also becomes inhibited, and the heart 
becomes dependent upon anaerobic glycolysis to produce ATP. 
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor which exists in all cell 






























promoter region of over 100 genes, to activate the transcription of genes which 
help cellular adaption to hypoxic conditions. Under normoxic conditions, HIF-1 
is expressed as two separate subunits; HIF-1α and HIF-1β. HIF-1β is 
constitutively stable whereas HIF-1α proline residues become hydroxylated by 
prolyl hydroxylate enzymes which uses oxygen as a co-substrate. The von 
Hippel-Lindau protein targets hydroxylated HIF-1α subunits and labels them for 
rapid degradation by the proteasome. Factor inhibiting HIF (FIH) can also 
hydroxylate HIF-1α at the asparagine residue which prevents the binding of 
HIF-1α to transcriptional co-activators p300 and CREB-binding protein, 
therefore preventing activation of the HRE36,37.  In conditions where oxygen is 
insufficient, however, hydroxylation of the HIF-1α subunit is prevented and HIF-
1α translocates to the nucleus where it binds to HIF-1β bind to form a 
heterodimer. The HIF-1 heterodimer binds to the HRE and interacts with the 
transcriptional co-activators to induce gene transcription. 
HIF-1 activation during hypoxia promotes glucose transporter 4 (GLUT-4) and 
hexokinase (HK) expression, and increases maximal myocardial glucose uptake 
and metabolism capacity36. HIF-1 also increases the expression of pyruvate 
dehydrogenase kinase (PDK) and lactate dehydrogenase (LDH). PDK inhibits 
the conversion of pyruvate to acetyl-CoA by PDH and therefore prevents 
pyruvate from entering the mitochondria. Pyruvate is then converted to lactate 
by LDH which recycles NADH to NAD+ in the process. NAD+ is required for 
further glycolysis, therefore increased expression of PDK and LDH increases 
ATP generation under low oxygen conditions38.  Thus hypoxic tissue gains the 
capacity to both increase glucose uptake, and glycolytic flux. 
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As described earlier, the β-oxidation of oleic acid produces enough energy 
substrates to generate 146 ATP molecules via TCA cycle and oxidative 
phosphorylation. The complete aerobic metabolism of one molecule of glucose 
produces a net of 31 ATP molecules.  During hypoxia, however, the complete 
anaerobic glycolysis  only produces 2 ATP molecules per glucose molecule39. 
As anaerobic glycolysis is less efficient at generating ATP than aerobic energy 
metabolism, ATP is utilised faster than it is recycled. If the release of protons 
from ATP hydrolysis is not matched with the consumption of protons in ADP 
phosphorylation, protons accumulate and intracellular pH decreases. In 
ischaemic tissue the lack of residual flow causes protons to accumulate, 
resulting in tissue acidosis. Acidosis decreases the sensitivity of contractile 
proteins to Ca2+ which depresses cardiac contractile function27,40,41.   
The increase in proton concentration also stimulates Na+ influx via Na+/H+ 
exchanger (NHE). Na+ is extruded via the Na+/Ca2+ exchanger (NCX) in 
exchange for Ca2+, therefore acidosis increases intracellular Ca2+ 
concentrations. Elevated intracellular Ca2+ levels activate proteases and 
phospholipases which compromise the integrity of the cell through digestion of 
cytoskeleton proteins and membrane phospholipids4.  Increases in Ca2+ also 
increases ROS generation via mitochondrial swelling and electron leakage, 
impairs myocardial relaxation and increases the susceptibility of the 
myocardium to arrhythmia42.  
The lack of ATP generated through anaerobic glycolysis also decreases Na+/K+ 
ATPase activity, leading to additional Na+ influx and K+ efflux. The imbalance in 
electrolytes increases membrane permeability, and therefore cell uptake of 
small ions and water, which causes the cell to swell4,36.  Irreversible cell injury 
44 
 
from membrane phospholipid damage and/or loss and destruction to the cellular 
cytoskeleton results in myocardial infarction43.    
Whether hypoxia induces or suppresses mitochondrial ROS generation is 
currently controversial; it is likely a question of degree. In extreme hypoxia, the 
lack of oxygen as a substrate would inhibit ROS production. Several studies, 
however, have demonstrated that mitochondrial ROS generation increases in 
cardiac myocytes as a result of hypoxia44,45.  Under normoxic conditions a small 
amount of electrons leak from complex I-III of the ETC and generate ROS in the 
mitochondrial matrix and intermembrane space46.  As oxygen is the terminal 
electron acceptor, a lack of oxygen prevents the transfer of electrons down the 
ETC. This causes electrons to accumulate and increases electron leakage 
generating ROS under hypoxic conditions. In the normoxic cell cytochrome c is 
capable of scavenging superoxide. During hypoxia, the backlog of electrons 
means that cytochrome c remains in its reduced form; its ability to scavenge 
superoxide is suppressed and mitochondrial superoxide leakage increases47. 
ROS also prevents the hydroxylation of HIF-1α by proline dehydroxylase 
enzymes, therefore preventing HIF-1degradation and promoting transcription of 
HRE genes48. It is therefore possible that increased mitochondrial ROS 
generation in response to hypoxia is an oxygen sensing process which protects 
cardiac myocytes from hypoxia induced damage.  Increased ROS generation 
causes lipid peroxidation and oxidative damage to cell proteins and DNA, , 






1.3.6 Energy metabolism in the vascular endothelium 
The energy demands and oxygen consumption of the endothelium are much 
lower than that of cardiac myocytes49,50. Under aerobic conditions the 
endothelium is capable of oxidising both fatty acids and glucose; however, the 
majority of endothelial cell ATP is generated via glycolysis49,51. LDH, 
glyceraldehyde phosphate dehydrogenase (GAPDH) and phosphofructokinase 
(PFK) activities are higher in endothelial cells, increasing lactate production 
under normoxic conditions. Lactate is extruded from the microvascular 
endothelium and diffuses across the endothelial membrane into the blood or 
surrounding cells, therefore endothelial derived lactate may be utilised by 
myocytes to produce additional ATP52,53. As endothelial oxygen consumption is 
relatively low compared to cardiac myocytes, endothelial energy metabolism is 
sustained at low oxygen tensions provided there is a sufficient glucose supply. 
A decrease in endothelial ATP production occurs only when oxygen tension 
falls to that comparable to zero flow ischaemia and endothelial cells are 
generally more resistant to hypoxia than cardiac myocytes50.  
 
1.4. Changes to cardiovascular redox status 
The myocardium and vascular endothelium generate free radicals as a result of 
hypoxia and cardiac ischaemia-reperfusion. When radical generation exceeds 
antioxidant capacity to defend against it, the cell experiences oxidative stress 
(section 1.4.2). This triggers a cascade of events which depresses cardiac 
function in the acute term, increases the likelihood of arrhythmias, and 
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chronically can lead to heart failure54,55.  It has been suggested that heart failure 
severity is proportional to the degree of free radical generation56.  
1.4.1 Reactive oxygen species 
Free radicals are highly reactive chemical species which possess one or more 
unpaired electrons. The main free radicals implicated in the pathogenesis of 
heart failure are superoxide (∙O2
-), the hydroxyl radial (∙OH) and hydrogen 
peroxide (H2O2)
57. As these species are derived from oxygen they are termed 
reactive oxygen species (ROS).  While H2O2 does not contain an unpaired 
electron and is not a free radical,  it is a potent oxidising agent, and is therefore 
also considered a ROS57. ∙O2
- is generated by the direct reduction of molecular 
oxygen by an electron (equation 1a). Further reduction of ∙O2
-
 , which may be 
carried by the antioxidant enzyme superoxide dismutase, generates H2O2 (1b) 
which in turn is reduced to ∙OH by the iron catalysed Fenton reaction (1c). 
Finally, ∙OH may be reduced to water (1d).  
 
 






OH and H2O2. 
 
∙O2
- is capable of either reduction or oxidation of other molecules and production 
of further ∙OH. ∙OH is an even more reactive than ∙O2





- + 2H+ + 2e- H2O2 (b)
H2O2 + H
+ + e- OH∙ (c)
OH∙ + H+ + e- H2O (d)
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molecule it comes into contact with. ∙OH may also be produced by the 
spontaneous combination of ∙O2
- and H2O2 via the Haber-Weiss reaction (2a) or 
through the reaction ∙O2
- or H2O2 catalysed by transition metals (the Fenton 
reaction) which also generates further ∙O2
- (2b-d). 
 






OH through (a) the Haber-Weiss reaction (a) and 
(b-d) Fenton reactions. . 
Both ∙O2
- and ∙OH are hydrophilic and do not passively diffuse across plasma 
membranes. ∙O2
- is transported across membranes via anion channels and can 
therefore affect adjacent cells. The life span of ∙OH is much shorter due to its 
reactivity and therefore localises close to its site of production58. H2O2 is more 
stable and oxidises molecules more slowly, however, its lipophilicity allows 
membrane diffusion and therefore access to other cells or organelles where it 
can generate further ∙O2
- and ∙OH. Singlet oxygen (1O2) is another non-radical 
classified as a ROS and can arise from H2O2 reactions with hypochlorite ions 
(OCl-; equation 3)59. It contains the same number of electrons as molecular 
oxygen, however, one of these electrons is in a higher energy orbital57. The 
excess energy of 1O2 is released through light emission or reaction with other 
molecules. 
∙O2
- +  H2O2 O2 + OH
∙ (a)
Fe2+ +  H2O2                              Fe
3+ + ∙O2
- + OH∙ + OH- (b)
Fe3+ +  H2O2                                      Fe
2+ + ∙O2
- + H+ (c)
∙O2





Equation 1.3. Generation of singlet oxygen. OCl
-





1.4.2 Myocardial ROS generation 
Several ROS generation pathways have been implicated in cardiac hypoxia and 
ischaemia-reperfusion injury. During ischaemia the myocardium releases 
chemotactic factors, such as TNF-α and interleukins, which stimulate neutrophil 
migration to ischaemic areas during reperfusion60. Neutrophil activation is a 
common feature in patients with heart failure and has been positively linked with 
increased infarct size61.  Activated neutrophils generate ∙O2
- by NADPH-
dependent oxidase resulting in further H2O2, 
∙OH and 1O2 generation. These 
ROS stimulate further inflammation by activating further chemotactic factors 
resulting in additional neutrophil activation, migration to the endothelium and 
further cytotoxic ∙O2
- generation57.  Neutrophils also produce chloramine 
(NH2Cl), a lipophilic radical capable of reacting with peptide bonds resulting in 
protein damage.  Neutrophil depletion decreases myocardial infarct size caused 
by ischaemia-reperfusion in dogs, further supporting the role of neutrophil 
derived ROS in ischaemia-reperfusion injury62.  
As mentioned in section 1.3.4, oxygen is utilised in the mitochondria as the 
terminal electron acceptor at complex IV of the ETC. Under normal 
physiological conditions, up to 5% of this oxygen leaks from this pathway and is 
converted to ∙O2
- via univalent reduction57. During hypoxia or ischaemia, 
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however, acidosis increases ∙O2
- protonation, forming the highly reactive 
hydroperoxyl radical (∙HO2)
63.   
The mitochondrial permeability transition (MPT) describes the opening of the 
mitochondrial permeability transition pore (MPTP) in the inner mitochondrial 
membrane, stimulated by increases in Ca2+ and inorganic phosphate (Pi) 
levels64, which increases its permeability to solutes of molecular masses up to 
1500 Da65. Not only does it depolarise and uncouple the mitochondria, but it 
also causes mitochondrial damage by osmotic swelling. With elevated 
intracellular Ca2+ and Pi levels, hypoxia increases the propensity for MPTP 
opening and ETC uncoupling. As the ETC uncouples, its capacity to leak 
electrons increases, causing increased ROS formation. As the MPTP are open 
at this point, this may also increase the likelihood of ROS to leaking into the 
cytosol57,66.  
The continued breakdown of ATP during hypoxia leads to an increase in 
intracellular ADP and AMP, and their  further breakdown to the nucleosides 
adenosine and inosine and the purines,  hypoxanthine and xanthine67. While 
xanthine and hypoxanthine are usually oxidised to urea by xanthine 
dehydrogenase using NAD+ as an electron acceptor,  Ca2+ dependent 
proteases convert xanthine dehydrogenase to xanthine oxidase during 
ischaemia68 which uses oxygen as an electron acceptor, to generate ∙O2
-. 
Increased ∙O2
- generation has been documented in various models of 
ischaemia-reperfusion in vivo, which is suppressed by the xanthine oxidase 
inhibitor allopurinol, implicating xanthine oxidase as a ROS source57. Allopurinol 
also decreased myocardial infarct size in canine hearts post ischaemia, further 
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demonstrating the role of xanthine oxidase derived ∙O2
- in myocardial 
ischaemia-reperfusion injury69.  
 
1.4.3 Endothelial nitric oxide generation 
Nitric oxide (NO) contains one unpaired electron and reacts rapidly with other 
molecules including ∙O2
-. The reaction between NO and ∙O2
- generates 
peroxynitrite (ONOO-) which can generate further ∙OH (equation 4).  
 




(a) generates nitrogen radicals and 
∙
OH (b).  
Although NO is capable of forming potentially damaging ONOO- and ∙OH, it is 
also an important cell signalling molecule, and is generated by several nitric 
oxide synthase (NOS) isoforms. Endothelial NOS (eNOS) produces NO to 
induce vascular relaxation and maintain coronary perfusion pressure57. During 
reperfusion following ischaemia, NO generation increases and induces 
vasorelaxation to facilitate blood flow to ischaemic tissue. NO also inhibits many 
atherogenic processes including platelet aggregation and adhesion,  oxidation 
of LDL by macrophages and smooth muscle cells proliferation57.  
 
1.4.4 Lipid, protein and DNA damage 
 Lipid peroxidation is a well characterized effect of ROS production and can 
result in significant damage to the phospholipid membranes of cells and 
NO + ∙O2
- ONOO- (a)





organelles, with serious implications for cell integrity and function8. ROS react 
with lipid molecules to create lipid radicals (equation 5), which in turn react with 
molecular oxygen to create lipid peroxy radicals (lipid-OO∙). Lipid-OO∙ initiate a 
chain reaction by reacting with other lipids to generate further lipid radicals.  
 
Equation 1.5. Lipid peroxidation cascade. 
In the presence of transition metal ions, lipid peroxides (lipid-OOH) are 
converted to either lipid-OO∙ or alkoxy radicals (lipid-O∙) which can also cause 
structural changes to the cell membrane57. In addition to playing a role in lipid 
peroxidation, lipid-OOH interfere with proteins by initiating polymerisation, 
breaking peptide chains and oxidising amino acids to form carbonyl and 
sulphydryl derivatives70. Damage to membrane proteins, such as 
transmembrane ion channels, also compromises membrane integrity. ROS 
mediated lipid and protein damage may therefore induce increased membrane 
permeability, cellular swelling and cellular necrosis. 
Non-membrane bound proteins are also vulnerable to ROS damage. ∙OH may 
promote protein polymerisation, resulting in cross linkages between two or more 
proteins. This may denature contractile proteins or decrease Ca2+ sensitivity, 
which would account for depressed contractile function following ischaemia-
reperfusion8,57. ∙OH may also react with purine and pyrimidine bases and 
deoxyribose, resulting in DNA damage59. 1O2 is also capable of attacking carbon 
: carbon double bonds and may induce DNA, protein and lipid damage59. 
∙ OH + Lipid-H H2O + Lipid
∙
Lipid∙ + O2 Lipid-OO
∙
Lipid-OO∙ + Lipid-H Lipid -OOH + Lipid ∙ 
52 
 
1.4.5 The effect of ROS upon Ca2+ and Na+ homeostasis 
The sarcoplasmic reticulum of muscle is responsible for intracellular Ca2+ 
homeostasis and sequesters intracellular Ca2+ via Ca2+ATPase, which is 
essential for initiating muscle relaxation following contraction. ROS have been 
demonstrated to decrease Ca2+ATPase activity, which decreases sarcoplasmic 
reticulum Ca2+ reuptake and interferes with contractile function during 
reperfusion following ischaemia8,57. As a result, intracellular Ca2+ overload leads 
to activation of contractile proteins and excessive force generation causing 
hypercontraction and decreased diastolic relaxation71. Hypercontraction causes 
severe injury to myocyte cytoskeletal structures and, if irreversible, initiates 
cellular necrosis.  
The sarcolemmal membrane Na+/K+ ATPase maintains intracellular Na+ and K+ 
concentrations and therefore is important for membrane potential regulation. 
Damage of the Na+/K+ ATPase by ROS contributes to ischaemia-reperfusion 
injury by elevating intracellular Na+ levels, adding to the Na+ caused by 
acidosis57,66. As mentioned earlier, Na+ enhances Ca2+ pool levels by the NCX, 
therefore an increased intracellular Na+ exacerbates Ca2+ overload and 
hypertrophy. 
 
1.4.6 The effect of ROS upon endothelial dysfunction 
Endothelial NO production is an important signalling molecule initiating 
vasorelaxation and preventing atherosclerosis. An increase in ROS, however, 
decreases NO availability through direct interaction (generating ∙OH) or the 
downregulation of eNOS57. NO depletion decreases the responsiveness of the 
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endothelium to stimuli, decreases NO dependent vasorelaxation and results in 
loss of endothelial cells, termed as endothelial dysfunction.  Endothelial 
dysfunction contributes to hypertension, atherosclerosis and other acute 
coronary syndromes with often lead to heart failure 55,72. Most of the ROS 
responsible for endothelial dysfunction derives from inflammatory cytokines, 




Redox status is a term which describes the balance between free radical 
generation and antioxidant capacity. Antioxidants are molecules which detoxify 
oxidants, such as free radicals, and prevent the oxidation of other molecules73. 
They are therefore essential in protecting the heart from ROS induced injury. 
Superoxide dismutase (SOD), catalyses the dismutation of ∙O2
- to H2O2, which 
in turn is decomposed to water and oxygen by catalase. α-tocopherol (Vitamin 
E) reacts with peroxyl radicals to yield a stable tocopheroxyl radical which is 
recycled back to α-tocopherol by ascorbate. Ascorbate also scavenges ∙O2
-, 
∙HO2 and 
∙OH59. Glutathione peroxidise (GSH-Px) uses reduced glutathione 
(GSH) as a substrate to decompose peroxides (including lipid peroxides and 
H2O2) to form water and oxidised glutathione (GSSG). GSH itself is an 
antioxidant which has a strong tendency to donate electrons and is capable of 
reducing other molecules directly, therefore is capable of recycling other 
oxidised antioxidants, for example, ascorbate. 
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Numerous studies have demonstrated the importance of the antioxidant system 
in protecting the heart from ROS induced injury. For example, mice over 
expressing SOD subjected to ischaemia for 35 minutes displayed decreases in 
myocardial infarction size post ischaemia compared to wild type mice74. SOD 
knockout mice display more myocardial hypertrophy in response to ischaemia 
induced myocardial infarction compared to wild type mice75. Upon reperfusion, 
SOD administration improved myocardial contractile function in ischaemic-
reperfused rabbit hearts compared to control hearts76. GSH administration also 
improved myocardial contractile dysfunction on the reperfusion of ischaemic 
isolated rat hearts77. Ascorbate and α-tocopherol have also been implicated in 
the protection against ischaemia induced myocardial injury78,79.  These studies 
emphasise the importance of ROS generation and altered redox status in 
myocardial dysfunction.  
To summarise, hypoxia and ROS generation, and changes in cellular redox 
status as a result of myocardial ischaemia can eventually cause irreversible cell 
injury, leading to necrosis and myocardial infarction. Identification of hypoxic 
myocardium and/or altered myocardial redox status may therefore provide an 
opportunity to diagnose vulnerable tissue and intervene before ischaemic injury 
becomes irreversible. 
 
1.5 Current techniques for the detection of cardiac redox status 
Currently, most redox sensing techniques involve the detection of free radicals 
rather than antioxidants. The short half-life of free radicals limits the direct 
detection of their formation in real time in biological systems. Although 
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technically challenging, some techniques have been developed to measure free 
radical generation and redox status. There is, however, a need to for better 
redox sensitive probes that are practical for the measurement of cardiac redox 
biology. 
 
1.5.1 Electron paramagnetic spin resonance spectroscopy 
EPR spectroscopy has been utilised for decades for the detection of free 
radicals in the heart. A variety of spin traps have been developed which, upon 
reaction with free radicals, form stable spin adducts which are detectable by 
EPR spectroscopy. The burst of free radicals associated with reperfusion 
following ischaemia, for example, has been measured in real time using EPR 
spectroscopy with spin traps N-tert-butyl-a-phenylnitrone (PBN) and 5,5-di- 
methyl- 1-pyroline-n-oxide (DMPO) in isolated perfused rat and rabbit hearts80-
82. Although EPR spectroscopy is a common technique utilised for ex vivo free 
radical detection and has a number of probes specific for individual free 
radicals, it has several limitations. EPR spectroscopy lacks sensitivity and 
therefore requires potentially toxic concentrations of spin traps in order to gain a 
measurable signal57. It is not ideal for detection of free radicals in vivo as spin 
traps and adducts may be metabolised. The instability of spin adducts in vivo 
also limits its use. As EPR spectroscopy quantifies the products of ROS and 
spin trap reactions it does not measure ROS directly. Furthermore, ROS-spin 






1.5.2 Fluorescent ROS probes 
A vast number of fluorescent probes have been developed for ROS detection. 
Like EPR, fluorescent redox probes form products upon reaction with targeted 
ROS. Dihydroethidium (DHE), for example, is oxidised by ∙O2
-, forming the 
fluorescent ethidium which is measurable by excitation fluorescence 355nm/ 
emission at 480 nm84. N-acetyl-3,7-dihydroxyphenoxazine (amplex red) reacts 
with H2O2 to produce the highly fluorescent resorufin and sodium terephthalate 
reacts with ∙OH to produce fluorescent bi-product 2-hydroxyterephthalate 
(excitation 530nm/emission 590nm)85. Used appropriately, fluorescent probes 
can be a good method of measuring ROS due to high spatial resolution and 
sensitivity. Although DHE is specific for ∙O2
- it can also catalyse the dismutation 
of ∙O2
- therefore the fluorescence signal may decrease with increasing ∙O2
- 
concentrations86. Furthermore, it has been suggested that ∙OH decreases 
ethidium fluorescence87.  At concentrations above 50 µM/ L amplex red can 
auto-oxidise to produce ∙O2
- and H2O2 which would interfere with the 
fluorescence signal84. Use of these probes is therefore limited in the detection of 
ROS generation associated with ischaemia and/or hypoxia. 
 
1.5.3 Luminescence 
Luminescent techniques can be used to measure the emission of light as a 
result of ROS generation. For example, 1O2 has one electron at a higher energy 
state and emits the surplus energy as light when relaxes to its ground state57. 
Although luminescence can be used to measure 1O2 on a cellular level, its 
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application for quantifying 1O2 in intact tissues in vivo is hampered by light 
absorption, scatter, and the very low levels of light emitted88.   
The chemiluminescence probe lucigenin is  specific for detecting ∙O2
-. Lucigenin 
is reduced by ∙O2
- to form a lucigenin radical. The lucigenin radical reacts with a 
second ∙O2
- to generate an energy rich dioxetane molecule which then emits 
light84. Although lucigenin is specific for ∙O2
-, the lucigenin radical produced 
upon its reduction is capable of reacting with molecular oxygen to create further 
∙O2
-. Lucigenin could therefore overestimate ROS generation.  
 
1.5.4 Ascorbyl radicals 
Most redox sensitive probes target free radicals directly. An alternative 
approach is to measure the change in antioxidant status as an indirect index of 
ROS production. Virtually every ROS is capable of oxidising ascorbate to an 
ascorbate radical, which can be detected directly by EPR spectroscopy57. More 
recently this approach has been enhanced by quantifying the uptake and 
metabolism of hyperpolarised ascorbate and/or dehydroascorbate  by 13C-NMR 
spectroscopy 89-91. The ratios of 13[C]-dehydroascorbate and 13[C]-ascorbate 
detected by NMR spectroscopy can therefore give real time measurements of 
intracellular ROS and antioxidant activity and therefore redox status. To date 
13[C]-dehydroascorbate and 13[C]-ascorbate have been detected in whole mice 
and rats in vivo. Hyperpolarised 13[C] labelled complexes, however, undergo 
rapid thermal decomposition and the signal can decay in minutes, limiting the 
time course of the experiment to minutes rather than hours.  It also requires the 
injection of supraphysiological concentrations of substrates which may 
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significantly alter the kinetics of the systems under investigation, requiring great 
care in the interpretation of the data that it achieves. Nevertheless, while still in 
its infancy, this approach shows promise as a potential means of probing 
intracellular redox status. 
 
1.6 Current techniques for the detection of myocardial hypoxia 
1.6.1 Invasive probes 
Oxygen sensing needles, such as the Eppendorf polygraphic electrode and 
Oxylab/Oxylite™ systems, are the current gold standard method in measuring 
tissue oxygenation92. The Eppendorf polygraphic electrode consists of a gold 
cathode and silver-chloride anode which electrochemically reduce oxygen at the 
probe tip. The current produced is proportional to the partial pressure of oxygen. 
The oxygen consumption of these probes, however, leads to a decrease in 
signal over time, potentially leading to an underestimation of tissue pO2
93. In 
contrast, the Oxylite system contains a fibre optic tip which is quenched in the 
presence of oxygen, therefore the signal increases with decreasing oxygen94.  
These electrodes are capable of reading lower pO2 than polygraphic electrodes 
and can be kept in the same location over time. However, both of these 
techniques are invasive, and often need guidance via ultrasound or computed 
tomography (CT) to place a needle containing the electrode in the correct 
tissue. They are more commonly used in assessing tumour pO2 and have not 
yet been used for the detection of myocardial hypoxia. Even if this was possible, 
oxygen sensing probes can only be placed in accessible blood vessels or 
interstitial spaces and cannot measure intracellular pO2 directly. They also offer 
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little or no spatial information and are of limited use in providing diagnostic or 
prognostic information in cardiology. 
 
1.6.2 Non-invasive imaging 
Various imaging techniques have been employed for the assessment 
myocardial ischaemia. Most of these techniques measure contractile function, 
tissue perfusion, cellular metabolism, and do not directly identify myocardial 
hypoxia. This section discusses some of the imaging modalities currently used 
to identify ischaemic myocardium.  
 
1.6.2.1 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) is a technique that uses the natural 
magnetic properties of the body to provide anatomical and functional 
information. Protons possess a spin which makes them act like a magnetic 
dipole. An MRI scanner applies a large external magnetic field to the patient, 
which causes an alignment of the proton axes, either in line with this field (low 
energy state), or antiparallel to this field (high energy state). An oscillating 
radiofrequency is applied which perturbs the magnetisation, followed by a 
recovery period in which initial equilibrium is restored (hence Nuclear Magnetic 
Resonance). This is characterised by two relaxation times; T1 which is a time 
constant for the recovery of magnetisation and T2 which is a time constant for 
the decay of magnetisation. Water T1 and T2 vary between different tissues and 
environments; therefore the contrast of an MRI image is dependent on factors 





Blood oxygen level dependent (BOLD) MRI is an example of how MRI can be 
used to measure oxygen status. BOLD-MRI  detects the difference between 
levels of oxyhaemoglobin and deoxyhaemoglobin as a measure of blood 
oxygenation96. As haemoglobin becomes deoxygenated its magnetisation 
increases which causes a more rapid decay of magnetisation (T2) of the water 
molecules that surround it, resulting in an oxygen-dependent loss of signal. As 
BOLD-MRI measures the oxygen status of haemoglobin in the bloodstream, it 
does not detect tissue hypoxia directly. The oxygenation of the myocardium 
itself would be better quantified by detection of myoglobin oxygenation, which is 
possible but it is difficult to quantify and produces a particularly weak signal; 
methods to detect this are only in the early stages of development97. 
 
1.6.2.2 Cardiac Nuclear Medicine 
The term emission tomography encompasses the two major imaging modalities 
used in nuclear medicine: single photon emission computed tomography 
(SPECT) and positron emission tomography (PET). Both SPECT and PET are 
used to detect radioisotopes which have been injected into a subject. SPECT is 
used to detect radioisotopes which emit a single gamma ray photon upon 
decay. A collimator filters gamma rays travelling in a specific direction which are 
then detected by a gamma camera. The paths of the emitted gamma rays can 
then be used to determine the site of radioisotope decay for image 
reconstruction. PET detects radioisotopes which upon decay emit positrons. 
The emitted positrons collide with surrounding electrons and annihilation 
occurs, resulting in the emission of two photons which travel in opposite 
directions. PET utilises an array of gamma cameras surrounding the subject to 
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detect the gamma rays as they are emitted. Because the system detects two 
positrons at 180 degrees to each other (using coincidence circuitry to select 
those that arose from the same annihilation), the  paths of the gamma rays can 
be used to determine the site of radioisotope decay without the use of 
collimators98. 
Numerous radiotracers have been developed for the detection of ischaemic or 
hypoxic tissue using SPECT or PET. Perfusion radiotracers are commonly used 
to image myocardial blood flow and characterise tissue at risk of ischaemia. The 
PET tracer 13NH3 is extracted from the blood by well perfused tissue and is 
converted to glutamine to become trapped within cardiac myocytes99,100.  The 
SPECT tracer 99mTc-sestamibi is also extracted by well perfused myocardium 
and accumulates in the mitochondria of viable myocytes. The depolarisation of 
the mitochondrial membrane, which occurs with ischaemia induced injury, 
results in the decreased uptake of 99mTc-sestamibi100. Although imaging 
myocardial perfusion provides an indication of tissue at risk of ischaemia and 
hypoxia, these tracers rely on energy dependent processes to become trapped. 
These tracers therefore do not image perfusion alone and may underestimate 
perfusion in hypoxic regions of the myocardium where flow is normal, but 
energy is depleted5.   
The PET tracer 18F-Fluorodeoxyglucose (18FDG) is a glucose analogue used to 
assess tissue glucose metabolism. 18FDG is transported into cells by glucose 
transporters where it is phosphorylated to 18FDG-phosphate by hexokinase to 
become trapped in the myocardium101. While a small proportion of 18FDG-
phosphate undergoes further metabolism, the majority of these metabolites also 
remain trapped within the myocardium, which mean that it is a generally 
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accepted, although possibly a flawed means of assessing glucose utilisation102.  
As hypoxic tissue switches from fatty acid to glucose metabolism, an increase in 
cardiac 18FDG uptake delineates hypoxic regions in the myocardium. Metabolic 
tracers, however, are not specific to changes in metabolism due to hypoxia 
alone. Cardiac uptake of 18FDG is affected by blood glucose concentrations, 
dietary status, and diabetes, all of which are potentially confounding factors in 
interpreting cardiac 18FDG PET scans, as is the fact that increased 18FDG 
uptake is also characteristic of inflammatory processes5.   
 
1.7 Nitroimidazoles for imaging tissue hypoxia 
Nitroimidazoles were originally developed as radiosensitisers to improve the 
effectiveness of radiotherapy in hypoxic tumours103. Their ability to target 
hypoxic tissue has since lead to their development as hypoxia targeting probes. 
A variety of radiolabelled nitroimidazoles have been investigated as hypoxia 
imaging agents for PET (18F) and SPECT (99mTc). The mechanism of 
nitroimidazole hypoxia selectivity is shown in figure 1.5. Nitroimidazole 
compounds are lipophilic, and passively diffuse across cells membranes 
regardless of oxygen status. Intracellularly, the nitroimidazole becomes reduced 
to a radical form, R-NO2
.-. Under normoxic conditions, R-NO2
.- is reoxidised by 
molecular oxygen to an uncharged R-NO2, which passively diffuses out of the 
cell (.O2
- is released as a by-product in this process). In hypoxic environments, 
however, the lack of oxygen favours the retention of the charged, less 
permeable R-NO2
.- species. This species can also reduce further to nitroso, 
hydroxylamine and finally amine compounds, the latter of which may bind to 




Figure 1.5. Hypoxia selective trapping mechanism of nitroimidazole compounds. Adapted from 




Of the various nitroimidazole derivatives, 18F labelled misonidazole (18FMISO) is 
the most extensively researched, mostly for applications in oncology, although 
its potential application in cardiology has also been explored. Increased 
18FMISO retention has been demonstrated in hypoxic cardiomyocytes104 and 
ischaemic myocardium in canine hearts post coronary artery occlucion104-106. 
Furthermore, 18FMISO retention was greater in viable regions of the heart 
compared to necrotic regions, and was found to be inversely related to blood 
flow, demonstrating its potential for selective non-invasive hypoxia 
imaging106,107. Imaging of the heart, however, was only possible 60 minutes post 
18FMISO injection, because it clears very slowly from the blood, and has a very 
low first pass tissue uptake. It also exhibits very high hepatic uptake, which may 
be problematic for imaging the heart.  It has therefore been suggested that for 
optimum signal detection, imaging with 18FMISO should be performed at least 2 














dose of injected radioactivity would be required for a sufficient signal after an 
hour or more, increasing the radiation dose of the subject, which is not ideal. 
Other radiolabelled nitroimidazoles investigated for their hypoxia targeting 
properties include SPECT agent 99mTc-BMS181321 and PET agent 18F-
fluoroazomycin arabinoside (18F-FAZA). 99mTc-BMS181321 displays similar 
properties to 18FMISO as it accumulates in hypoxic, viable myocardium and 
retention is independent of flow103.  Like 18FMISO, however, 99mTc-BMS181321 
is limited as a hypoxia imaging agent due to its slow clearance from normoxic 
tissue and high first pass liver uptake.  18F-FAZA displays better clearance from 
both blood and normoxic tissue than 18FMISO, but has a poorer hypoxic to 
normoxic retention than other nitroimidazoles92.  These limitations have 
prevented the transition of radiolabelled nitroimidazoles for use as cardiac 
hypoxia imaging agents in the clinic. 
 
1.8 Copper bis (thiosemicarbazone) (Cu-BTSC) complexes 
There is a growing body of experimental evidence demonstrating the hypoxia 
selectivity of Cu-ATSM. 64Cu-ATSM has displayed higher hypoxia sensitivity 
than other Cu-BTSC complexes, including 64Cu-pyruvaldehyde-bis-(N4-
methylthiosemicarbazone) (64Cu-PTSM), in hypoxic Chinese hamster ovary 
cells109 and EMT6 tumour cells110-112.  64Cu-ATSM also displayed significantly 
higher hypoxia selectivity than 18FMISO in EMT6 cells112. 61/64/67Cu-ATSM 
retention in hypoxic regions of tumours in vivo has been demonstrated, whereas 
64Cu-PTSM displayed non-specific tissue distribution112,113. 64Cu retention from 
64Cu-ATSM has also been demonstrated in cardiac myocytes114 and in an ex 
vivo isolated perfused rat heart model during hypoxia but not normoxia114,115. 
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Lewis et al. used three models of hypoxia in dogs to demonstrate the hypoxia 
selectivity of 60/61/64Cu-ATSM in the heart: global hypoxia induced by inhalation 
of hypoxic gas, acute ischaemia by occlusion of the LAD and demand 
ischaemia by LAD stenosis with dobutamine administration to increase heart 
rate116. Significant accumulation of Cu from Cu-ATSM was seen in hypoxic 
regions of all three heart models.  
While 60Cu-ATSM has been approved for the clinical diagnosis of lung tumours 
at Washington University Medical School (St. Louis, US)112 there have been few 
trials investigating the potential of Cu-ATSM for the diagnosis of hypoxic 
myocardium. A preliminary clinical trial in 2001 compared the accumulation of 
18FDG to that of 62Cu from 62Cu-ATSM in seven patients with CAD117. While 
accumulation of 18FDG was detected in five of these patients, 62Cu 
accumulation was only detected in one. It is possible that 62Cu-ATSM is only 
capable of detecting very severe hypoxia, which is inducible (and survivable) in 
acute experimental models, but does not commonly occur in cardiac patients.  
Other analogues of Cu-ATSM are currently being screened, which selectively 
accumulate in myocardium at less severe degrees of hypoxia. 
Although it has been established that Cu-ATSM targets hypoxic tissue, there 
may be other important factors which contribute to Cu-ATSM hypoxia 
selectivity. The importance of such factors on Cu-ATSM hypoxia selectivity is 
still relatively under researched, yet understanding them is crucial for the 




1.8.1 The proposed trapping mechanism of Cu-BTSC complexes 
Figure 1.6 displays a proposed mechanism of the trapping of a hypoxia 
selective Cu-BTSC5.  Cu-BTSC are small, lipophilic complexes and enter the 
cell through passive diffusion across the cell membrane. Intracellularly, the Cu-
BTSC encounters bioreductive molecules (as yet unidentified) which reduce the 
chelated Cu2+ to Cu+, converting the neutral Cu(II)-BTSC species to a charged 
[Cu(I)-BTSC]- species, which is less lipophilic, and therefore less capable of 
diffusion out of the cell118. If the cell is normoxic and has sufficient oxygen, the 
[Cu(I)-BTSC]- species is readily re-oxidised back to Cu(II)-BTSC, which may 
diffuse out of the cell and wash out into the blood stream. If the [Cu(I)-BTSC]- 
encounters a more hypoxic environment, however, the lack of oxygen prevents 
reoxidation to Cu(II)-BTSC. The [Cu(I)-BTSC]- is less stable than Cu(II)-BTSC 
and may dissociate to the BTSC ligand and the copper ion, which becomes 
trapped. It has been suggested that the [Cu(I)-BTSC] complex is prone to 
protonation, forming the Cu(I)-BTSCH complex, before dissociation of copper 
from the ligand119,120. An acidotic environment where protons are more 
abundant may therefore accelerate the dissociation of copper from the ligand118. 
The free copper released by the complex is then chelated by intracellular 




Figure 1.6. Proposed uptake and trapping mechanism of copper from hypoxia selective Cu-




1.8.2 Cu-BTSC redox potential and hypoxia selectivity 
Previous studies have demonstrated a relationship between Cu-BTSC redox 
potential and hypoxia selectivity. Using cyclic voltammetry the Cu(II/I) 
reduction/oxidation (redox) potential for a range of Cu-BTSC with different alkyl 
substitutions were compared to their corresponding hypoxia selectivites110,122. A 
general inverse relationship was established between hypoxia selectivity and 
redox potential, i.e. the ratio of intracellular hypoxic : normoxic radiocopper 
retention  increases as the redox potential decreases110. As the redox potential 
becomes more negative, the complex becomes harder to reduce and is 
therefore more stable. For example Cu-ATSM has a Cu(II/I) redox potential of -
0.59V, whereas Cu-PTSM has a redox potential of -0.51V. Although Cu-PTSM 
and Cu-ATSM are both taken up into normoxic tissue, Cu-PTSM is more easily 
reduced than Cu-ATSM and therefore less stable, such that it dissociates and 
deposits its copper core into tissues even when they are normoxic.  In contrast, 
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Cu-ATSM is stable in normoxic tissue, and only dissociates where there is 
insufficient oxygen to reoxidise it, thereby providing it with hypoxia selectivity. 
 
1.8.3 Tuning Cu-BTSC redox potential 
The redox potential of Cu-BTSC complexes may be altered through chemical 
modification of the ligand109,110,122. The Cu-BTSC family of complexes therefore 
possess a range of hypoxia sensitivities. Alkylation at the R1-R4 positions 
changes the ligand backbone to create a different BTSC species. This renders 
each BTSC more or less hypoxia selective. For example, Cu-ATSM is alkylated 
at the R1-R4 positions and is more hypoxia selective than Cu-PTSM, which is 
alkylated at R1, R3 and R4 positions (figure 1.6). 
The redox potential of each complex is manipulable by the alkylation at the R1 
and R2 positions, which increases the electron donating strength of the 
ligand110,119.  Doing so makes the complex harder to reduce and increases its 
stability, and thus its hypoxia selectivity. This offers an explanation to the 
increased hypoxia selectivity of Cu-ATSM compared with Cu-(PTSM)123.   
Maurer et al., used density functional theory to model Cu-BTSC electron density 
to better understand the chemical reduction of these complexes119. It was 
suggested that double alkylation at the R1 and R2 positions of Cu-ATSM 
protects the complex from electron reduction, such that only the copper ion is 
reduced, generating a [Cu(I)ATSM]- species. The single R1-R2 alkylation of Cu-
PTSM allows the electron reduction of the PTSM complex itself, to generate a 
[Cu(II)-PTSM]- species. Cu(II)-PTSM]- is less readily oxidised compared with 
Cu(I)-[ATSM]-, even under normoxic conditions, meaning that it remains as an 
anion. It is also more prone to protonation, accelerating dissociation and the 
69 
 
release of its radiocopper core, even under normoxic conditions. For this reason 
Cu-PTSM may be utilised as a perfusion tracer as it is trapped in tissue with 
adequate perfusion124.  The [Cu(I)-ATSM]- species is much more stable than 
[Cu(II)- PTSM]- and therefore resides in the cell for longer, increasing the 
likelihood that it may interact with molecular oxygen to become reoxidised. 
When oxygen is eliminated from the environment (i.e. hypoxia) the transiently 
trapped [Cu(I)-ATSM]-  becomes more likely to dissociate. Cu-ATSM is 




Figure 1.7.  Structure of A) general Cu-BTSC, B) Cu-PTSM and C) Cu-ATSM. * N3 and N4 












1.8.4 Potential Cu-BTSC reductants: NADH dependent enzymes 
 Under hypoxic conditions the intracellular NADH/NAD+ ratio is elevated125, 
particularly within the mitochondria, potentially providing a  reducing 
environment capable of contributing to the overall reduction of hypoxia selective 
Cu-BTSC118. Early studies demonstrated that NADH alone was not capable of 
reducing Cu-KTS, even when in vast excess126. Similarly NADH had no effect 
on Cu-PTSM reduction alone, however, when incubated with sub mitochondrial 
brain particles, Cu-PTSM reduction became NADH dependent. This suggests 
that while NADH is not capable of Cu-BTSC reduction alone, it may be an 
essential cofactor127. Further to this, the NADH concentration required for 
mitochondrial Cu-ATSM reduction is higher than that for Cu-PTSM, supporting 
the theoretical NADH sensitivity of Cu-ATSM in hypoxic conditions where NADH 
is elevated. In an attempt to identify whether the BTSC complexes are reduced 
by the ETC, mitochondrial fractions were incubated with 62Cu-PTSM and treated 
with three inhibitors of the ETC: Rotenone which inhibits electron transfer from 
NADH to ETC complex I, TTFA which inhibits transfer from FADH2 to complex 
II, and Antimycin A which blocks electron transfer from ubiquinol to complex III. 
Antimycin A and Rotenone caused increased 62Cu accumulation, whereas 
TTFA had no effect, suggesting that Complex I of the ETC may be a key 
reductant in Cu-BTSC dissociation. Results from similar experiments involving 
rotenone also implicate Complex I as a Cu-ATSM reductant115. These data 
support the suggestion that although NADH alone is incapable of reducing Cu-
ATSM, mitochondrial NADH dependent mechanisms may be responsible for 
Cu-ATSM hypoxia selectivity. It is worth noting, however, that these 
experiments were carried out in isolated brain mitochondria. While this may 
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have implications in utilising Cu-ATSM or Cu-PTSM in brain imaging, these 
results are not necessarily transferable to other hypoxic organs. Subcellular 
fractionation was used to demonstrate that while Cu-ATSM and Cu-PTSM 
reduction in brain tissue is mediated by the mitochondria, reduction occurs 
predominantly in the cytosol in Ehrlich ascites tumour cells and cardiac 
myocytes114,115,127,128. Furthermore, hypoxia increased overall Cu-ATSM 
reduction yet did not alter the ratio of where it was reduced114.  Although these 
studies indicate that copper released from Cu-BTSC complexes accumulates in 
different subcellular locations in different cell types, the mechanism of Cu-BTSC 
reduction cannot be confirmed from these data.   
 
1.8.5 Potential Cu-BTSC reductants: thiols 
Thiol containing molecules have also been implicated as potential Cu-ATSM 
reductants.  The most abundant intracellular thiol is the cysteine containing tri-
peptide GSH, which exists in a mM range of concentrations. Reduced GSH acts 
as an antioxidant through its strong electron donating tendency. In 1972, 
Petering measured a spectrophotometric colour change when Cu-KTS, which 
has a higher hypoxia selectivity than Cu-PTSM, was incubated with GSH 
(monothiol) and dithiolthreitol (dithiol) under anaerobic conditions126. He also 
demonstrated that the reaction rate increased with increasing thiol 
concentration. Furthermore, thiol depletion in Ehrlich ascites tumour cells with 
thiol conjugating agent N-ethylmaleimide and through heat treatment caused a 
decrease in Cu-KTS reduction intracellularly129, suggesting that thiols may be a 
key BTSC reductant. More recently, systemic administration of GSH depletion 
agents buthionine sulphoximine (BSO) and diethyl maleate (DEM) was 
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demonstrated to decrease heart, lung, liver and kidney 67Cu retention  in rats 
injected with 67Cu-PTSM, which supported this assertion; however, actual tissue 
thiol concentrations were not reported in this study, which makes it difficult to 
confirm whether this was indeed the case130. 
Results from a study performed by Xiao et al., implied that Cu-ATSM does not 
react with thiols to become reduced131. Copper chelating proteins Atx1 and Ctrl 
c were incubated with GSH and Cu-ATSM in an anaerobic glovebox. 
Spectrophotometry was used to read the absorbance of each solution to 
determine Cu-ATSM dissociation, which decreases the absorbance at 562 nm. 
As no change in absorbance was observed, results indicated that thiols were 
not capable of reducing Cu-ATSM. However, the amount of Cu-ATSM used in 
these studies was much higher (µM range) than of that in physiological models 
(<fM) to allow a measureable change in UV absorbance, therefore a large 
portion of Cu-ATSM may not have been reduced. It is difficult to extrapolate 
these findings to the clinical conditions where these tracers may be applied, 
where tracer concentrations of Cu-ATSM are greatly exceeded by the presence 
thiols, such as GSH, in mM concentrations. While thiols, and in particular GSH, 
may be responsible for the initial reduction of Cu-BTSC to a charged, unstable 
Cu-BTSC- species, it is unclear whether changes in thiol status have any impact 
on the hypoxia selectivity of the BTSC complexes. 
 
1.8.6 The effect of ROS on Cu-BTSC dissociation 
As the hypoxia selectivity of each Cu-BTSC is determined by its redox potential, 
changes in cellular redox state could affect the reduction of these complexes. 
Few studies have measured the direct effects of a compromised redox state on 
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the reduction of Cu-BTSC complexes.  One study demonstrated the increase of 
Cu retention from Cu-ATSM in neuroblastoma cells pre-treated with the GSH 
depletion agent, BSO132. Although there was evidence of oxidative protein 
damage implicating an increase in ROS generation, GSH levels were not 
measured; therefore the effect of GSH concentration on Cu-ATSM reduction 
cannot be confirmed. These cells were also incubated with a very high 
concentration of BSO (5mM) which may have affected cell viability and Cu 
accumulation. 62Cu retention from 62Cu-ATSM has recently been demonstrated 
in the brains of patients with mitochondrial myopathy, encephalopathy, lactic 
acidosis and  stroke-like episodes133. This syndrome is associated with 
increased ROS generation through mitochondrial dysfunction, however, it is 
unlikely that 62Cu-ATSM was targeting areas of oxidative stress alone (acidosis 
has also been implicated in Cu-ATSM dissociation), and these regions may 
have also been subject to focal hypoxia or ischaemia.   
  
1.8.7 The effect of intracellular pH on Cu-BTSC dissociation 
In addition to reduction, it has been suggested that Cu-BTSC dissociation is 
dependent on protonation119,120. As previously discussed, ischaemic tissue is 
frequently acidotic due to anaerobic glycolysis, loss of ionic homeostasis and 
lack of washout.  It is therefore feasible that hypoxic selective uptake of Cu-
BTSC may be modified by intracellular pH status. UV-vis spectroscopy studies 
demonstrated that the stability of Cu-KTS decreased substantially as pH 
decreased, rendering Cu-KTS more susceptible to dissociation126. Consequent 
studies, however, also demonstrated that as pH decreased, the reaction rate 
between Cu-BTSC and GSH also decreased134. It was concluded, however, 
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that a decrease in pH affected Cu-KTS dissociation more strongly than it did it 
reaction with thiols, meaning that a decrease in pH would favour Cu-KTS 
dissociation despite slowing the reduction process. Further to this, the effect of 
acidosis on the dissociation of Cu-ATSM and Cu-PTSM was explored119 using 
cyclic voltammetry, where it was apparent that Cu-PTSM was less stable in 
more acidic environments than Cu-ATSM. Cu-PTSM became less prone to re-
oxidation, while Cu-ATSM was still readily oxidised with acid present. 
Interestingly, Cu-PTSM required a higher concentration of acid for reduction to 
become irreversible compared to Cu-GTS, which contains no alkyl groups at the 
R1-R2 backbone positions. Computational energy calculations also predicted 
that protonation of the Cu-BTSC complexes would preferentially occur on at 
least one of the N3 or N4 positions of the ligand (figure (b)), which would then 
become less stable and prone to dissociation. Studies have also estimated that 
the pKa of each Cu-BTSC complex has a similar relationship to alkylation at the 
R1 and R2 position as redox potential does i.e. Cu-ATSM has a lower pKa than 
Cu-PTSM, and is therefore more stable under control conditions 135. This 
implies that Cu-BTSC complexes are less stable and vulnerable to dissociation 
in acidotic environments. 
 
1.9 Aims of this project 
The tissue deposition of copper from hypoxia selective Cu-BTSC such as Cu-
ATSM may therefore rely on these key factors: reductants, ROS, oxygen and 
pH. The relative importance of each factor, however, remains unclear. This 
thesis therefore investigates the effects of thiol concentration and acidosis on 
the hypoxia selectivity of Cu-ATSM. As thiols are strong electron donors they 
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therefore increase intracellular antioxidant capacity. In addition to altering the 
reduction rate of Cu-ATSM, thiol concentration may impact ROS generation 
which has also been suggested in Cu-ATSM reduction and hypoxia selectivity. 
To address these questions, an isolated perfused rat heart model and cultured 
bovine aortic endothelial cells (BAEC) were utilised to investigate the effect of 
thiol concentration modification (and therefore altered redox state) and 
intracellular acidosis on the pharmacokinetics and hypoxia selectivity of 64Cu-
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Experiments investigating the possible mechanisms which promote Cu-ATSM 
hypoxia selectivity are detailed in chapters 3-5. Two main biological models 
were employed; an isolated perfused rat heart model and an isolated bovine 
aortic endothelial cell (BAEC) model.  This chapter describes the methods 
employed for each experiment. 
 
2.2 The isolated perfused heart model  
2.2.1 Coronary perfusion in vivo  
Adequate perfusion of the heart itself is crucial in providing essential 
components such as oxygen and energy substrates, but also in removing any 
waste products which accumulate (e.g. CO2, lactic acid). The heart is constantly 
working and needs sufficient blood flow to meet its metabolic needs. An 
extensive coronary vasculature system therefore exists that supplies and 
removes blood to and from the myocardium itself.  
in vivo, the heart pumps blood from the left ventricle through the aorta  and then 
to the systemic vasculature. As the left ventricle fills with blood from the left 
atrium, the pressure increases until it exceeds that of the aorta and the ventricle 
contracts, ejecting blood into the aorta. The decrease in ventricular pressure 
compared to aortic pressure causes the aortic valve to close and prevents the 
blood from re-entering the left ventricle. This pressure also drives blood into the 
coronary ostia located behind the aortic valve, which subsequently enters the 
main coronary arteries, arterioles and capillaries which penetrate the entire 
myocardium. Venules deliver blood from the capillary bed to veins, blood drains 
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into the coronary sinus and then into the right atrium with blood from the 
systemic circulation136.  
 
2.2.2 Langendorff isolated heart perfusion 
The isolated perfused heart is a widely utilised ex vivo model.  The first 
description of this method with mammalian hearts was published by Oskar 
Langendorff in 1895137. The heart is excised from the donor animal, hung on a 
metal cannula via the aorta and perfused in a retrograde manner with a 
physiological salt solution containing excess glucose.  
 
2.2.3 Why use the Langendorff isolated heart perfusion technique? 
There are several advantages and disadvantages to using an isolated perfused 
organ model such as the Langendorff technique. Evidently this ex vivo method 
lacks certain factors which usually affect the heart in vivo, such as 
neurotransmitters, hormones, central and autonomic nervous stimulation. 
Experimental results gained from an isolated perfused heart model therefore 
cannot be directly translated to an in vivo model.  However, as the heart can be 
studied directly without these peripheral influences it permits investigation of 
pharmacological, biochemical and physiological interventions which may 
otherwise be detrimental or even fatal to an animal in vivo 138,139.  
When planning experiments with isolated perfused hearts it is important to 
appreciate that although the heart can be studied for several hours it is 
continuously deteriorating and may deteriorate more rapidly with certain 
80 
 
interventions. It is therefore important to have an appropriate timeline for all 
perfusion protocols.  
Practically the Langendorff technique is a quick, low cost model that yields 
reproducible results in large numbers. Rat hearts are usually preferred over 
smaller species as they are relatively easy to prepare, however, it may be of 
interest to the investigator to use other species to suit their needs. Mouse 
hearts, for example, which are more difficult to prepare and perfuse, allow the 
investigation of genetic modification on cardiac function and biochemistry139. 
Isolated perfused heart protocols typically use crystalloid solutions such as 
Krebs-Henseleit buffer (KHB) to perfuse the heart. It is possible to perfuse the 
heart with blood from a donor animal, however, this preparation is more 
complicated as it requires the two subjects to be closely monitored (the heart 
and the donor animal). Blood perfused preparations also eliminate the 
possibility of introducing pharmacological interventions as the blood is circulated 
back to the donor animal. Perfusing the heart with a crystalloid buffer also has 
its limitations. First, crystalloid buffers have a much lower oxygen carrying 
capacity than blood140. It is therefore necessary to compensate for this by 
increasing the coronary flow rate to approximately 4-5 times that of flow rate in 
vivo. The vast increase in flow gives rise to endothelial stress which can 
compromise the integrity of the vessel walls138. The absence of proteins lowers 
the osmotic pressure of such buffers, which can increase the incidence of tissue 
oedema141. There is also a lack of antioxidants and glucocorticosteroids which 
will contribute to the deterioration of the heart as it becomes more susceptible to 
immune stimuli and free radical damage138. Despite these challenges, buffer 
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perfused hearts are easy and cheap to prepare and remain physiological for 
several hours.  
 
2.2.4 Basic perfusion apparatus 
A schematic diagram of the basic apparatus used in the isolated perfused heart 




Figure 2.1. Schematic diagram of basic Langendorff preparation apparatus.   
 
2.2.5 Krebs-Henseleit buffer 
Throughout the perfusion protocols Krebs-Henseleit buffer (KHB) comprised of 

















(1.16 mM), NaHCO3 (25 mM), Glucose (11.1 mM), CaCl2 (2.2 mM) and EDTA 
(0.48 mM) dissolved in distilled H2O. This composition differs from classic KHB 
composition. For heart perfusion experiments, ETDA was added to chelate free 
heavy metal ions for purposes of 31P NMR spectroscopy (described below). 
EDTA also chelates Ca2+ ions, therefore the CaCl2 concentration described 
above is higher than that of traditional KHB compositions to account for this. 
The KHB composition was also phosphorus-free, again to facilitate of 31P NMR 
spectroscopy studies, which would detect phosphorous in the perfusate and 
potentially obscure measurement of phosphorous metabolites in the heart. KHB 
was modified to pH 7.4 by adding NaOH or HCl and then filtered using a 
custom-made vacuum pump filtration system. 
 
2.2.6 Gas mixtures 
Normoxic KHB was gassed with 95% O2/5% CO2.  Hypoxic KHB was gassed 
with 95% N2/5% CO2 for at least 20 minutes before it was required. In chapter 5, 
an additional perfusion protocol was introduced where hypoxia was induced by 
gassing KHB with a 20% O2 gas mixture(20% O2/75% N2/5% CO2) created by a 
GSM-3 gas mixer (CWE instruments, US). 
 
During preliminary experiments, an OxyLite™ fluorescent oxygen probe 
connected to an Oxylab pO2™ recorder (Oxford Optronix, Oxford, UK) was 
inserted into the arterial perfusion line to measure the oxygenation of the KHB 
before the cannula. Figure 2.2 displays the KHB pO2 after switching to KHB 
gassed with 95% N2/5% CO2. pO2 began to decrease 2 mins after switching to 
anoxic KHB and rapidly decreased from 98.0 ± 10.8 to 8.5 ± 3.1mmHg within 8 
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mins. By 60 mins, KHB pO2 was 0.4 ± 0.1 mmHg. The OxyLite™ and Oxylab 
pO2™ are only sensitive to pO2 of 0-100 mmHg, therefore oxygenation of 




Figure 2.2 pO2 of KHB gassed with 95% N2/5% CO2.Data are expressed as means ± standard 
deviation, n=3. 
 
2.2.7 Temperature, flow rate and pressure measurements 
Glassware was water-jacketed and supplied with water by a heater circulator to 
maintain KHB at 37oC throughout each experiment. Once the perfusion 
apparatus was set up, the temperature of the KHB was measured by placing a 
thermometer into the lumen of the cannula. In these experiments, hearts were 
perfused with a constant flow of KHB which was controlled by a peristaltic pump 
(Gilson, USA). Flow rate was calibrated manually by adjusting the speed of the 
pump and measuring the volume of KHB that eluted from the cannula over 1 
min.  






















Two DTXPlus™ pressure transducers (BD, UK) where connected to a 
PowerLab/4SP data acquisition system and LabChart® version 7.2 software 
was used to measure contractile function parameters (ADInstruments, UK). One 
pressure transducer was placed after the cannula to detect perfusion pressure 
while the other pressure transducer was connected to a fluid-filled balloon which 
was inserted into the left ventricle of the heart to detect heart rate, left 
ventricular developed pressure (LVDP) and left ventricular end diastolic 
pressure (LVEDP). The readings from each pressure transducer were 
calibrated before the experiments using a sphygmomanometer. 
 
2.2.8 Preparation of heart for perfusion 
Adult male Wistar rats (300-350g; Harlan, UK) were anaesthetised with 
pentobarbitone (Pentoject 0.7mL/ kg i.p) and administered heparin (200IU, i.p) 
simultaneously. Once the animal was anaesthetised and did not respond to 
reflex tests, hearts were excised and placed in ice-cold KHB. The heart was 
cannulated according to the Langendorff method and perfused with KHB under 
constant flow (14mL/ min). 
 
2.2.9 Exclusion criteria studies 
Prior to commencing experiments involving heart perfusions, cardiac contractile 
function was measured from 7 hearts to establish the exclusion criteria for each 
parameter (figure 2.3). Measurements of heart rate, perfusion pressure, LVDP 
and LVEDP were taken every 5 mins for 60 mins. Each parameter was within 
20% of the 1st value measured at t=0 mins. Heart rate increased from 268.5 ± 
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33.8 to 277.5 ± 29.1 beats per minute (b.p.m.) after 60 mins perfusion. 
Perfusion pressure also increased from 75.6 ± 10.8 to 86.5 ± 28.8 mmHg 
whereas LVDP decreased from 135.8 ± 31.5 to 113.5 ± 26.8 by the end of 
perfusion. LVEDP was set at 5.9 ± 1.1 and increased to 7.4 ± 2.5 mm Hg by the 
end of perfusion. Hearts in subsequent studies underwent a 10 mins 
stabilisation period of 10 mins. During this period it was decided from the criteria 
outlined in figure 2.3 if the hearts were healthy enough for continued use in the 
study.  
 
Figure 2.3. Exclusion criteria established from isolated perfused rat hearts. Data are expressed 
as means ± standard deviation (n=7). 
2.2.10 Perfusate analysis for lactate, glucose and protein content 
2.2.10.1 Lactate and glucose analysis  
Perfusate samples were collected directly from the heart at appropriate time 
points when the perfusion protocol changed. Aliquots were kept on ice and 
stored at -20oC. Perfusates were later defrosted and analysed for lactate and 

















































































glucose content using a 2300 STAT Plus™ glucose and lactate analyser (YSI 
UK Ltd, UK). The glucose and lactate analyser uses membranes containing 
lactate oxidase and glucose oxidase which react with lactate and glucose to 
produce H2O2. H2O2 is oxidised at a platinum anode to produce protons, oxygen 
and electrons. The electron flow is proportional to the concentration of lactate or 
glucose present in the sample measured142.  
 
2.2.10.2 Protein and creatine kinase (CK) analysis 
In addition to contractile function measurements, heart viability was determined 
by analysing the perfusate samples for protein content. Myocardial injury 
increases the release of proteins such as CK into the blood/perfusate. CK 
measurement assays require several steps and are time consuming and prone 
to error. Here, the CK assay was compared to the bicinchoninic acid (BCA) 
protein assay and the differences in viability measurements were assessed.  
Hearts were perfused according to the Langendorff method as described above 
and were subject to 16 minutes of zero flow ischaemia followed by a reperfusion 
period of 35 mins in which perfusate samples were collected from the heart. 
Samples were then compared to perfusates collected from normoxic control 
hearts for CK and protein content. Perfusate samples of 10 µL  were pipetted 
into two 96 well microtitre plates in duplicate; one plate was analysed for CK 






2.2.10.2.1 CK assay 
CK catalyses the conversion of phosphocreatine (PCr) and ADP to creatine and 
ATP. PCr and ADP are added to the perfusate samples, hence increases in CK 
produces more ATP. Hexokinase is added to catalyse the reaction of ATP and 
glucose to form glucose-6-phosphate, which in turn is oxidised by glucose-6-
phosphate dehydrogenase to thio-NADH. The conversion of glucose 6-
phosphate to thio-NAD results in a measureable change in absorbance at 405 
nm which can be measured using a spectrophotometer143.  
Table 2.1 lists the reagents used in the CK assay. All the reagents for the CK 
assay were dissolved in 0.1 mM glycylglycine (pH 6.75).  Purified rabbit muscle 
CK was purchased from Boehringer-Mannheim, Switzerland. All other reagents 
were purchased from Sigma-Aldrich, UK. Fresh dithiothreitol and thiol-NAD 
were weighed out each day and thiol-NAD solutions were made separately and 
protected from light until the time of the assay. In addition to perfusate samples, 
a series of CK dilutions of known concentration were pipetted (10 µL) into each 
microtitre plate to construct a standard concentration curve. 200 µL of the 
reagent mixture was added to each well immediately before reading the optical 
absorbance at 405 nm using a spectrophotometer plate reader (SpectraMax 
190, Molecular Devices). The absorbance reading was repeated every minute 







Table 2.1. List of reagents required for the CK assay. 
Reagent Concentration 
  PCr 20 mM 
Glucose 20 mM 
Magnesium acetate 10 mM 
ADP 1 mM 
AMP 10 mM 
Thio-NAD 0.4 mM 
Dithiothreitol 10 mM 
Hexokinase 0.5 U/mL 
Glucose-6-phosphate dehydrogenase 1 U/ mL 
     
2.2.10.2.2 BCA assay 
BCA assay kits were obtained from Fisher Scientific, UK. The BCA assay 
requires two pre-made solutions containing Cu2+ and BCA. In the biuret 
reaction, peptide bonds reduce Cu2+ to Cu+ which produces a colour change 
from green to blue144. BCA ions chelate Cu+ ions, producing a colour change 
from blue to purple which is measureable by spectrophotometry at 562 nm and 
is directly proportional to the amount of protein present. The Cu2+ and BCA 
solution were mixed to give a concentration ratio of 1:50 respectively. In 
addition to perfusate samples, a series of bovine serum albumin solutions of 
known concentration were pipetted (10 µL) into each microtitre plate to 
construct a standard concentration curve. BCA/Cu2+ mixture (200µL) was then 
pipetted into each well and plates were left to incubate at room temperature for 
25 mins before reading the optical absorbance at 562 nm using a 





2.2.10.2.3 Comparison of CK and BCA assays for cardiac viability 
Figure 2.4 displays standard concentration calibration curves obtained using the 
CK and BCA assays. In all cases, CK activity and protein concentration were 
directly proportional to the colourimetric changes measured at 405 nm or 652 
nm respectively. Figure 2.5 displays the CK activity and protein concentrations 
of perfusates from ischaemic and control hearts.  To display the results more 
clearly, only the readings from the 5 min time point are displayed from the CK 
assay. There was a clear increase in CK activity and protein concentration from 
ischaemic/reperfused hearts compared to control hearts. These results confirm 
that either assay can be used to measure cardiac viability, it was therefore 
decided to use the BCA assay to detect cardiac protein release as a measure of 
viability in all heart perfusion studies.  
 
Figure 2.4. Calibration of standard solutions of (A) CK and (B) protein plotted against 
absorbance. Data are expressed as means ± standard deviation (n = 3). 


























































Figure 2.5. Perfusate (A) CK activity and (B) protein content from ischaemia reperfused hearts 
and time-matched controls. Data are expressed as means ± standard deviation (n = 3 per 
group). 
2.3 Isolated bovine aortic endothelial cells 
Vascular endothelial cells have important roles in cardiovascular homeostasis. 
The dysfunctional endothelium has been implicated in multiple cardiovascular 
pathologies including atherosclerosis, hypertension and heart failure. 
Endothelial dysfunction has also been associated with hypoxia. Bovine aortic 
endothelial cells (BAEC) was therefore used in addition to isolated perfused rat 
hearts to investigate the hypoxia selectivity of 64Cu-ATSM in BAEC under 
various conditions. 
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2.3.1 Culture of BAEC 
BAEC were isolated from bovine thoracic aortas obtained from a local abattoir. 
Briefly, aortas were coated in collagenase for 5 mins and gently scraped with a 
scalpel to isolate the endothelial monolayer from the rest of the aorta. Isolated 
BAEC were cultured in DMEM supplemented with 10% fetal calf serum (FCS), 
penicillin (100 IU/ mL), streptomycin (100 IU/ mL) and L-glutamine (2mM). 
Primary cultures of BAEC were grown in 25cm2 gelatin coated flasks. Flasks 
were incubated at 37oC and 21% O2/5% CO2 until confluent.  
Like all endothelial cell in culture, BAEC grow in a strongly contact-inhibited 
monolayer and have similar morphological characteristics of the endothelium in 
vivo145. The BAEC phenotype is often described as having a cobblestone 
appearance once confluent (figure 2.6). BAEC confluence was therefore 
confirmed by this phenotype. 
 






1 mL of trypsin (Sigma-Aldrich, UK) was added to 25cm2 flasks of confluent 
BAEC to break down protein-protein interactions between cells and the gelatin 
on the flask.  The trypsin was diluted in ethylenediaminetetraacetic acid (EDTA) 
which chelates metal ions, such as Ca2+ which may inhibit trypsin activity. To 
prevent cell damage, DMEM was added to the flask immediately at an 
appropriate volume as to split the culture into subsequent flasks.  The BAEC 
culture was then split into 75cm2 gelatin coated flasks and incubated as before.  
 
2.3.2 MTT viability assay 
To assess BAEC viability, the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) assay was used. MTT is a water soluble salt which 
has a yellow colour when in solution. MTT is readily taken up into cells and 
reduced by NADH/ NADPH dependent enzymes in viable, metabolically active 
cells146. The reduction of MTT forms 1-(4,5-dimethylthiazol-2-yl)-3,5-
diphenylformazan (MTT formazan), an insoluble purple crystalline solid which 
accumulates in cells which can be dissolved using organic solvents. The 
reduction of MTT to MTT formazan crystals produces a colour change which 
can be measured spectrophotometrically at 570 nm to give an index of viability.   
In these studies, BAEC were seeded into 96 well plates and cultured as before. 
Once confluent, the medium was aspirated from each well and MTT (0.5 mg/ 
mL) was added (100 µL per well) for 4 hrs. The MTT was then aspirated and 50 
µL DMSO was added per well. Plates were placed on a shaker for 10 mins 
before reading the optical absorbance at 570 nm using a spectrophotometer 
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plate reader (SpectraMax 190, Molecular Devices). The results were plotted as 
Abs 570 nm vs. treatment group.  
2.4 Thiol measurement assays 
2.4.1 Thiol concentration modification 
In chapters 3 and 4, agents which pharmacologically modify thiol concentration 
were used: diethyl maleate (DEM), buthionine sulphoximine (BSO) and N-
acetylcysteine (NAC). DEM conjugates GSH in the presence of GSH-S-
transferases and therefore depletes intracellular GSH pools147. BSO inhibits γ-
glutamylcysteine synthetase which prevents GSH synthesis, thereby also 
depleting GSH concentration148. NAC is a cysteine derivative which contributes 
to the intracellular thiol pool and GSH synthesis149. NAC also directly 
replenishes GSH non-enzymatically by direct thiol exchange with GSSG.   
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2.4.2 The DTNB assay 
The results described in chapters 3 and 4 relied on accurate measurements of 
intracellular thiol concentration. First described by Ellman in 1959, 5,5’-dithiobis-
(2-nitrobenzoic acid) (DTNB) or otherwise known as Ellman’s reagent is the 
most widely used chemical for detection of thiol content150. Reduced thiols react 
with DTNB to cleave the disulphide bond and generate 2-nitro-5-thiobenzoate 
(NTB-). In water, NTB- becomes an NTB2- ion which is yellow in colour. The 
change in colour associated with DTNB conversion to NTB2- is therefore directly 
proportionally to thiol concentration.  
To measure thiol content with the DTNB assay, 150 µL DTNB (Sigma-Aldrich, 
UK) was added to samples pipetted into clear microtitre plate. The plate was 
incubated for 5 mins before 50 µL of NADPH solution was added to each well 
and mixed with a pipette. A spectrophotometer plate reader was then used to 
measure the absorbance of each well at 412 nm.  
2.4.3 The OPA assay 
An alternative method to measuring thiol content is by reaction with o-
phthalaldehyde (OPA). OPA is a dialdehyde which reacts with thiols and 
primary amines to form a fluorophore. The OPA assay is therefore considered 
more specific for measuring GSH, which contains both amines and thiols than 
the DTNB assay151. As OPA reacts with primary amines, protein concentration 
could affect measurement of thiol concentration. In these experiments, 
however, cellular thiol content was corrected for protein to avoid this. 
OPA was purchased from Sigma-Aldrich, UK. OPA is light sensitive; therefore 
precautions were taken to limit exposure to light throughout protocols. OPA was 
dissolved in methanol (10 mg/mL) in a foil covered tube. 150 µL 
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phosphate/ETDA buffer (pH 8.0) was added to samples in a black opaque plate 
before adding 15 µL OPA solution to each well. Plates were then covered in foil 
and placed in a dark room for 25 mins. A microtitre plate reader was used to 
measure the fluorescence at 350nm excitation and 420nm emission 
(Chameleon V, Hidex, Finland).  
 
2.3.4 Comparison of the DTNB and OPA assays 
Prior to commencing the experiments in chapters 3 and 4, the DTNB and OPA 
assays were both used to measure the concentration of thiols extracted from 
BAEC with modified thiol concentration and the results were compared. BAEC 
were cultured as described above and seeded into 24 well plates. When 
confluent the medium was replaced with medium containing BSO (10, 25 and 
100 µM) for 24 hrs or left untreated. After each treatment period, the medium 
was aspirated and wells were washed twice with ice-cold phosphate buffered 
saline (PBS; 10 mM, pH 7.4). ice-cold trichloroacetate (TCA) (6.5%; 100µL) was 
added to each well for 10 mins on ice, aspirated and stored at -70oC. 100 µL 
NaOH (1M) was added to each well for 2 hrs before aspirating and storing at -
20oC.  
10 µL of each TCA extract was pipetted into the well of a clear and a black 
opaque microtitre plate. In addition to TCA extracts, a series of GSH (Sigma-
Aldrich, UK) solutions of known concentration were pipetted (10 µL) into each 
microtitre plate to construct a standard concentration curve. The DTNB and 
OPA assays were then carried out on the clear and black plates respectively.  
Figure 2.7 displays the standard calibration curves constructed from samples of 
GSH of known concentration. The standard calibration graph obtained using the 
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DTNB assay (A) was sigmoidal. In Ellman’s original paper, only the linear part 
of the curve was used to calculate sample thiol concentrations. It is therefore 
possible that some thiol concentrations outside of this range are not accurately 
detected by this assay. The standard calibration curve obtained from the OPA 
assay, however, was linear from 0-0.5 nmol GSH. 
 
Figure 2.7. Standard GSH calibration curves from (A) DTNB and (B) OPA assays. Data is 
expressed as means ± standard deviation (n=3 per group). 
 
Figure 2.8 shows thiol concentrations obtained from the same TCA extracts of 
BAEC incubated with BSO. As expected, BSO decreased intracellular thiol 






















































concentrations in a dose-dependent manner. Decrease in thiol concentration 
appeared less marked from DTNB analysis compared with OPA analysis. This 
may be attributed to inaccurate extrapolation from the DTNB standard 
calibration curve, leading to an underestimation of the amount of thiol in a 
sample. It is also worth noting that the OPA assay detects thiol concentration in 
the presence of amines and it is therefore possible that it is more sensitive to 
changes in GSH content rather than general thiol concentration. As BSO 
treatment decreases GSH concentration rather than general thiol concentration, 
the OPA assay may be a more appropriate method for detecting changes in 
thiol concentration where GSH concentration is manipulated. The OPA assay 
was therefore used to measure the thiol concentration of TCA extracts from 
isolated perfused rat heart tissue in chapter 3 and BAEC in chapter 4.  
 
 
Figure 2.8. Thiol content of TCA extracts from BSO treated BAEC. Thiol concentration was 
determined using the DTNB and OPA assays. Data are expressed as means ±  standard 























































2.5 31P NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a non-invasive modality 
which can be used to study tissue metabolism. As described in 1.5.2.1, some 
atomic nuclei possess a spin which makes them act like a magnetic dipole.  
When a large, static magnetic field is applied, the axes of these nuclei align 
either in line with the magnetic field (low energy state) or antiparallel to this field 
(high energy state). An oscillating frequency is applied which perturbs 
magnetisation followed by a recovery period in which initial equilibrium is 
restored, hence the term nuclear magnetic resonance. The most abundant 
phosphorous atomic nucleus is 31P which, like the 1H nucleus, possesses spin 
which makes it act like a magnetic dipole.  31P nuclei exist in different chemical 
environments which give rise to different resonances. The main resonances 
detectable by 31P NMR spectroscopy are from phosphocreatine (PCr), inorganic 
phosphate (Pi) and adenosine triphosphate (ATP), meaning that this technique 
can be used to assess phosphorus metabolism and tissue energetic status in 
living systems95. Furthermore, the frequency of the Pi signal is highly sensitive 
to changes in pH. 31P NMR spectroscopy was therefore utilised to determine 
intracellular pH in isolated perfused hearts undergoing protocols to induce 
acidosis (chapter 5).  
Isolated rat hearts were perfused within the bore of a 15 mm 31P/1H birdcage 
coil which was inserted into a Bruker 9.4T Avance III NMR spectrometer. 
Shimming was optimised on the line shape of the water signal in each heart. 
The imaging gradients of the magnet were warmed to maintain the bore of the 
spectrometer at 37oC. 31P spectra were acquired with a pulse-acquire sequence 
with a 60o flip angle, repetition time of 3.8 sec and 64 scans to give a total 
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experiment time of 4 mins per spectrum. 31P NMR spectra were acquired 
sequentially in a time-resolved fashion under all interventions.  
The resonance of the phosphocreatine (PCr) peak was set to 0 parts per million 
(ppm) and the resonance of the inorganic phosphate (Pi) was referenced to that 
of PCr in each spectrum. The difference in resonance between the PCr and Pi 
peak was used to calculate pHi using equation 5.1, where δPi represents the 
difference in PCr and Pi peak resonance
152. 
pHi = 6.72 + log(δPi -3.17)/ (5.72 - δPi) 
Equation 2.1. Measurement of pHi using δPi acquired from 
31
P NMR spectra 
The area under the PCr peak was set to 1 from the first spectrum from each 
heart and the areas under the PCr peaks from subsequent spectra and Pi, γ 




Figure 2.9. Example 
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2.6 Protocols for investigating 64Cu -ATSM hypoxia selectivity 
2.6.1 64Cu production 
64Cu was provided by Dr K Shaw or Dr R Paul and was produced in the PET 
imaging centre, St. Thomas’ Hospital, London, UK153. 64Cu was produced by the 
64Ni(p,n)64Cu reaction using a CTI RDS 122 cyclotron with an 11MeV proton 
beam with a gold target plated with 64Ni. HCl (9M) was used to dissolve 64Cu 
from the target, which was transferred to an AG1-8X anion exchange column 
(Bio-Rad, UK) made in 9M HCl for purification. Unreacted 64Ni was eluted from 
the column using 9M HCl. Subsequent elutions using 6M HCl removed any co-
impurities before eluting 64Cu in 0.1M HCl to give a stock solution of 64CuCl2. 
The amount of radioactivity was measured using a dose calibrator (CRC-25R 
Capintec, USA).  
 
2.6.2 Radiolabeling ATSM with 64Cu  
ATSM was provided by Prof. P Blower (Imaging Sciences and Biomedical 
Engineering department, King’s College London) and dissolved in DMSO (1 mg/ 
mL).  10 µL of the ATSM solution was added to 50-100 MBq 64CuCl2 which was 
then diluted into 2 mL of water. The solution was agitated gently and left at 
room temperature for 20 min. A SEP-PAK® C18 Classic cartridge (Waters, 
Hertfordshire, UK) was used to filter the labelled 64Cu-ATSM. 1 mL ethanol was 
passed through the cartridge 0.5 mL at a time; the 1st fraction was discarded 
and 64Cu-ATSM was eluted in the 2nd fraction. 64Cu-ATSM radioactivity was 
then measured using a radioisotope calibrator (CRC-25R Capintec, USA). 2µL 
64Cu-ATSM was pipetted onto a Silica Gel 60 F254 STRIP (Merck, Germany) and 
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ATSM labelling efficiency was assessed by radio-TLC (Cu-ATSM has a 
retention factor of 0.79), using 100% ethanol as the mobile phase. For isolated 
perfused heart studies, the ethanol 64Cu-ATSM stock solution was diluted with 
KHB to 20 MBq/ mL. For isolated BAEC studies, 64Cu-ATSM was diluted in 
Dulbecco’s modified Eagle’s medium (DMEM) to 1 kBq / mL. Final ethanol 
concentrations were 10% or less.  
 
2.6.3 Measurement of 64Cu from 64Cu-ATSM in isolated perfused rat hearts 
To measure cardiac 64Cu retention in isolated perfused rat hearts, a custom-
made triple γ-detector system (figure 2.10). Three Na/ I γ- radiation detectors 
(Raytest Isotopenmessgeräte GmbH, Germany) were directed at the input 
perfusion line (detector 1), the heart (detector 2) and the output perfusion line 
(detector 3). Lead collimators were placed around each detector to prevent 
shine-through. All three detectors were connected to a Gina Star™ data 
acquisition system (Raytest Isotopenmessgeräte GmbH, Germany) and data 





Figure 2.10. The triple γ-detector system for measurement of 
64
Cu retention in isolated perfused 
rat hearts. 
 
2.6.4 Time activity curve retention and clearance rate analysis 
Figure 2.11 displays an example of the time activity curve data obtained from 
the Gina Star™ system. Time activity data were used to determine 64Cu 
retention from 64Cu-ATSM injections and the pharmacokinetics of each 
injection. 64Cu retention was calculated at appropriate time points immediately 
before a change in perfusion protocol (i.e. switching to hypoxic buffer, infusing 
drugs, subsequent 64Cu-ATSM injections or the end of experiment; individual 
perfusion protocols and 64Cu-ATSM injection times are detailed in chapters 3 
and 5).  64Cu retention was calculated as a percentage of the maximum injected 
activity before the next injection and corrected for background radioactivity from 








Pharmacokinetic analysis of time activity curve data was performed using 
MATLAB® (version 7.11.0 MathWorks®, US) and fitted with a bi-exponential 
function (equation 2.3). 
f(t) = ae-bt + ce-dt    
Equation 2.2. Bi-exponential function fitted to all time activity curve data. 
 
b and d represent the slow and fast clearance rate constants (SCR and FCR) 
and a and c are the amplitudes assigned to these constants respectively. 
2.6.5 64Cu retention in BAEC incubated with 64Cu-ATSM 
The experimental protocols for BAEC incubation with 64Cu-ATSM are described 
in more detail in chapter 4. Before executing these experiments, readings from 
the gamma counter were calibrated against stock solutions of 64CuCl2
 and 




2.6.5.1 Gamma counter calibration 
Stock 64CuCl2 was diluted to produce a series of known concentrations which 
were counted using a 1282 Compugamma gamma counter (LKB Wallac, 
Australia). The results were plotted on a graph (figure 2.12) and its equation 
was used to determine 64Cu content in cell supernatants in subsequent 
experiments.    
 
Figure  2.12 Gamma counter linearity. Decay (CPS) was plotted against the radioactivity (0-
37MBq) of 
64
CuCl2 aliquots. Data are expressed as means ± standard deviation, n=3. 
 
2.6.5.2 Incubation time optimisation of 64Cu-ATSM 
BAEC were cultured as described in chapter 4. Confluent BAEC were incubated 
with 1kBq 64Cu-ATSM diluted in serum free DMEM to 1 kBq/ mL. 64Cu-ATSM 
and DMEM were removed every 15 mins for 120 mins. Cells were lysed with 
trypsin/ETDA immediately and aliquoted into tubes for counting. At the end of 
each experiment, all cell supernatants were counted for 64Cu in the gamma 
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counter and 64Cu content was determined according to figure 2.12. Supernatant 
protein concentration was determined using the BCA assay and 64Cu BAEC 
retention was corrected for protein. Figure 2.13 displays the results from this 
incubation time optimisation study. BAEC retention of 64Cu from 64Cu-ATSM 
increased steadily over the first 60 mins and plateaued at 60 mins (3.1 ± 1.3 
kBq/ mg protein). It was therefore decided that BAEC would be incubated with 
64Cu-ATSM for 60 mins in subsequent experiments. 
 
 
Figure 2.13  
64
Cu retention in BAEC incubated with 
64
Cu-ATSM over time (0-120 minutes). Data 
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Intracellular thiols (in particular GSH) have been suggested to be key 
reductants of Cu-BTSCs118. To date, however, there is no evidence for the 
direct effect of tissue thiol or GSH concentrations on the hypoxia selectivity of 
Cu-ATSM5. This is the first of two chapters describing the investigations into the 
effects of intracellular thiol concentration, through GSH level modification, on 
Cu-ATSM hypoxia selectivity in the cardiovascular system. 
 
3.1.1 GSH changes during myocardial hypoxia and ischaemia 
GSH is the most abundant intracellular thiol-containing molecule with a 
concentration of 0.5-10mM in mammalian cells154. It contains a cysteine residue 
which can non-enzymatically donate electrons to oxidising species such as free 
radicals and ROS, becoming oxidised itself and dimerising to glutathione 
disulphide (GSSG). Glutathione peroxidase uses GSH as an electron donor in 
the reduction and detoxification of intracellular peroxides. GSH is also able to 
directly reduce and repair oxidised thiols in cell proteins and membranes which 
would otherwise compromise cell function155.  GSSG is then readily recycled to 
GSH by glutathione reductase, using the oxidation of NADPH. Changes in 
intracellular redox status are reflected in the oxidation/reduction of GSH/GSSG 
and are often measured as the ratio of GSH:GSSG, which is usually greater 
than 10:1 in healthy tissue. 
A decrease in cardiac GSH:GSSG ratio by approximately 30% was observed in 
isolated perfused mouse hearts subject to 15 mins ischaemia and 30 mins 
reperfusion156. The decrease in GSH:GSSG reported suggests the generation 
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of ROS upon reperfusion. In isolated perfused rat hearts cytosolic GSH 
concentration decreased by 40% in the first 5 mins of reperfusion and it did not 
decline further during the following 25 mins of reperfusion, further suggesting 
that GSH depletion is mediated by the burst of ROS generation immediately 
upon reperfusion of ischaemic myocardium157. GSH synthesis is a two-step 
process which requires ATP-dependent enzymes γ-glutamylcysteine synthetase 
and GSH synthetase155. Thus, depletion of ATP during ischaemia further 
prevents GSH replenishment. Augmentation of intracellular GSH levels using 
the prodrug N-acetylcysteine (NAC) has been demonstrated to protect isolated 
perfused rabbit hearts from ischaemia-reperfusion injury158, and decrease 
oxidative stress and improve post-surgical outcome in patients with CAD159. 
GSH is evidently a key protectant of the myocardium against oxidative stress. 
Myocardial hypoxia in the absence of ischaemia does not cause depletion of 
GSH157; similar tissue GSH concentrations have been reported in normoxic and 
hypoxic isolated hearts157,160. Hypoxia caused a decrease in GSH concentration 
and GSH:GSSG ratios in isolated hearts perfused with glucose free buffer, 
demonstrating the dependence of GSH regeneration upon glycolysis161,162.  
In summary, cardiac GSH levels are sensitive to both redox status and energy 
metabolism. Whilst cardiac GSH levels are maintained during hypoxia, ROS 
generation and downregulation of energy metabolism decrease intracellular 
GSH pools. Cardiac hypoxia coupled with ischaemia may also increase GSH 
pools. GSH status may therefore vary from heart to heart depending on the 
relative contributions of oxygen deficiency and impaired energy metabolism. As 
GSH represents the largest intracellular pool of reducing equivalents, and the 
first stage of Cu-ATSM trapping is reduction, it is essential (to understand the 
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mechanism of trapping) to determine whether intracellular thiol content (and 
changes in GSH concentration) play any part in the hypoxia-dependent tissue 
retention of Cu-ATSM. 
3.1.2 Experimental approach 
In this study, two well established agents which pharmacologically modify 
intracellular thiol concentration were used: buthionine sulphoximine (BSO) and 
N-acetylcysteine (NAC) to determine the effect of intracellular thiol status on 
64Cu-ATSM hypoxia selectivity and pharmacokinetics in isolated perfused rat 
hearts. BSO prevents GSH synthesis by inhibiting γ-glutamylcysteine 
synthetase 148, while NAC is a cysteine derivative which contributes to the 
intracellular thiol pool and GSH synthesis149. NAC also directly replenishes GSH 













3.2 Materials and methods 
3.2.1 Chemicals and reagents 
BSO (DL-buthionine (S,R)-sulfoximine 99%), trichloroacetic acid (TCA) and the 
bicinchoninic acid (BCA) assay kit were obtained from Fisher Scientific, UK. 
NAC (N-acetyl-L-cysteine 99%) and O-phthalaldehyde (OPA) were both 
obtained from Sigma-Aldrich, UK.  64Cu-ATSM was synthesised and labelled as 
described in chapter 2. 
 
3.2.2 Animals 
Male Wistar (275-350g) rats were used throughout. Rats were given ad libitum 
access to food and water. All experimental procedures were carried out in 
accordance with Home Office regulations as detailed in the Home Office 
Guidance on the Operation of Animals (Scientific Procedures) Act 1986. 
 
3.2.3 Thiol concentration modification protocols 
Rats were randomly assigned to treatment groups. Cardiac thiol levels were 
depleted by pre-treating rats bi-daily for two days with intraperitoneal (i.p) 
injections of BSO dissolved in 0.9% NaCl (total dose 4 mmol/ kg body weight). 
Hearts were excised and Langendorff-perfused 24 hrs after the final dose. 
Cardiac GSH levels were augmented by supplementing KHB with NAC (4 






3.2.4 Perfusion protocols 
Hearts were excised and perfused with KHB as described in chapter 2. All 
hearts were perfused with normoxic KHB for a stabilisation period of 10 min to 
ensure cardiac contractile function criteria were met before continuing the 
experiment. Hearts were perfused according to the protocols described in figure 
3.1. Three boluses of 64Cu-ATSM (2MBq) were injected into the perfusion line at 
t=10 mins, t=30 mins and t=45 mins. Samples of perfusate (approximately 1.5 
mL) were collected directly from the heart at t=25, 26, 27, 28, 29, 30, 35, 40, 50 
and 60 mins.  
 
Figure 3.1. Perfusion protocols for hearts from all treatment groups. (A) normoxic control or 
normoxic thiol depleted (pre-treated with BSO), (B) normoxic thiol augmented, (C) hypoxic 
control or hypoxic thiol depleted and (D) hypoxic thiol augmented groups. 
 
3.2.5 Thiol concentration analysis 
At the end of each perfusion protocol, hearts were snap frozen in liquid nitrogen 
and stored at -70oC. They were subsequently ground into a fine powder under 
liquid nitrogen using a steel pestle and mortar. 0.5g of powder was weighed into 
A Stabilisation Normoxic KHB
B
C
Stabilisation Normoxic KHB + NAC
D
Stabilisation Hypoxic KHB
Stabilisation Hypoxic KHB + NAC








centrifuge tubes and 2.5 mL ice-cold 6.5% TCA was added.  Samples were 
then incubated for 20 mins on ice. Tubes were then centrifuged for 10 mins at 
10,000 rpm at 4oC. The TCA supernatant was aspirated and 0.25mL NaOH (1 
mM) was added to the cell pellet. TCA supernatants were analysed for thiol 
content using the OPA fluorescence assay and NaOH samples were analysed 
for protein content using the BCA assay kit, both described in chapter 2. 
  
3.2.6 64Cu-ATSM pharmacokinetic analysis 
Cardiac 64Cu-ATSM activity was detected utilising the custom built triple 
detector system. Time activity curve data were analysed with Microsoft Excel 
and MATLAB® to provide radiocopper retention and pharmacokinetic 
measurements, as described in chapter 2. 
 
3.2.7 Statistical analysis 
All data are presented as the mean ± standard deviation. Statistical significance 










3.3.1 Cardiac thiol concentration  
Normoxic control hearts contained an average thiol concentration of 7.9 ± 2.0 
nmol/ mg (figure 3.2). Perfusion with hypoxic buffer had no effect on thiol 
concentration (8.0 ± 1.7 nmol/ mg protein). Consistent with the preliminary data, 
pre-treatment with BSO significantly (p<0.05) decreased thiol concentrations 
(3.7 ± 1.0 nmol/ mg protein), which remained unaffected by hypoxia (3.3 ± 0.6 
nmol/ mg protein). Perfusion with NAC significantly (p<0.05) increased cardiac 
thiol concentrations in normoxic (59.3 ± 8.3 nmol/ mg protein) hearts, which was 
not affected by perfusion with hypoxic buffer (67.1± 13.9 nmol/ mg protein). 
 
 
Figure 3.2. Effect of (A) BSO pre-treatment and (B) NAC perfusion on myocardial thiol (SH) 
concentration.  Data are expressed as means ± standard deviation (n=5 per group). *p<0.05 vs. 
untreated controls. 
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Functional parameters were measured throughout each experiment to assess 
the effect of thiol modification and hypoxia on the heart. Heart rate, coronary 
perfusion pressure, left ventricular developed pressure (LVDP) and left 
ventricular end diastolic pressure (LVEDP) were measured in real time, while 
cardiac lactate and protein release into the coronary effluent was analysed after 
the experiment.  
 
3.3.2.1 Heart rate 
Hearts rates from all experiments are displayed in figure 3.3. Heart rates of 
normoxic untreated controls remained stable (altering less than 10%) until the 
end of perfusion (269.0 ± 17.3 to 259.3 ± 28.8 b.p.m. after 60 mins). Hypoxia 
caused heart rates to decrease from 264.1 ± 22.7 to 232.0 ± 24.3 b.p.m. within 
5 mins of switching to hypoxic KHB and continued to decline until the end of 
perfusion (170±49.8 b.p.m.). Thiol depletion did not affect heart rate during 
normoxia (271.7 ± 33.5 to 252.0 ± 35.6 b.p.m. after 60 mins). Thiol depletion 
had no further effect on heart rate during hypoxia which decreased from 288.3 ± 
16.0 to 201.4 ± 58.4 b.p.m. by the end of perfusion. Thiol augmentation also did 
not affect heart rates during normoxia (283.7 ± 12.8 to 268.3 ± 30.7 b.p.m.) or 




Figure. 3.3. Heart rate (mmHg) of normoxic control (top left), hypoxic control (top right), 
normoxic thiol depleted (centre left), hypoxic thiol depleted (centre, right) normoxic thiol 
augmented (bottom left) and hypoxic thiol augmented (bottom right) hearts.. Data are expressed 
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3.3.2.2  Coronary Perfusion Pressure 
Figure 3.4 displays the coronary perfusion pressures of hearts from all 
protocols. Perfusion pressure was maintained in normoxic control hearts 
throughout each experiment (69.5 ± 9.2 mmHg to 71.5 ± 5.5 mmHg). Perfusion 
with hypoxic buffer caused a steady increase in perfusion pressure and was 
37% higher by the end of perfusion (67.7 ± 12.6 mmHg to 92.9 ± 20.9 mmHg). 
The average perfusion pressure of thiol depleted hearts was 16.7% higher than 
that of control hearts at the beginning of the perfusion protocol (79 ± 24.5 
mmHg vs. 67.7 ± 12.6 mmHg control). Thiol depletion also caused a 38% 
increase in perfusion pressure after 60 mins perfusion with normoxic buffer 
(77.3 ± 19.8 mmHg to 107.0 ± 31.7 mmHg) and a 30% increase under hypoxic 
conditions (80.7 ± 29.3 mmHg to 105.1 ± 34.9 mmHg). Perfusion with buffer 
containing NAC also increased perfusion pressure by 17% during normoxic 
perfusion (70.5 ± 12.7 mmHg to 83.9 ± 21.9 mmHg) and 18% during hypoxic 










Figure 3.4. Coronary perfusion pressure (mmHg) of hearts as described in figure 3.3. Data are 
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3.3.2.3 Left ventricular developed pressure (LVDP) 
During the normoxic control period, all hearts maintained a LVDP above 
110mmHg with the exception of thiol depleted hearts, where LVDP was below 
110mmHg for the first 25 mins of perfusion (figure 3.5).  In normoxic control 
experiments, end LVDP was 10% less than the original starting value, 
consistent with the previously established exclusion criteria (122.9 ± 34.9 
mmHg to 110.4 ± 14.9 mmHg).  Hypoxia caused a rapid decline in LVDP, 
decreasing by 83.8% (122.6 ± 23.5 mmHg to 19.9 ± 10.0 mmHg). Thiol 
depletion did not affect LVDP in normoxic hearts (104.6 ± 28.4 mmHg to 102.5 
± 21.9mmHg), however, caused a decrease in LVDP in hypoxic hearts (110.2 ± 
38.2 mmHg to 26.9 ± 18.1 mmHg) with end values 35% higher than hearts 
perfused with hypoxic buffer alone. Thiol augmentation also did not affect LVDP 
in normoxic hearts (121.6 ± 29.5 mmHg to 106.3 ± 15.6 mmHg.  As with 
hypoxic buffer perfusion alone, thiol augmentation caused LVDP to decrease 
during hypoxia, however, values were 2.2 fold higher than hypoxic hearts by the 






Figure. 3.5. LVDP (mmHg) of hearts as described in figure 3.3.. Data are expressed as means ± 
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3.3.2.4 Left ventricular end diastolic pressure (LVEDP) 
LVEDP was pre-set to between 4 and 10 mmHg before each experiment in all 
hearts (figure 3.6). During the stabilisation period, LVEDP did not alter more 
than 10%, consistent with exclusion criteria data, and was stable over 60 
minutes perfusion with normoxic buffer, while perfusion with hypoxic buffer 
caused a 10 fold increase in LVEDP (5.5 ± 1.2 mmHg to 69.3 ± 19.5 mmHg). 
Thiol depletion caused LVEDP to almost double during normoxic perfusion (6.9 
± 1.0 mmHg to 12.2 ± 2.1 mmHg), although the increase observed due to 
hypoxia was not significantly (p<0.05) different from hypoxia alone (6.4 ± 1.1 
mmHg to 65.4 ± 41.9 mmHg). Hypoxia caused LVEDP to increase in thiol 
augmented hearts, however, end values were 30% lower compared to hypoxia 




Figure. 3.6. LVEDP (mmHg) of hearts as described in figure 3.3.. Data are expressed as means 
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3.3.3 Cardiac lactate release, glucose consumption and protein release 
3.3.3.1 Lactate release 
Figure 3.7 displays the lactate concentration of perfusate samples collected 
from all hearts. Lactate release from normoxic control hearts was minimal 
during normoxia and remained stable throughout perfusion (0.08 ± 0.01 nmol to 
0.11 ± 0.07 nmol /mL /g dry wt).  Lactate release increased rapidly in hypoxic 
control hearts within minutes of introducing hypoxic KHB buffer, peaking after 3 
mins (0.40 ± 0.07 nmol /mL /g dry wt). Thiol depletion did not affect lactate 
release from normoxic hearts (0.08 ± 0.03 to 0.14 ± 0.06 nmol /mL /g dry wt). 
Lactate release was similar in hypoxic thiol depleted hearts to that of hypoxia 
alone, increasing from 0.07 ± 0.006 to 0.29± 0.11 nmol /mL /g dry wt within 3 
mins. Thiol augmentation did not affect lactate release during normoxia (0.05 ± 
0.02 to 0.09 ± 0.02 nmol /mL /g dry wt) and during hypoxia lactate release was 
similar to that of hypoxia alone, increasing from  0.11 ± 0.04 to 0.37 ± 0.03 nmol 




Figure 3.7. Lactate concentration of perfusate samples collected from hearts as described in 
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3.3.3.2 Glucose consumption 
Cardiac glucose consumption remained constant throughout all perfusion 
protocols (figure 3.8). There were no changes detected in myocardial glucose 
consumption from all protocols. During normoxic perfusions, perfusate glucose 
concentration ranged from 10.7± 0.03 to11.2 ± 0.54 mmol/ L in normoxic control 
hearts, 10.6 ± 0.23 to 11.3 ± 0.35 mmol/ L in thiol depleted hearts and 10.5 ± 
0.37 to 11.2 ± 0.41 mmol/ L in thiol augmented hearts.  During hypoxic 
perfusions, perfusate glucose concentration ranged from 10.6± 0.25 to 11.1 ± 
0.19 mmol/ L in hearts perfused with hypoxic buffer alone, 10.7 ± 0.28 to 11.1 ± 
0.43 mmol/ L in thiol depleted hypoxic hearts and 10.7 ± 0.61 to 11.2 ± 0.46 
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Figure 3.8. Glucose concentration of perfusate samples collected from hearts as described in 






3.3.3.3 Cardiac protein release 
Figure 3.9 displays protein concentrations of the perfusate collected for all 
hearts.  Hypoxia did not cause an increase in cardiac protein release compared 
with normoxia (0.01 ± 0.007 to 0.02 ± 0.12 vs. 0.01 ± 0.006 to 0.03 ± 0.013 mg 
/mL /g dry wt). Thiol depletion increased protein release in hypoxic hearts (0.04 
± 0.02 to 0.05 ± 0.02 mg /mL /g dry wt vs.  0.01 ± 0.01 to 0.03 ± 0.008 mg /mL 
/g dry wt during normoxia. Thiol augmentation, however, appeared to increase 
cardiac protein release during both normoxia (peaking at 0.24 ± 0.15 mg /mL /g 
dry wt) and hypoxia (peaking at 0.54 ± 0.10 mg /mL /g dry wt), however, these 
results probably reflect increases in perfusate cysteine concentration rather 







Figure 3.9. Protein concentration of perfusate samples collected from  as described in figure 
3.3.. Data are expressed as means ± standard deviation (n = 5). 
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3.3.4 Myocardial 64Cu retention from 64Cu-ATSM in thiol-modified hearts 
Representative time-activity curves from hearts administered with three bolus 
injections of 64Cu-ATSM are displayed in figure 3.10. These data were obtained 
from the 2nd γ-detector from the γ-triple detector system described in chapter 2.
 
Figure 3.10. Representative time-activity curves demonstrating 
64
Cu uptake from 
64
Cu-ATSM in 
(A) normoxic hearts and (B) hypoxic hearts. Curves represent untreated hearts (control) thiol 




The degree of cardiac tracer trapping was calculated as the amount of tracer 
trapped in the heart 15 minutes post injection as a percentage of the peak 
activity in the heart immediately after injection. Perfusion with normoxic buffer 
did not affect the degree of 64Cu retention from 64Cu-ATSM injections after 10, 
30 or 45 perfusion (13.1 ± 1.7 %, 13.7 ± 3.9 % and 13.3 ± 2.1 % respectively). 
Perfusion with hypoxic buffer increased 64Cu retention significantly (p<0.05) in 
untreated hearts after 5 mins (early hypoxia 45.6 ± 5.8 %) which increased 
further after 20 mins (late hypoxia 59.1 ± 6.3 %). Thiol depletion did not affect 
64Cu retention from any of the three 64Cu-ATSM injections in normoxic protocols 
(13.3 ± 2.8 %, 11.1 ± 2.6 % and 13.2 ± 4.6 %), nor did it affect the retention of 
copper in hypoxic hearts compared to hearts perfused with hypoxic buffer alone 
(46.5 ± 5.5 % during early hypoxia and 51.3 ± 12.1 % during late hypoxia). Thiol 
augmentation also did not affect 64Cu retention in normoxic hearts from any of 
the three 64Cu injections (14.5 ± 1.9 %, 17.5 ± 4.6 % and 16.0 ± 2.6 %). Thiol 
augmentation did not enhance hypoxia selective 64Cu retention during early 
hypoxia compared to that of hypoxia alone (44.9 ± 5.2 %), however, during late 
hypoxia thiol augmentation significantly (p<0.05) decreased in 64Cu retention 




Figure 3.11. Effect of thiol depletion (BSO) and augmentation (NAC) on 
64
Cu retention in (A) 
normoxic and (B) hypoxic hearts. Data are expressed as the % of total activity injected (means 
± standard deviation, n=5 per group). *p<0.05 vs. normoxia (injection 1), #p<0.05 vs. early 
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3.3.5 Pharmacokinetic analysis of time-activity curve data 
To determine whether thiol modification changed the pharmacokinetics of 64Cu-
ATSM washout,  time activity curves of tracer washout were fitted with a bi-
exponential function to obtain a fast clearance rate (FCR), a slow clearance rate 
(SCR), and indices of their respective importance in governing overall washout 
(their amplitudes).  These data are summarised in tables 3.1 and 3.2. Neither 
the FCR nor the SCR or their amplitudes changed during the normoxic 
perfusion protocol (figures 3.12-3.13). Thiol depletion or augmentation had no 
effect on either FCR or SCR during normoxic perfusion, or their respective 
amplitudes. The amplitude of the FCR was significantly (p<0.05) higher than 
that of the SCR during normoxia, and was unaffected by thiol concentration 
modification (figure 3.14). 
 
During late hypoxia, the FCR increased significantly (p<0.05) over control 
values to an equal degree in both untreated and thiol modified hearts while the 
SCR fell significantly (p<0.05) in all groups, irrespective of drug regimen (figures 
3.12 and 3.11).  With progressive hypoxia, the amplitude of the SCR rose 
significantly (p<0.05), and the corresponding FCR fell.  This was unaffected by 




Figure 3.12. FCR of each 
64
Cu-ATSM injection as determined by the bi-exponential analysis of 
64
Cu clearance from heart tissue based on time-activity curve data. Data are expressed as 
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Figure 3.13. SCR of each 
64
Cu-ATSM injection as determined by the bi-exponential analysis of 
64
Cu clearance from heart tissue based on time-activity curve data. Data are expressed as 
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Figure 3.14. Amplitude of the FCR and SCR for all injections of 
64
Cu-ATSM in all hearts (means 
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Table 3.1. FCR and SCR values from figures 3.12-3.13. Data are expressed as the rates of 
64




]; means ± standard deviation, n=5 per 
group). 
      Injection FCR (kfc [min
-1]) 
    Control BSO NAC 
Normoxic 1: Normoxia 1.2 ± 0.2 1.1 ± 0.1 1.3 ± 0.2 
hearts 2: Normoxia 1.1 ± 0.2 1.1 ± 0.2 1.4 ± 0.1 
 
3: Normoxia 1.2 ± 0.1 1.2 ± 0.2 1.4 ± 0.4 
     
     Hypoxic 1: Normoxia 1.2 ± 0.2 1.1 ± 0.2 1.2 ± 0.2 
hearts 2: Early hypoxia 1.9 ± 0.4 1.8 ± 0.5 1.9 ± 0.3 
 
3: Late hypoxia *2.5 ± 0.6 *2.2 ± 0.5 *2.2 ± 0.8 
     





Control BSO NAC 
     Normoxic 1: Normoxia 0.01. ± 0.002 0.008 ± 0.002 0.01 ± 0.006 
hearts 2: Normoxia 0.01 ± 0.002 0.01 ± 0.008 0.01 ± 0.006 
 
3: Normoxia 0.01 ± 0.002 0.01 ± 0.004 0.01 ± 0.004 
     
     Hypoxic 1: Normoxia  0.01 ± 0.007  0.01 ± 0.002 0.01 ± 0.002 
hearts 2: Early hypoxia  0.007 ± 0.005  0.008 ± 0.005  0.009 ± 0.002 
 
3: Late hypoxia *0.003 ± 0.003 *0.004 ± 0.002 *0.005 ± 0.002 
   
   *p < 0.05 vs. normoxic equivalent  













Table 3.2. Amplitudes of FCR and SCR from figure 3.14. Data are expressed as weights 
corresponding to the 
64
Cu FCR or SCR of each 
64
Cu-ATSM injection (means ± standard 
deviation, n=5 per group). 
  Injection FCR amplitude (arbitrary units) 
    Control BSO NAC 
Normoxic 1: Normoxia   0.7 ± 0.02 0.8 ± 0.07 0.7 ± 0.07 
hearts 2: Normoxia   0.6 ± 0.04 0.7 ± 0.07 0.6 ± 0.04 
 
3: Normoxia   0.6 ± 0.04 0.6 ± 0.1 0.6 ± 0.06 
     
     Hypoxic 1: Normoxia  0.8 ± 0.04 0.8 ± 00.07 0.8 ± 0.04 
hearts 2: Early hypoxia   0.4 ± 0.06 0.4 ± 0.06 0.4 ± 0.05 
 
3: Late hypoxia   0.2 ± 0.03 0.2 ± 0.06 0.2 ± 0.03 
     
     
  
SCR amplitude (arbitrary units) 
  
Control BSO NAC 
     Normoxic 1: Normoxia * 0.2 ± 0.03 * 0.2 ± 0.04 * 0.2 ± 0.03 
hearts 2: Normoxia * 0.3 ± 0.04 * 0.2 ± 0.04 * 0.3 ± 0.05 
 
3: Normoxia * 0.3 ± 0.03 * 0.3 ± 0.05 * 0.4 ± 0.04 
     
     Hypoxic 1: Normoxia * 0.2 ± 0.04 * 0.2 ± 0.04 * 0.2 ± 0.02 
hearts 2: Early hypoxia 0.5 ± 0.1 0.5 ± 0.02 0.5 ± 0.06 
 
3: Late hypoxia * 0.7 ± 0.05 * 0.7 ± 0.05 * 0.7 ± 0.05 
   












3.4 Discussion and conclusions 
3.4.1 Effect of thiol concentration on 64Cu-ATSM hypoxia selectivity 
3.4.1.1 Cardiac 64Cu retention from 64Cu-ATSM 
Our study is the first attempt to investigate the effect of modifying thiol 
concentration on 64Cu retention from 64Cu-ATSM in the heart. Donnelly et al. 
have reported that BSO incubation does not affect Cu retention from Cu-ATSM 
(measured using a metal-responsive element luciferase assay) in 
neuroblastoma SH-SY5Y cells under normoxic conditions132. Evidence of 
cellular protein oxidation in these cells indicated compromised redox status 
through GSH depletion; however, this group did not confirm the link by 
measuring intracellular thiol concentrations. In these experiments, it was 
demonstrated that measurable thiol depletion or augmentation does not affect 
64Cu retention from 64Cu-ATSM. This is with the exception of the thiol 
augmented group where a decrease in 64Cu retention was observed during late 
hypoxia compared to untreated hypoxic controls. It is possible that over longer 
periods of NAC supplementation, increases in thiol concentration prevents the 
reduction of Cu(II)-ATSM to Cu(I)-ATSM- by free radicals. Thus, the antioxidant 
function of GSH may scavenge reductant which may otherwise reduce Cu-
ATSM.  It is not currently known whether BTSC complexes are sensitive to free 
radical production and the effects of free radical generation and redox status on 






 3.4.1.2 Cardiac 64Cu-ATSM pharmacokinetics 
In these studies, the hypoxia-dependent accumulation of Cu-ATSM in cardiac 
tissue has been confirmed, as has been shown previously115,116, 114,163, but are 
the first to perform pharmacokinetic analysis in the heart. Kinetic analysis of the 
time-activity curve data allowed us to determine the effect of hypoxia and thiol 
concentration on the FCR and SCR of 64Cu-ATSM in the heart. Previously the 
pharmacokinetics of hypoxia tracer 99mTc-nitroimidzole in isolated perfused 
hearts was investigated and  it was suggested that the FCR represents tracer 
washout through the vasculature and SCR is an index of cellular tracer 
trapping164.  Here, it was demonstrated that the FCR increases and the SCR 
decreases with increasing hypoxia severity. During normoxia, the FCR is the 
dominant rate governing tracer washout.  It is currently unclear why the FCR 
may increase during late hypoxia.  It is possible that as vasodilation occurs, the 
myocardial surface area to volume ratio of the vasculature falls, such that there 
is a decreased likelihood of the tracer interacting with cell membranes which 
would otherwise slow its passage through the heart.  As the heart becomes 
hypoxic, the SCR becomes the dominant rate, describing the increased trapping 
of the tracer within the myocardium.  Thiol depletion or augmentation did not 
affect FCR, SCR or corresponding amplitudes during normoxia or hypoxia. This 
reinforces the retention data demonstrating that thiol concentration does not 
determine 64Cu-ATSM dissociation, hypoxia selectivity or pharmacokinetics.  
While it has been demonstrated that cardiac thiol concentration does not 
influence the hypoxia selectivity or pharmacokinetics of Cu-ATSM,  the 
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possibility that intracellular thiols are important in Cu-ATSM reduction cannot be 
excluded. In 1972 Petering demonstrated the reactivity of Cu-BTSC with thiols 
reporting that Cu-KTS, another Cu-BTSC, was reduced by incubation with GSH 
in a dose dependent manner134. Even in hearts which were significantly thiol 
depleted by BSO, the thiol concentrations were still in vast excess of the 
amount of tracer injected. Even if compromised by disease, intracellular thiol 
concentrations are always much greater than the small amounts of radiotracer 
injected. For example, ischaemia-reperfusion caused a decrease in myocardial 
GSH concentration from 0.56 to 0.18 µM/ gram tissue in rats, a concentration 
still sufficient for Cu-ATSM reduction165. It is therefore possible that intracellular 
thiols are essential in Cu-ATSM reduction leading to its dissociation in hypoxic 
tissue. It has been demonstrated that thiol concentration does not change 
during hypoxic perfusion, while 64Cu retention from 64Cu-ATSM significantly 
increases. Furthermore it was demonstrated that modification of thiol 
concentration does not affect 64Cu retention from 64Cu-ATSM under normoxic or 
hypoxic conditions. These results confirm that myocardial thiol concentration 
does not determine Cu-ATSM hypoxia selectivity or clearance from tissue; 
however, the presence of thiols may still be essential in Cu-ATSM reduction and 
copper deposition. 
 
3.4.2 Thiol concentration modification 
Our measurements of intracellular thiol concentrations of untreated normoxic 
control hearts were consistent with those previously reported166. It was 
demonstrated that perfusion with hypoxic KHB does not alter cardiac thiol 
concentration in these experiments, which has also been reported previously in 
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experiments where glucose-containing hypoxic buffers were used157,160. Others 
have reported that hypoxia causes a depletion of cardiac thiol content; however, 
this is due to the lack of energy substrate in the perfusion buffer157,161,162. In 
these studies, glucose was replaced with mannitol to maintain oncotic pressure 
and prevent hypoxia induced oedema167. GSH pools are maintained by GSH 
reductase which reduces GSSG to GSH using NADPH as an electron donor. 
Intracellular NADPH pools are replenished by the reduction of NADP+ by NADH 
from glycolysis or fatty acid β-oxidation. GSH synthesis by γ-glutamylcysteine 
synthetase and GSH synthetase is also ATP dependent. Hypoxic hearts which 
cannot metabolise fatty acids therefore require glucose to maintain GSH levels. 
Since mannitol is not metabolised by the myocardium, and maintenance of GSH 
levels is energy substrate dependent168,169, it is the combination of hypoxia and 
lack of energy substrate which depletes GSH, and not hypoxia alone.  
Thiol concentrations of hearts excised from BSO pre-treated rats were 
approximately 60% lower than those of untreated control hearts. Our thiol 
depletion protocol was adopted from a previous study which reported a 70% 
decrease in thiol concentration, although the hearts in that study underwent an 
ischaemia and reperfusion protocol which would have depleted GSH further166. 
Perfusion with NAC for 35 mins increased cardiac thiol concentrations by 7 fold.  
A total concentration of 4mM NAC was used as this dose has been commonly 
used to scavenge free radicals in isolated perfused rat hearts170-172. To date,  
the myocardial thiol concentrations reported in similar studies have not been 
corrected to intracellular protein concentration158,173; meaning that the current 
results cannot be directly compared to previous research. These studies do 
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confirm, however, that NAC increases cardiac GSH in a dose-dependent 
manner.   
 
3.4.3 Cardiac function 
3.4.3.1 Contractile function 
The contractile function of each heart was monitored during the 10 min 
stabilisation period at the beginning of each perfusion protocol. Only hearts with 
stable contractile function during this period (as determined by the exclusion 
criteria laid out in chapter 2) were used in this study. In normoxic untreated 
hearts, contractile function remained stable throughout the perfusion protocol. 
Switching to hypoxic KHB caused a decrease in heart rate and LVDP and an 
increase in perfusion pressure and LVEDP within 5 mins. This is consistent with 
previous reports174,175. Decreased oxygen availability caused the heart to switch 
from fatty acid to glucose metabolism for ATP generation. Glycolysis is not as 
efficient as fatty acid β-oxidation at generating ATP, therefore less ATP is 
available to sustain cardiac contractility and heart rate and LVDP fall. Increased 
intracellular Ca2+ during hypoxia prevents complete ventricular relaxation and 
consequently increases LVEDP and perfusion pressure176.  
To date no studies have been published investigating the combined effects of 
hypoxia and thiol depletion on isolated perfused rat hearts. Other studies, 
however, have reported that myocardial thiol depletion through BSO pre-
treatment does not affect contractile function during normoxic perfusion177,178. In 
these studies, perfusion pressure was kept constant. In the model described in 
this thesis, where coronary flow rate is kept constant, thiol depletion caused a 
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38% increase in perfusion pressure after 60 mins of normoxic perfusion. There 
was, however, no change in other contractile parameters in these hearts. GSH 
depletion may result in a decreased ROS scavenging activity in the heart. 
Excess ROS may react with NO and prevent endothelial relaxation, resulting in 
vasoconstriction and increased perfusion pressure. During hypoxia, however, 
contractility of thiol depleted hearts was similar to untreated controls.   
Although several studies have investigated the protective effects of NAC on 
cardiac contractile function during ischaemia-reperfusion, the effects of NAC on 
normoxic contractile function have not been reported. NAC increases 
intracellular free radical scavenging activity through thiol replenishment; it would 
therefore be expected that NAC perfusion would have the opposite effect to 
thiol depletion on perfusion pressure. In the current study, however, hearts 
perfused with NAC displayed a 17% increase in perfusion pressure by the end 
of normoxic perfusion. It is possible that NAC decreases NO generation and 
therefore hinders vasodilation through NO signalling.  A recent report confirms 
that NAC decreases eNOS phosphorylation, leading to suppressed endothelial 
NO generation in rat aorta179.  While the mechanism by which NAC inhibits 
eNOS activity remains unclear, decreases in H2O2 levels have been suggested. 
During hypoxia, NAC perfusion tended to preserve perfusion pressure, LVDP 
and LVEDP compared with untreated hypoxic controls. In ischaemia-
reperfusion models the protective effects of NAC are attributed to antioxidant 
activity; however, little is known about the preservative effects of NAC in the 
hypoxic myocardium. It has been suggested that NAC maintains cytosolic Ca2+ 
pools by preventing or reversing ROS induced protein thiol modification of SR 
proteins, thereby maintaining muscle contraction during oxidative stress180. 
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3.4.3.2 Lactate production, glucose consumption and viability 
The hypoxic myocardium produces lactate as a byproduct of anaerobic 
glycolysis. Lactate exits the cell via MCT and is released into the blood (or 
perfusate) if there is residual flow. As expected, perfusate lactate concentration 
increased during hypoxia but not normoxia and was not influenced by thiol 
concentration. As measuring intracellular pO2 was not possible at the time of 
experiment, the increase in lactate production and release confirms that hearts 
perfused with hypoxic buffer were oxygen deprived. Lactate release, however, 
was transient and began to decrease within 10 mins of switching to hypoxic 
buffer. This is consistent with previous studies in which perfusion with hypoxic 
buffer resulted in a transient increase in lactate release from the heart181,182. 
Transient increases in glycolytic intermediates fructose-6-phosphate and 
fructose diphosphate were also reported while inorganic phosphate and AMP 
levels continued to rise with increasing hypoxia181. As hypoxia decreased 
contractility in hearts in the current study, it is probable that glucose metabolism 
slows with decreasing energy demand and therefore less lactate is produced.    
There was no detectable change in glucose consumption during hypoxia as 
perfusate glucose concentration stayed in close range to that of KHB (11mM). 
The amount of glucose extracted by the heart during hypoxia is negligible 
compared to the high concentration of glucose provided by KHB, which is being 
perfused thought the heart at 14ml/min. Changes in first pass glucose extraction 
were therefore unfortunately not measureable by this relatively insensitive 
approach. 
Cardiac viability was confirmed by the lack of protein released into the perfusate 
from all hearts. The results display an increase in protein release, however, in 
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NAC perfused hearts. It was later noted that the BCA assay used to detect 
protein also reacts with cysteine, which explains the false positive results in 
these groups, however, since lactate production and cardiac function were 
unaffected by NAC administration, it is unlikely that cellular damage would be 
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4.1.1 Hypoxia induced ROS generation in the endothelium 
Although the endothelium is less susceptible to hypoxia induced injury 
compared to cardiac myocytes, ROS generation as a result of hypoxia has been 
implicated in the pathophysiology of vascular disease. In the vascular 
endothelium ROS are generated constitutively as signalling molecules and 
regulate several processes including vascular tone, cell growth, inflammatory 
responses, proliferation and cell death183. An excess in endothelial ROS 
generation and may lead to endothelial and vascular dysfunction which 
contributes to other cardiovascular diseases including atherosclerosis.  The 
mechanism by which the endothelium generates ROS anaerobically remains 
unclear, however, mitochondrial derived ∙O2
- has been suggested183,184. The 
balance between intracellular antioxidants, such as GSH, and ROS generation 
is therefore an important factor in hypoxia induced endothelial dysfunction. 
 
4.1.2 Changes in endothelial GSH 
 GSH prevents ROS induced cellular injury by directly scavenging ROS, 
detoxifying H2O2 and replenishing membrane and intracellular protein thiols. In 
the endothelium, NO depletion through ROS-NO interactions is prevented by 
GSH; therefore GSH preserves NO dependent endothelial function such as 
vascular tone. GSH is also capable of binding NO directly to form S-
nitrosoglutathione (GSNO). GSNO is more stable than NO and has been 
implicated in the transport of NO to other vascular cells185,186. GSNO reacts with 
GSH molecules and releases NO where GSH concentrations are sufficient187. 
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The interactions between GSH and ROS/NO are therefore essential for 
maintaining endothelial and vascular functions. During hypoxia, however, ROS 
generation may exceed GSH activity and lead to endothelial dysfunction. 
Several studies have demonstrated decreases in endothelial GSH 
concentration due to severe or prolonged hypoxia.  For example, GSH levels in 
bovine aortic endothelial cells (BAEC) decreased to 10% of normoxic control 
cells after 6 hrs incubation with anoxic gas (95% N2/5% CO2)
186.  GSH 
concentration further decreased to 5% of that of normoxic cells after 24hrs. Baht 
et al observed a significant decrease in GSH in pulmonary artery endothelial 
cells (PAEC) after incubation with anoxic gas for 12 hrs which decreased further 
over time, however, was reversible upon reoxygenation for 6 hrs188.  These 
findings further support the premise that hypoxia induces ROS generation in 
endothelial cells. 
Imaging the hypoxic endothelium may therefore be beneficial in the research 
and diagnosis of hypoxia induced endothelial dysfunction, which may lead to in 
cardiovascular pathologies. To date there has been no attempt made to 
investigate the hypoxia selectivity of Cu-ATSM in cardiovascular endothelial 
cells.  
 
4.1.3 Experimental approach 
In this study, three agents which pharmacologically modify thiol concentration 
were utilised: diethyl maleate (DEM), BSO and NAC to determine the effect of 
intracellular thiol status on 64Cu-ATSM hypoxia selectivity in isolated BAEC. 
BSO and NAC deplete and augment thiol concentration as described in chapter 
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3. DEM conjugates GSH in the presence of GSH-S-transferases, therefore also 





















4.2 Materials and methods 
4.2.1 Chemicals and reagents 
Diethyl maleate (DEM), DL-buthionine (S,R)-sulfoximine 99% (BSO), 
trichloroacetic acid (TCA) and the bicinchoninic acid (BCA) assay kit were 
obtained from Fischer Scientific, UK. Dulbecco’s modified Eagle’s medium 
(DMEM), dimethylthiazol diphenyltetrazolium bromide (MTT), N-acetyl-L-
cysteine 99% (NAC) and O-phthalaldehyde (OPA) were all obtained from 
Sigma-Aldrich, UK.  64Cu-ATSM was synthesised as described in chapter 2. 
 
4.2.2 Cell culture 
BAEC (passage 6-10) were cultured in gelatine coated 24 well plates and 
cultured as described in chapter 2. For MTT assays, BAEC were cultured in 96 
well plates. 
 
4.2.3 Thiol concentration modification  
4.2.3.1 MTT viability assay 
DEM was dissolved in DMSO (10 mM) before diluting in DMEM. BSO and NAC 
were dissolved directly in DMEM. All drugs were sterile filtered before BAEC 
treatment. Initially, confluent BAEC were treated with DEM 100 µM, BSO (100 
µM), DEM + BSO (100 µM each), NAC (10 or 100mM) for 24hrs, H2O2 (250 µM) 
for 30 mins or left untreated. After the treatment period, the MTT assay was 





4.2.3.2 Effect of DEM, BSO and NAC on BAEC thiol concentration: time 
and dose optimisation studies  
24 well plates of BAEC were incubated with DEM (25, 50 or 100 µM), BSO (25, 
50 or 100 µM), DEM + BSO (100 µM each) or NAC (7.5, 15 or 30 mM) for 2, 4, 
6, 8 and 24 hrs. Additional plates of BAEC were incubated with NAC (0.01, 0.1, 
1, 5, 10, 20 and 30 mM) for 0.5 and 1 hr. 
 
4.2.3.3 Thiol and protein extraction and analysis 
After each treatment period, the medium was aspirated and wells were washed 
twice with ice-cold phosphate buffered saline (PBS). 100 µL of ice-cold TCA 
(6.5%) was added to each well for 10 mins on ice, aspirated and stored at -
70oC. 100 µL NaOH (1M) was added to each well for 2 hrs before aspirating 
and storing at -20oC. TCA extracts were analysed for thiol content using the 
OPA fluorescence assay and NaOH extracts were analysed for protein content 
using the BCA assay, both described in chapter 2.  
 
4.2.4 Determination of hypoxia protocol 
BAEC were transferred to an atmosphere regulated work station (SCI-tive, 
Ruskin Technology) at 1% O2 /5% CO2 for 48 hrs before being treated with BSO 
(10 or 100 µM) for 24 hrs or NAC (7.5 or 30 mM)  for 2 hrs. Parallel plates were 
treated identically and incubated at 21% O2/5% CO2 for the same time periods. 
After treatment periods, BAEC viability was analysed via MTT assay as 




4.2.5 64Cu-ATSM hypoxia selectivity in BAEC 
BAEC were incubated at 21% O2/5% CO2 or 1% O2 /5% CO2 and treated as in 
section 4.2.4. After treatment periods, the medium was aspirated and BAEC 
were washed twice with PBS (37oC). 1 kBq 64Cu-ATSM (for synthesis see 
chapter 2) diluted in FCS free DMEM (1kBq/ mL) was added to each well for 1 
hr. Medium was then aspirated and GSH and protein was extracted as before. 
Half of the TCA and NaOH extracts were obtained for measurement of 
intracellular 64Cu content using a gamma counter (1282 Compugamma, LKB 
Wallac, Australia).  The medium and PBS aspirated from each well were also 
analysed for 64Cu content. 
 
4.2.6 Statistical analysis 
All data are presented as means ± standard deviation. Statistical significance 












4.3.1 Preliminary dose response findings 
4.3.1.1 Effect of modifying thiol concentration on BAEC viability 
Preliminary MTT assays were performed on BAEC treated with DEM, BSO and 
NAC to assess cellular viability post-treatment (figure 4.1). BAEC treated with 
100 µM DEM (0.66 ± 0.03 Abs 570 nm), 100 µM BSO (0.64 ± 0.04 Abs 570 
nm), 100 µM DEM + 100 µM BSO (0.68 ± 0.11 Abs 570 nm) or 10mM NAC 
(0.73 ± 0.07 Abs 570 nm) for 24 hrs displayed similar viability to that of 
untreated BAEC (0.67 ± 0.05 Abs 570 nm). Treatment with 100 mM NAC, 
however, significantly decreased viability by 25% (0.50 ± 0.08 Abs 570 nm; 
p<0.05).  H2O2 also decreased BAEC viability by 30% (0.46 ± Abs 570 nm; 
p<0.05).  
 
Figure 4.1. BAEC viability. Data are expressed as means ± standard deviation, n=3 plates with 
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4.3.1.2 Effect of DEM, BSO and NAC on BAEC thiol concentration 
In preliminary dose response studies BAEC were treated with DEM, BSO or a 
combination of both for 2, 4, 6, 8 and 24 hrs (figure 4.2). Thiol concentration in 
untreated control BAEC ranged between 26.4 ± 4.6 and 34.7 ± 4.3 nmol/ mg 
protein over 24 hrs. Incubation with 100 µM DEM for 2 hrs (27.3 ± 6.5 nmol/ mg 
protein) did not affect thiol concentration. Incubation with 100 µM DEM for 4, 6 
and 8 hrs tended to increase thiol levels (42.2 ± 16.5, 45.1 ± 11.5 and 43.5 ± 
9.0 nmol/ mg protein respectively); however, values were not significant 
compared with time-matched controls. Treatment with 100 µM DEM for 24 hrs, 
however, caused thiol concentration to significantly increase to above that of 
control BAEC (83.2 ± 16.0 nmol/ mg protein; p<0.05). 
In the same study, incubation with 100 µM BSO for 2, 4, 6 or 8 hrs did not affect 
thiol concentration (26.6 ± 6.1, 37.5 ± 10.7, 38.2 ± 11.9 and 26.0 ± 4.4 nmol/ mg 
protein respectively). Incubation with 100 µM BSO for 24 hrs, however, 
significantly decreased thiol concentration to 50% of that in control BAEC (15.2 
± 1.3 nmol/ mg protein; p<0.05). Treatment with DEM + BSO combined had no 
effect on thiol concentration from 2-8 hrs. After 24 hrs treatment, however, DEM 





Figure 4.2. Thiol concentrations of BAEC treated with thiol depletion agents. Data are 
expressed as means ± standard deviation, n= 3 plates with three replicate wells per group. 
*p<0.05 vs. untreated control. 
 
Following analysis of the results displayed in figure 4.2, a second study was 
executed to further confirm the effect of DEM and BSO on BAEC thiol 
concentration. The design of this study was altered to investigate the effects of 
a range of DEM and BSO doses on BAEC thiol concentration. In addition, thiol 
augmenting agent, NAC, was added to the protocol. 
In this study thiol concentrations of untreated control BAEC remained similar to 
those displayed in figure 4.2, ranging between 29.1 ± 9.6 and 31.8 ± 11.0 nmol/ 
mg protein over the time course of 24 hrs. Contrary to preliminary results, 
incubation with 100µM DEM tended to decrease thiol content from 2-8 hrs, 

































however, after 24 hrs thiol concentration increased as before (figure 4.3; table 
4.1). Incubation with lower concentrations of DEM (25 and 50 µM) from 2-8 hrs 
did not affect thiol concentration. Incubation with 25, 50 and 100 µM DEM for 24 
hrs increased thiol concentration, however, was not significant compared to 
control BAEC. 
 
Figure 4.3. Thiol concentrations of BAEC treated with DEM. Data are expressed as means ± 










































Table 4.1. Thiol concentrations of BAEC incubated with DEM (as seen in figure 4.3).  
 
BAEC thiol concentration (nmol/ mg protein) 
Time (hrs) Control  DEM (25 µM) DEM (50 µM) DEM (100 µM) 
     2 30.7 ± 8.5 27.8 ± 20.0 28.5 ± 13.2 25.5 ± 12.2 
4 29.3 ± 9.6 27.8 ± 10.3 26.5 ± 11.5 25.9 ± 14.1 
6 29.1 ± 10.7 28.5 ± 12.5 25.7 ± 11.5 25.4 ± 14.2 
8 30.8 ± 11.4 30.0 ± 10.3 32.6 ± 13.4 28.6 ± 16.4 
24 31.8 ± 11.0 103.4 ± 83.5 83.1 ± 35.7 74.1 ± 50.1 
  
    *p< 0.05 vs. control 
 
Similar to the preliminary results displayed in figure 4.2, treatment with 100µM 
BSO did not affect thiol levels from 2-8 hrs; however, after 24 hrs thiol 
concentration significantly decreased to 50% of control values (figure 4.4; table 
4.2). Similarly, incubating BAEC with lower BSO concentrations (25 and 50 µM) 
resulted in a significant decrease (p<0.05) in thiol concentration after 24 hrs.    
 
Figure 4.4. Thiol concentrations in BAEC treated with BSO. Data are expressed as means ± 
standard deviation, n= 6 plates with three replicate wells per group. *p<0.05 vs. untreated 
control. 































Table 4.2. Thiol concentrations of BAEC incubated with BSO (as seen in figure 4.4).   
 
BAEC thiol concentration (nmol/ mg protein) 
Time (hrs) Control  BSO (25 µM) BSO (50 µM) BSO (100 µM) 
     2 30.7 ± 8.5 25.4 ± 11.9 27.0 ± 12.4 27.2 ± 8.4 
4 29.3 ± 9.6 23.5 ± 1.5 25.4 ± 6.2 25.0 ± 6.9 
6 29.1 ± 10.7 32.5 ± 2.1 26.7 ± 3.1 30.1± 10.6 
8 30.8 ± 11.4 27.6 ± 6.7 31.9 ± 8.8 24.0 ± 7.2 
24 31.8 ± 11.0 * 14.8 ± 1.32 * 16.6 ± 5.9 * 14.3 ± 4.0 
       
    *p< 0.05 vs. control 
 
 
Initially, BAEC were incubated with 7.5 mM, 15 mM or 30 mM NAC for the same 
time periods as DEM and BSO. All NAC concentrations caused a significant 
increase (p<0.05) in thiol concentrations after 2 hrs (figure 4.5 A; table 4.3 A). 
Over time thiol concentration returned towards control levels in BAEC treated 
with 7.5 mM and 15 mM NAC, however, remained significantly higher (p<0.05) 
in the 30mM treatment group throughout the experiment. This discovery led to a 
second, smaller study which explored the effect of a larger range of NAC 
concentrations on BAEC thiol concentration at the shorter time points of 0.5 and 
1 hr (figure 4.5 B; table 4.3 B). Incubation with concentrations less than10 mM 




Figure 4.5. Thiol concentrations of BAEC treated with NAC. Data are expressed as means ± 
standard deviation, (A) n= 6 (B) n=3 plates, each with three replicate wells per group.  *p<0.05 
vs. untreated control. 
 






































































Table 4.3A. Thiol concentrations of BAEC incubated with NAC (as displayed in figure 4.5A).   
 
BAEC thiol concentration (nmol/ mg protein) 
Time (hrs) Control  NAC (7.5 mM) NAC (15 mM) NAC (30 mM) 
     2 30.7 ± 8.5 * 44.5 ± 10.7 * 47.8 ± 9.5 * 52.5 ± 12.5 
4 29.3 ± 9.6 41.3 ± 3.8 43.4 ± 4.2 * 50.9 ± 8.3 
6 29.1 ± 10.7 41.5 ± 6.7 39.9 ± 5.9 * 54.2 ± 3.8 
8 30.8 ± 11.4 40.7 ± 7.0 40.4 ± 5.3 * 58.6 ± 13.6 
24 31.8 ± 11.0 32.2 ± 11.3 35.1 ± 12.9 * 48.1 ± 23.5 
       
    *P < 0.05 vs. time-matched control 
      
Table 4.3B. Thiol concentrations of BAEC incubated with NAC (as displayed in figure 4.5B). 
 
BAEC thiol concentration (nmol/ mg protein) 
 0.5 hrs 1 hrs 
   Control 20.0 ± 0.6 25.4 ± 4.1 
NAC (0.01 mM) 23.5 ± 6.7 32.9 ± 1.5 
NAC (0.1 mM) 37.8 ±  13.5 32.8 ±  17.1 
NAC (1mM) 42.8 ± 29.7 36.6 ± 2.4 
NAC (5mM) 54.1 ±  23.4 44.7 ±  16.4 
NAC (10mM) * 62.6 ±  15 52.1 ±  19.8 
NAC (20 mM) * 68.0 ±  20.1 * 59.1 ±  11.3 
NAC (30 mM) * 75.2 ±  2.4 * 82.9 ±  11.5 
  
  *p<0.05 vs.  control 
 
The protocol was then further refined prior to experiments with 64Cu-ATSM. 
From the results displayed in figures 4.2 and 4.3 it was clear that thiol 
concentrations of BAEC treated with DEM were much more variable compared 
to treatment with BSO and NAC. It was therefore decided that DEM was no 
longer suitable in the final protocol. In the final dose response study the highest 
and lowest doses of BSO and NAC at appropriate time points were used (100 
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and 25 µM BSO at 24 hrs, 30 and 7.5 mM NAC at 2 hrs). In addition, a 
concentration 10 fold lower than the highest concentration of each compound 
was added to the protocol. 
In this study, thiol concentrations in untreated control BAEC averaged 21.6 ± 
2.6 nmol/ mg protein (figure 4.6). Incubation with 10, 25 and 100 µM BSO for 24 
hrs significantly decreased (p<0.05) thiol concentration to 15.3 ± 0.4, 8.0 ± 1.0 
and 6.6 ± 0.2 nmol/ mg protein respectively. Incubation with 3 mM NAC for 2 
hrs increased thiol concentration to 34.2 ± 3.3 nmol/ mg protein, however, this 
was not significant compared to control values. Incubation with 7.5 and 30 mM 
NAC significantly increased (p<0.05) BAEC thiol concentrations to 46.3 ± 5.3 






Figure 4.6. Effect of tailored treatment protocols on BAEC thiol concentration. Cells were 
incubated with (A) BSO for 24 hrs and (B) NAC for 2 hrs. Data are expressed as means ± 
standard deviation, n= 3 plates with three replicate wells per group. *p<0.05 vs. control. 
 
4.3.1.3 Effect of low oxygen and thiol concentration on BAEC viability 
In the next stage of designing a protocol, two doses of BSO (10 and 100µM) 
and two doses of NAC (7.5 and 30 mM) were utilised. BAEC were incubated in 
either 21% or 1% O2 for 24 hrs before treatment (either with BSO for 24 hrs or 
NAC for 2 hrs) to assess the combined effect of low oxygen and thiol 























































NAC treatment did not compromise BAEC viability (table 4.4). Incubation with 
H2O2 decreased BAEC to approximately 50% control levels (p<0.05). Similarly, 
in 1% O2 BSO or NAC did not compromise BAEC viability compared with BAEC 
incubated in the absence either of drug; however, there was a significant 
decrease (p<0.05) in cell viability across all treatment groups incubated in 1% 
O2 compared with the 21% O2 group. Furthermore, BAEC incubated in 1% O2 
contained significantly less protein in all treatment groups compared with their 





Figure 4.7. Effect of low oxygen on BAEC viability, determined by the MTT assay. Data are 
expressed as means ± standard deviation, n=3 plates with four replicate wells per group. 
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Figure 4.8. BAEC protein concentration in BAEC subject to treatment protocols in 4.7. Data are 
expressed as means ± standard deviation, n=3 plates with four replicate wells per group, 
#p<0.05 vs. 21% O2 equivalent. 
 
 
Table 4.4. BAEC viability and protein levels (as displayed in figures 4.7-4.8) 
 
BAEC viability (abs 570 nm)   Protein (mg/ mL) 
Time (hours) 20% O2 1% O2   20% O2 1% O2 
      Control 0.72 ± 0.11  0.41 ± 0.08 
 
0.3 ±  0.13 # 0.18 ±  0.04 
BSO (10 µM) 0.86 ± 0.08 0.47 ± 0.03 
 
0.35 ±  0.11 # 0.2 ±  0.2 
BSO (25 µM) 0.81 ± 0.17 0.41 ± 0.03 
 
0.40 ±  0.14 # 0.18 ±  0.05 
BSO (100 µM) 0.89 ± 0.13 0.46 ± 0.01 
 
0.45 ±  0.10 # 0.26 ±  0.04 
NAC (3 mM) 0.75 ± 0.08 0.42 ± 0.04 
 
0.37 ±  0.09 # 0.16 ±  0.01 
NAC (7.5 mM) 0.74 ± 0.04 0.5 ± 0.04 
 
0.38 ±  0.15 # 0.22 ±  0.04 
NAC (30 mM) 0.73 ± 0.06 0.5 ± 0.07 
 
0.37 ±  0.13 # 0.15 ±  0.07 
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4.3.2 Effect of BAEC thiol concentration on 64Cu retention from 64Cu-ATSM  
After establishing a protocol which depleted and augmented thiol concentration, 
the effects of thiol concentration on the hypoxia selectivity of 64Cu-ATSM in 
BAEC were investigated. In this protocol BAEC were incubated with 64Cu-ATSM 
in the absence BSO or NAC after thiol concentration had been modified. An 
extra group of NAC treated BAEC in which NAC was included in the medium 
during the 64Cu-ATSM incubation period was therefore included in the study. 
Seeding BAEC was also staggered so that cells incubated in 21% O2 contained 
a similar amount of protein as 1% O2 group by the time of experiment. 
 
4.3.2.1 BAEC thiol concentration 
Thiol concentrations of BAEC incubated with 64Cu-ATSM are displayed in figure 
4.9. Incubation in 1% O2 alone caused a significant decrease (p<0.05) in thiol 
concentration (14.6 ± 1.6 nmol/ mg protein) compared with 21% O2 (21.8 ± 2.1 
nmol/ mg protein). Incubation with 10 and 100 µM BSO significantly decreased 
(p<0.05) thiol concentration compared to control cells in 21% O2 (9.8 ± 3.9 and 
4.7 ± 1.2 nmol/ mg protein respectively). Similarly, BAEC incubated in 1% O2 
contained significantly lower (p<0.05) thiol concentrations after treatment with 
10 µM (8.5 ± 2.3 nmol/ mg protein) and 100 µM (6.4 ± 2.3 nmol/ mg protein) 
BSO. 
Treatment with NAC for 2 hrs prior to 64Cu-ATSM incubation failed to increase 
thiol levels in BAEC incubated at 21% O2 with either 7.5 or 30mM (20.6 ± 6.7 
and 23.7 ± 2.2 nmol/ mg protein respectively). In 1% O2, 7.5 and 30 mM NAC 
increased BAEC thiol concentration to (21.8 ± 16.8 nmol/ mg protein and 27.3 ± 
153 nmol/ mg protein respectively, however, these increases were not 
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statistically significant when compared to BAEC incubated with 1% O2 alone. 
Incubating BAEC with NAC for an additional hour during 64Cu-ATSM incubation 
significantly increased (p<0.05) thiol concentrations with both 7.5 and 30 mM 
21% O2 (32.5 ± 3.4 and 67.0 ± 10.5 nmol/ mg protein respectively) and in 1% 





Figure 4.9. Thiol concentrations in BAEC incubated with (A) BSO for 24hrs and (B) NAC for 2 
hrs prior to 1 hour incubation with 
64
Cu-ATSM in the absence of NAC or (C) NAC for 2 hrs prior 
to 1 hour incubation with 
64
Cu-ATSM and NAC.  Data are expressed as means ± standard 
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4.3.2.2 BAEC 64Cu retention from 64Cu-ATSM 
Following incubation with 64Cu-ATSM, the media was extracted and BAEC were 
washed with ice-cold PBS. The media and PBS were then analysed for 
extracellular 64Cu activity (figure 4.10). Extracellular activity was similar in the 
media and PBS samples collected from control BAEC incubated in 21% and 1% 
O2  (48.7 ± 1.3 and 47.8 ± 1.9 kBq/ mL respectively). Furthermore, 10 and 100 
µM BSO did not affect extracellular activity from BAEC at 21% (48.7 ± 2.6 and 
48.7 ± 2.5 kBq/ mL respectively) or 1% O2 (48.0 ± 3.1 and 47.6 ± 2.6 kBq/ mL 
respectively). Similarly, incubation with 7.5 and 30 mM NAC for 2 hrs did not 
affect extracellular activity from BAEC incubated at 21% (49.7 ± 1.3 and 48.6 ± 
2.3 kBq/ mL respectively) or 1% O2 (47.0 ± 0.6 and 46.9 ± 1.7 kBq/ mL 
respectively). Extracellular activity was similar from BAEC treated with 7.5 mM 
and 30 mM NAC for 3 hrs in 21% O2. In 1% O2, incubation with 7.5 mM NAC did 
not significantly affect extracellular activity (45.9 ± 1.1 kBq/ mL) however, 30 







Cu in medium and PBS wash (combined) from BAEC incubated with (A) BSO for 
24hrs and (B) NAC for 2 hrs prior to 1 hour incubation with 
64
Cu-ATSM in the absence of NAC 
or (C) NAC for 2 hrs prior to 1 hour incubation with 
64
Cu-ATSM and NAC.  Data are expressed 
as means ± standard deviation, n=3 plates with four replicate wells per group. *p<0.05 vs. 
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Figure 4.11 displays the effect of thiol concentration modification on BAEC 64Cu 
retention after incubation with 64Cu-ATSM. Control BAEC retained 1.7 ± 0.1 
kBq/ mg protein in 21% O2 conditions. 1% O2 caused a significant increase 
(p<0.05) in 64Cu retention compared to 21% O2 (3.0 ± 0.5 kBq/ mg protein). All 
treatment groups of BAEC in 1% O2 retained significantly more (p<0.05) 
64Cu 
than 21% equivalents. In 21% O2, 
64Cu retention remained similar to control 
levels in BAEC incubated with 10 µM BSO (1.9 ± 0.1 kBq/ mg protein), 
however, 100 µM BSO significantly increased (p<0.05) 64Cu compared to 
controls (2.6 ± 1.0 kBq/ mg protein). 10 and 100 µM BSO did not alter 64Cu 
retention in BAEC incubated at 1% O2 (3.1 ± 0.6 and 3.9 ± 0.5 kBq/ mg protein 
respectively).  
Incubation with 7.5 and 30 mM NAC for 2 hrs did not affect 64Cu retention in 
BAEC incubated at 21% O2 (2.0 ± 0.5 and 2.0 ± 0.01 kBq/ mg protein 
respectively). At 1% O2, however, 7.5 and 30 Mm NAC significantly increased 
(p<0.05) 64Cu retention to 5.4 ± 0.4 and 4.7 ± 1.0 kBq/ mL respectively. Under 
21% O2 treatment with 7.5 and 30 mM NAC for 3 hrs did affect 
64Cu retention 
compared to control BAEC (1.8 ± 0.03 and 2.7 ± 0.3 kBq/ mg protein 
respectively). At 1% O2, however, 7.5 and 30 mM NAC caused significant 







Cu retention in BAEC incubated with (A) BSO for 24hrs and (B) NAC for 2 hrs 
prior to 1 hour incubation with 
64
Cu-ATSM in the absence of NAC or (C) NAC for 2 hrs prior to 1 
hour incubation with 
64
Cu-ATSM and NAC.  Data are expressed as means ± standard deviation, 
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Figure 4.12 displays the correlation between BAEC thiol concentration and 64Cu 
retention from 64Cu-ATSM. Under 21% conditions there is no linearity observed 
in this relationship (r2=0.1183). Under 1% conditions, however, there is a 




Figure 4.12. Correlation between BAEC thiol concentration and 
64
Cu retention from 
64
Cu-ATSM 
incubated in 21% and 1% O2. Data are expressed as means ± standard deviation, n=3 plates 
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4.4 Discussion and conclusions 
4.4.1 Effect of thiol concentration and low oxygen on BAEC 64Cu retention 
from 64Cu-ATSM 
As expected, there was significantly more retention of 64Cu from 64Cu-ATSM in 
low oxygen BAEC compared with BAEC incubated in 21 % O2.  Thiol 
augmentation did not affect 64Cu retention from 64Cu-ATSM in normoxic BAEC, 
however, thiol depleted cells treated with 100 µM BSO caused a significant 
increase in 64Cu retention compared to normoxic controls. A possible 
explanation for this result is an increase in reducing ROS available in response 
to GSH depletion. It has been demonstrated that incubation with BSO for 24 hrs 
increases endothelial ROS generation in a dose dependent manner189.  An 
increase in ROS generation could increase the rate at which 64Cu-ATSM is 
reduced, therefore increasing 64Cu retention.  
Thiol depletion did not affect hypoxia selective retention of 64Cu from 64Cu-
ATSM. Thiol augmentation by incubation with NAC, however, significantly 
increased 64Cu retention from 64Cu-ATSM under hypoxic conditions with all 
doses and time points. It is surprising that incubating BAEC with NAC for 2 hrs 
followed by a washout period for 1hr would increase 64Cu retention as thiol 
concentrations were not significantly augmented in this group. It is possible, 
however, that excess intracellular NAC reduced 64Cu-ATSM before sufficient 
amounts of NAC were washed from the cell. As BAEC were incubated in low 
oxygen conditions, the 64Cu may have become trapped before NAC was 
washed out. Incubation with NAC and 64Cu-ASTM together without NAC 
washout caused a further increase in hypoxic dependent 64Cu trapping and was 
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dose dependent. This implies that high concentrations of cysteine substrates 
increase 64Cu-ATSM reduction if incubated for a sufficient amount of time.  
 
4.4.2 Modification of BAEC thiol concentration 
In preliminary dose-response studies, DEM treatment for 2 - 8hrs did not affect 
BAEC thiol concentrations. As a GSH conjugating agent it was expected that 
DEM would decrease thiol concentration at these earlier time points. Previous 
studies investigating the effect of DEM on endothelial thiol concentration have 
reported mixed results. Incubation with a high concentration of DEM (0.5 mM) 
for 1 hr decreased  thiol concentration by 60% in human umbilical vein 
endothelial cells (HUVEC)190.  Kokura et al. observed a decrease in HUVEC 
thiol concentration after 15 mins incubation with 0.5 mM DEM followed by a 
gradual increase over 4 hours191. Lower concentrations of DEM (25 and 50 µM) 
had no effect on PAEC thiol concentration from 0.5 – 1 hr192, however, 100 µM 
DEM decreased PAEC thiol concentration by 40% after 0.5 hr in a different 
study193. It has been suggested that at earlier time points, DEM is only effective 
at conjugating GSH to the point of depletion at a dose of 100 – 500 µM in most 
cell types192. As the lower end dose of 100 µM was used in these studies, it may 
be possible that DEM concentration was insufficient to significantly deplete 
thiols in BAEC. 
In the initial, thiol depletion study, an increase in BAEC thiol concentration after 
24 hrs incubation with DEM was observed, consistent with previous 
studies192,194.   Conjugation of GSH by DEM increases de novo GSH synthesis 
over longer periods of time and GSH concentration often exceeds control 
values. When this study was repeated with a wider range of DEM 
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concentrations, thiol concentration still did not decrease over time and the 
rebound effect was highly variable between wells. It was therefore decided that 
DEM was not an appropriate thiol depletion agent for these studies. Treatment 
with BSO for 24 hrs, however, significantly decreased thiol concentration in all 
studies. The preliminary dose response results demonstrated that 100 and 50 
µM BSO depleted GSH to a similar concentration; it was therefore decided 
that100, 25 and 10 µM were to be used in the next study. A short term decrease 
in GSH concentration in BSO treated BAEC (2-8 hrs) with any concentration 
was not observed in these studies. This was expected as BSO prevents GSH 
synthesis by inhibition of γ-glutamylcysteine synthetase, therefore without 
additional oxidative stress the depletion of existing GSH pools requires time. 
These findings were consistent with other endothelial GSH depletion studies 
utilising BSO over 16-24 hrs192-194. 
It is well established that NAC increases endothelial thiol levels by increasing 
GSH synthesis195,196. In these studies, incubation with a high concentration (30 
mM) of NAC significantly increased BAEC thiol concentration at all time points; 
however, thiol concentrations were optimal after 2 hours of incubation with 7.5 – 
30 mM NAC. Following this discovery, the effects of NAC incubation with a 
range of doses (0.01mM – 30 mM) for 05 - 1 hr were investigated. At these 
shorter incubation times thiol concentration was only increased with higher NAC 
concentrations (10-30mM). NAC traverses cell membranes through passive 
diffusion; it is therefore possible that incubation decreases over time due to 
equilibrium with the media, therefore a high concentration of NAC is required to 
significantly increase intracellular thiol concentration. 
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The protocol was further refined for experiments in low oxygen and with 64Cu-
ATSM. In the following  study, BAEC were incubated with 10, 25 and 100 µM 
BSO for 24 hrs and 3, 7.5 and 30 mM NAC for 2 hrs. Thiol concentration was 
significantly decreased in response to all BSO doses, however, 10 and 25 µM 
BSO decreased thiol concentrations to the same extent. There was also no 
significant thiol increase observed with 3 mM NAC incubation. It was therefore 
decided that 10 and 100 µM BSO and 7.5 and 30 mM NAC were used in the 
final protocol. 
Contrary to the results in chapter 3, incubation in low oxygen conditions 
significantly decreased thiol concentrations in untreated BAEC (figure 4.9). In 
this study, BAEC were subjected to low oxygen for a much longer period of time 
(48 hrs), therefore ROS generation (through mitochondrial ETC dysfunction) 
and consequent GSH depletion was likely.  In thiol depleted BAEC, thiol levels 
were depleted to a similar level at 1% and 21 % O2. 
In the radiotracer retention study, it was noted that thiol concentration was not 
significantly affected by NAC incubation 1 hr incubation period with 64Cu-ATSM 
post-treatment in the absence of NAC. As mentioned earlier, NAC passively 
diffuses from cells and it is probable that intracellular NAC equilibrates with the 
media after its removal; therefore augmentation of intracellular thiol 
concentration was less marked. It was therefore decided to add a further group 
to the study in which BAEC were incubated with NAC during the 64Cu-ATSM 
treatment period. BAEC thiol concentration was significantly increased when 
NAC was left in the media during 64Cu-ATSM incubation.  In particular, at 1% 
O2, incubation with 7.5 and 30 mM NAC increased thiol concentrations over 2 
and 3 fold higher compared to 21% O2 equivalents respectively. This may be a 
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cellular defence mechanism; increased ROS generation in response to hypoxia 
may increase cellular uptake of NAC for GSH synthesis. 
 
4.4.3 Effect of thiol concentration and low oxygen on BAEC viability 
To assess the effects of DEM, BSO and NAC on BAEC viability, different 
concentrations of each were incubated with BAEC for 24 hrs. Results from MTT 
assays confirmed that these drugs had no effect on BAEC viability, with the 
exception of 100 mM NAC, which caused a decrease in BAEC viability by 25%. 
This was comparable to the effect of 250 µM H2O2, a positive marker of cell 
death, therefore 100 mM NAC was not used in this study. 
Before the final experiments with 64Cu-ATSM,  the effect of a combination of low 
oxygen and modified thiol concentration on BAEC viability were investigated. A 
significant decrease in cell viability was observed in all treatment groups 
incubated at 1% O2 compared to 21% O2. As the MTT assay is an assessment 
of mitochondrial activity, cell number could possibly affect the outcome. This led 
to a further study which mimicked the same conditions to assess the effects of 
low oxygen and thiol concentration modification on cell protein as a measure of 
cell population. BAEC incubated in 1% O2 contained significantly less protein in 
all treatment groups compared with their normoxic equivalent. This data 
suggests that differences in cell density, as seen in this low oxygen model, will 
affect viability results measured by the MTT assay and should be accounted for 
in experimental protocol design. 
The results obtained from NAC treated BAEC are contrary to those in chapter 3, 
where there was no observable increase in myocardial 64Cu retention from 
64Cu-ATSM in NAC supplemented hearts. Our thiol augmented isolated 
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perfused heart model underwent constant perfusion, hence myocardial NAC 
supplementation and wash out was simultaneous. The concentrations of NAC in 
the BAEC study are far higher than physiological conditions in vivo, even with 
NAC supplementation. This study does, however, support that thiols can reduce 
Cu-ATSM under hypoxic conditions, supporting the theory that thiols are 
















Chapter 5  






















The myocardium must produce sufficient ATP to maintain contractility and cell 
viability. In the normoxic myocardium, oxygen is required for the efficient 
generation of ATP via fatty acid β-oxidation and the mitochondrial ETC. During 
hypoxia the heart switches from fatty acid β-oxidation to glycolysis to generate 
ATP anaerobically. Anaerobic glycolysis is not as efficient at generating ATP 
and the net hydrolysis of ATP leads to an increase in intracellular H+ which 
decreases pH.   
Myocardial hypoxia and ischaemia are therefore both potentially associated with 
acidosis, although the severity of that acidosis may vary between ischaemic and 
hypoxic pathologies. Acidosis activates sarcolemmal NHE which extrudes H+ in 
exchange for Na+ to help maintain a physiological pH at the expense of 
increasing intracellular Na+ concentrations. During ischaemia, however, lack of 
residual blood flow leads to an accumulation of H+ and acidosis becomes more 
severe. Bak and Ingwall used 31P NMR spectroscopy to demonstrate that 
acidosis as a result of ischaemia is more severe than that caused by hypoxia 
alone197.  The severity of acidosis is dependent upon both the extent of tissue 
hypoxia and ischaemia; therefore intracellular pH may vary between different 
cardiac pathophysiologies.  
As was discussed in chapter 1, it is possible that the hypoxia-selective retention 
of Cu from Cu-ATSM is dependent upon ligand protonation, and that acidosis 
may promote this. Changes in intracellular pH may therefore modify the rate of 
dissociation of the complex, and decrease the specificity and reliability of these 
complexes as hypoxia-specific tracers.  To date, there have been no reports on 
the investigation of the effects of acidosis on cardiac Cu-ATSM hypoxia 
181 
 
selectivity. As acidosis is a common (and potentially variable) feature of cardiac 
ischaemia and hypoxia, the effect of acidosis on Cu-ATSM hypoxia selectivity 
and pharmacokinetics was investigated. 
In this study, the ammonium prepulse technique was employed to induce 
acidosis in isolated perfused rat hearts.  In solution, NH4Cl dissociates to NH
3+, 
Cl- and H+. During the washout period, NH3+ is washed from the cell, leaving 
behind H+ and therefore decreasing pH198. To further exacerbate acidosis, the 
NHE was inhibited with zoniporide. Zoniporide specifically inhibits NHE-1 which 
is the major isoform of NHE expressed in the myocardium199. Intracellular 
buffering capacity with HCO3
- was also decreased by perfusing with HCO3
- free 
buffer. The progression of myocardial acidosis was measured using 31P NMR 
spectroscopy (described in chapter 2). The effect of acidosis on 64Cu-ATSM 












5.2 Materials and methods 
5.2.1 Chemicals and reagents 
NH4Cl and the bicinchoninic acid (BCA) assay kit were obtained from Fischer 
Scientific, UK. Zoniporide was obtained from Tocris Bioscience, UK.  64Cu-
ATSM was synthesised as described in chapter 2. 
 
5.2.2 Animals 
Male Wistar rats (275-350g) were used throughout. Rats were given ad libitum 
access to food and water. All experimental procedures were carried out in 
accordance with Home Office regulations as detailed in the Home Office 
Guidance on the Operation of Animals (Scientific Procedures) Act 1986. 
 
5.2.3 Perfusion protocols 
Hearts were excised, cannulated, and perfused with KHB as described in 
chapter 2, and electrically paced at 320 b.p.m. All hearts were perfused with 
normoxic KHB for a stabilisation period of 10 min to ensure cardiac contractile 
function criteria were met before continuing the experiment. Hearts were 
perfused according to the protocols described in figure 5.1. To induce acidosis, 
hearts were infused with NH4Cl and zoniporide solution (20 mmol/ L and 1 
mmol/ L respectively) for 5 mins at 2 mL/ min followed by perfusion with 
zoniporide only for 20 mins. Perfusion buffer was also switched to NaHCO3
 free 
KHB supplemented with 20mM HEPES and 25 mM NaCl to prevent buffering. 
Three boluses of 64Cu-ATSM (2MBq) were injected into the perfusion line at 
t=10 mins, t=42 mins and t=66 mins. Samples of perfusate (approximately 1.5 
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mL) were collected directly from the heart at appropriate time points and 
assessed for lactate, glucose and protein release (described in chapter 2). 
 
 
Figure 5.1. Perfusion protocols for hearts from all treatment groups. There were six perfusion 
protocols for (A) normoxic control, (B) normoxic acidosis, (C) 0% O2, (D) 0% O2 acidosis, (E) 
20% O2 and (F) 20% O2 acidosis groups. 
 
5.2.4 Measurement of cardiac acidosis via 31P NMR spectroscopy 
Parallel groups of hearts were subjected to the protocols outlined in figure 5.1 
(omitting the 64Cu-ATSM injections) and 31P NMR spectra were obtained to 
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5.2.5 64Cu-ATSM pharmacokinetic analysis 
Cardiac 64Cu-ATSM pharmacokinetics were characterised utilising a custom 
built triple detector system. Time activity curve data were analysed with 
Microsoft Excel and MATLAB® to provide radiocopper retention and 
pharmacokinetic measurements, as described in chapter 2. 
5.2.5 Statistical analysis 
All data are presented as the mean ± standard deviation. Statistical significance 

















5.3.1 Effect of hypoxia and NH4Cl prepulse protocols on cardiac pHi 
5.3.1.1 Myocardial pHi during hypoxia 
Figures 5.2-5.5 display representative spectra and average pHi of the hearts 
from all 6 protocols. During normoxia, cardiac pHi remained stable between 
7.13 ± 0.03 and 7.18 ± 0.03 throughout the experimental perfusion (figure 5.2). 
Hypoxia was induced by perfusing hearts with KHB gassed with 0% O2 which 
caused a decrease in pHi from 7.12 ± 0.07 to 7.03 ± 0.08 after 8 mins, however, 
this was not significant when compared to time-matched normoxic pHi and 
returned to 7.1 ±0.09 after 28 mins (figure 5.3).  
 
5.3.1.2 Effect of NH4Cl prepulse and NHE inhibition on myocardial pHi 
Inducing acidosis in these experiments was a two-step procedure: infusing 
NH4Cl in combination with zoniporide for 5 mins, and then washing NH4Cl out in 
the presence of zoniporide for 20 mins.  During normoxia, NH4Cl and zoniporide 
caused pHi to decrease from 7.1 ± 0.06 to 6.3 ± 0.12 (p<0.05) within 20 mins 
(figure 5.4). When zoniporide was washed out, pHi returned to 7.1 ± 0.1 after 15 
mins. Similarly, perfusion with 0% O2 KHB plus NH4Cl and zoniporide caused 
pHi to decrease from 7.1 ± 0.07 to 6.3 ± 0.10 (p<0.05) within 15 mins, which 
returned to 7.1 ± 0.1 after reoxygenation and zoniporide wash out for 15 mins 






Figure 5.2. (A) Representative stacked plot of 
31
P NMR spectra acquired from a normoxic 
control heart.  (B) Single spectra from stacked plot. (C) Myocardial pHi (data are expressed as 
means ± standard deviation, n = 5). 


































Figure 5.3. (A) Representative stacked plot of 
31
P NMR spectra acquired from a hypoxic control 
(0% O2) heart.  (B) Single spectra from stacked plot. (C) Myocardial pHi (data are expressed as 
means ± standard deviation, n = 5). 
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Figure 5.4. (A) Representative stacked plot of 
31
P NMR spectra acquired from a normoxic 
acidotic heart.  (B) Single spectra from stacked plot. (C) Myocardial pHi (data are expressed as 
means ± standard deviation, n = 5).*p<0.05 vs. time-matched normoxic control pHi. 


















 Figure 5.5. (A) Representative stacked plot of 31P NMR spectra acquired from a hypoxic (0% 
O2) acidotic heart.  (B) Single spectra from stacked plot. (C) Myocardial pHi (data are expressed 
as means ± standard deviation, n = 5).*p<0.05 vs. time-matched normoxic control pHi. 
 
 


















5.3.1.3 Myocardial metabolite concentration 
5.3.1.3.1 Phosphorous metabolite concentration during normoxia and 
hypoxia 
To measure phosphorous metabolite concentration the area under each peak 
was compared to that of the initial PCr peak in the first spectrum of each heart; 
therefore all metabolite concentrations are expressed as arbitrary units (figures 
5.6-5.9). Metabolite concentrations remained stable in normoxic untreated 
control hearts. PCr peak areas averaged between 0.75 ± 0.4 and 1.3 ± 0.3, Pi 
between 0.58 ± 0.09 and 1.01 ± 0.21 and ATP between 0.77 ± 0.08 and 1.27 ± 
0.25. Hypoxia with 0% O2 caused PCr levels to fall from 0.91 ± 0.10 to 0.15 ± 
0.15 within 16 mins, while Pi peak area increased from 0.74 ± 0.29 to 1.33 ± 
0.43 and ATP decreased from 0.56 ± 0.18 to 0.46 ± 0.24.  
There was no measurable sugar phosphate peak in the spectra acquired from 
normoxic control hearts. Hypoxia with 0% O2 caused a gradual increase in 
sugar phosphate concentration which peaked at 1.02 ± 0.30 after 28 mins.  
5.3.1.3.2 Metabolite concentration during acidosis 
In normoxic hearts, acidosis caused a decrease in PCr concentration from 0.85 
± 0.19 to 0.02 ± 0.02 within 20 mins, an increase in Pi concentration from 0.69 ± 
0.29 to 1.76 ± 0.67 and a decrease in ATP concentration from 0.77 ± 0.13 to 
0.55 ± 0.08. By the end of the experimental protocol when zoniporide had been 
washed out for 23 mins and metabolite concentration returned towards basal 
values, PCr increased to 0.78 ± 0.40, Pi decreased to 0.20 ± 0.17 and ATP 
increased to 0.67 ± 0.42. Similarly to normoxic control hearts, there were no 
measurable sugar phosphate peaks in spectra from normoxic acidotic hearts.    
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A combination of acidosis and hypoxia with 0% O2 caused a decrease in PCr 
levels from 1.05 ± 0.15 to 0.17 ± 0.24, an increase in Pi from 0.78 ± 0.29 to 2.5 
± 0.29 and a decrease in ATP from 0.87 ± 0.18 to 0.46 ± 0.38 after NH4Cl had 
been washed out for 15 mins. PCr and Pi values began to recover after NH4Cl 
and zoniporide was washed out, but failed to return to basal values by the end 
of the experimental protocol (PCr 0.39 ± 0.22 and Pi 1.16 ± 0.60).  ATP levels 
completely failed to recover by the end of the hypoxia/acidosis washout period 
(0.27 ± 0.12 at 64 mins). Sugar phosphate levels were undetectable from these 









Figure 5.6. PCr levels of hearts undergoing normoxic, hypoxic (0% O2) or acidotic perfusion 
protocols. Grey shaded areas represent perfusion with hypoxic buffer. PCr peak areas from the 
first spectra in each heart were normalised to 1.  Data are expressed as means ± standard 
deviation (n = 5). 
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Figure 5.7. Pi levels of hearts undergoing normoxic, hypoxic (0% O2) or acidotic perfusion 
protocols. Grey shaded areas represent perfusion with hypoxic buffer. P i peak areas are with 
respect to PCr peaks.  Data are expressed as means ± standard deviation (n = 5). 
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Figure 5.8. ATP levels of hearts undergoing normoxic, hypoxic (0% O2) or acidotic perfusion 
protocols. Grey shaded areas represent perfusion with hypoxic buffer. ATP peak areas are with 
respect to PCr peaks.  Data are expressed as means ± standard deviation (n = 5). 
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Figure 5.9. Sugar phosphate levels of hearts undergoing normoxic, hypoxic (0% O2) or acidotic 
perfusion protocols. Grey shaded areas represent perfusion with hypoxic buffer. Peak areas are 
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5.3.1.4 Cardiac Function 
5.3.1.4.1 Heart Rate 
Heart rates from all protocols are displayed in figure 5.10. As hearts were paced 
at around 315 b.p.m., there was little variation in heart rate during normoxic 
control perfusion (314.3 ± 1.7 – 316.8 ± 3.9 b.p.m.). Hypoxia with 0% O2 for 15 
mins caused heart rate to fluctuate between 252 ± 127.4 and 360.3 ± 71.88 
b.p.m, indicating spontaneous infrequent arrhythmias. After 35 mins, however, 
heart rates decreased to between 255 ± 37.9 and 282 ± 7.7 b.p.m. for the 
remainder of the experimental protocol.  
Acidosis caused a decrease in heart rate from 319.2 ± 5.9 to 246.1 ± 151.3 
b.p.m. within 5 mins of NH4Cl infusion. Once acidosis was induced by washing 
out NH4Cl, heart rates were not measurable as hearts lost all sinus rhythm. For 
this reason these values have not been included in figure 5.12. In normoxic 
hearts, washout of zoniporide for 15 mins caused a recovery in sinus rhythm 
and heart rate (319.3 ± 6.2 b.p.m.). Hypoxia with 0% O2 plus acidosis induced a 
loss in sinus rhythm (from 317.9 ± 4.8 b.p.m.) within 1 min; however, 
reoxygenation and zoniporide washout did not lead to a recovery of sinus 




 Figure 5.10. Heart rates (b.p.m) of hearts undergoing normoxic, hypoxic (0% O2) or acidotic 
perfusion protocols). Grey shaded areas represent perfusion with hypoxic buffer. Data are 
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5.3.1.4.2 Coronary Perfusion Pressure 
Coronary perfusion pressures of hearts from each protocol are displayed in 
figure 5.11. In normoxic control hearts, perfusion pressure increased slightly 
from 94.6 ± 4.7 to 107.2 ± 3.9 mmHg over the course of perfusion.  Hypoxia 
with 0% O2 caused an increase in perfusion pressure from 106.4 ± 16.6 mmHg 
to 131.2 ± 22.4 by the end of perfusion.  
Infusion of NH4Cl in normoxic hearts did not affect initial perfusion pressure 
(90.5 ± 10.0 mmHg); however, washout of NH4Cl with zoniporide infusion 
caused an increase in perfusion pressure which reached a plateau after 10 
mins at 131.1 ± 25.2 mmHg. This decreased slightly after zoniporide washout; 
however, final perfusion pressure remained at 121.5 ± 27.9 mmHg. Hypoxia 
with 0% O2 plus acidosis appeared to cause an initial rapid decrease in 
perfusion pressure to 73.2 ± 71.5 mmHg; however, this gradually began to 
increase reaching 131.1 ± 38.7 mmHg by the end of the acidosis protocol and 
reoxygenation did not cause it to recover by the end of the experimental 




Figure 5.11. Coronary perfusion pressure (mmHg) of hearts undergoing normoxic, hypoxic (0% 
O2) or acidotic perfusion protocols. Grey shaded areas represent perfusion with hypoxic buffer. 
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5.3.1.4.3 Left ventricular developed pressure (LVDP) 
During normoxic control protocols LVDP remained stable between 97.3 ± 19.2 
and 121.3 ± 27.2 mmHg (figure 5.12). Hypoxia with 0% O2 resulted in a gradual 
decrease in LVDP from 87.5 ± 32.9 to 5.1 ± 2.0 mmHg by the end of the 
experimental protocol.  
In hearts from normoxic acidosis protocols, infusion with NH4Cl caused a rapid 
reduction in LVDP from 90.7 ± 21.9 to 22.5 ± 11.1 mmHg within 5 mins. 
Washout of NH4Cl caused a further decrease to 5.5 ± 4.7 mmHg within 1 
minute. After zoniporide was washed out, LVDP returned to 67.2 ± 15.2 mmHg 
by the end of experimental protocols.  Hypoxia with 0% O2 plus acidosis also 
caused a decrease in LVDP from 97.1 ± 32.1 to 4.5 ± 3.7 mmHg after 25 mins. 
Reoxygenation did not cause the LDVP to recover which remained at 10.8 ± 
10.2 mmHg by the end of the experimental protocol, suggesting the hearts were 




Figure 5.12. LVDP (mmHg) of hearts undergoing normoxic, hypoxic (0% O2) or acidotic 
perfusion protocols. Grey shaded areas represent perfusion with hypoxic buffer. Data are 
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5.3.1.4.4 Left ventricular end diastolic pressure (LVEDP) 
During normoxic control protocols, LVEDP remained stable throughout and 
ranged between 19.5 ± 4.79 and 24.6 ± 5.8 mmHg (figure 5.13). Hypoxia with 
0% O2 led to a rise in LVEDP from 28.3 ± 11.3 to 88.4 ± 25.9 mmHg by the end 
of the hypoxic period.  
In normoxic hearts, acidosis caused a decrease in LVEDP from 16.4 ± 5.3 to 
38.2 ± 24.8 mmHg after 25 mins, however, washout of zoniporide resulted in a 
fall in LVEDP to 29.1 ± 22.4 mmHg after 23 mins. Hypoxia with 0% O2 KHB + 
acidosis caused an increase in LVEDP from 15.4 ± 18.9 to 48.6 ± 21.5 mmHg 
after 25 mins, however, continued to increase after reoxygenation and 






Figure 5.13. LVEDP (mmHg) of hearts undergoing normoxic, hypoxic (0% O2) or acidotic 
perfusion protocols. Grey shaded areas represent perfusion with hypoxic buffer. Data are 
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5.3.1.4.5 Lactate release 
Figure 5.14 displays the lactate concentration of perfusate samples collected 
from all hearts. Lactate release from normoxic control hearts was minimal 
during normoxic perfusion (0.85 ± 0.01 to 0.11 ± 0.03 nmol /mL /g dry wt). 
Hypoxia with 0% O2 caused a rapid increase in lactate release within 5 mins 
(0.38 ± 0.03 nmol /mL /g dry wt). In normoxic hearts, perfusion with NH4Cl 
caused a small increase in lactate release from 0.10 ± 0.03 to 0.15 ± 0.11 nmol 
/mL /g dry wt within 2 minutes which decreased again upon NH4Cl washout. 
Lactate release from acidotic hearts perfused with 0% O2 KHB was similar to 
that of normoxic acidotic hearts (lactate release peaking after 3 mins at 0.14 ± 
0.01 nmol /mL /g dry wt). 
 
Figure 5.14. Lactate concentration of perfusate samples collected from hearts undergoing 
normoxic, hypoxic (0% O2) or acidotic perfusion protocols. Data are expressed as means ± 
standard deviation (n = 5). 
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5.3.1.4.6 Glucose consumption 
Perfusate glucose concentrations from all hearts are displayed in figure 5.15. 
During normoxic protocols, perfusate glucose ranged between 10.6 ± 1.1 and 
11.4 ± 0.4 mmol/L. Glucose concentration also remained stable in hearts 
perfused with 0% O2 KHB, ranging between 10.8 O2 ±  1.7 and 11.5 ± 0.2 
mmol/L). Induction of acidosis also had no effect on perfusate glucose 
concentration from hearts perfused with normoxic or 0% O2 KHB (ranging from 
10.7 ± 1.0 to 11.8 ± 1.7 mmol/L and 10.7 ± 1.2 to 11.8 ± 1.3 mmol/L).  
 
 
Figure 5.15. Glucose concentration of perfusate samples collected from hearts undergoing 
normoxic, hypoxic (0% O2) or acidotic perfusion protocols. Data are expressed as means ± 
standard deviation (n = 5). 
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5.3.1.4.7 Protein release 
Figure 5.17 displays the protein concentrations of perfusates from all hearts. 
There was no release of protein from untreated hearts perfused with normoxic 
or 0% O2 KHB (ranging from 0.005 ± 0.008 to 0.02 ± 0.02 mg /mL /g dry wt and 
0.004  ± 0.007 to 0.01 ± 0.01 mg /mL /g dry wt respectively). Induction of 
acidosis also did not induce protein release in normoxic perfused hearts. 
Hypoxia with 0% O2 plus acidosis, however, caused an increase in cardiac 
protein release from 0.01 ± 0.008 to 0.04 ± 0.001 mg /mL /g dry wt after 26 
mins, returning to 0.015 ± 0.016 mg /mL /g dry wt by the end of the 
experiments.  
 
Figure 5.16. Protein concentration of perfusate samples collected from hearts undergoing 
normoxic, hypoxic (0% O2) or acidotic perfusion protocols. Data are expressed as means ± 
standard deviation (n = 5). 
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5.3.2 Effect of hypoxia with 20% O2 saturated buffers and ammonium 
prepulse protocols on cardiac pHi 
In the preliminary studies, it was found that hearts subjected to 0% O2 hypoxia 
and acidosis combined did not recover contractile function upon reoxygenation 
(figure 5.10 and 5.12). As these tracers are intended to delineate hypoxically 
compromised, but viable tissue, it was apparent that this protocol was too 
extreme, and perhaps of limited relevance.  A further less extreme protocol 
utilising hypoxia induced by perfusion with KHB gassed with 20% O2 was 
therefore included in the study. 
 
5.3.2.1 Myocardial pHi during hypoxia with 20% O2 
Hypoxia with 20% O2 did not affect pHi which averaged between 7.13 ± 0.11 
and 7.22 ± 0.1, and was the same when compared to time-matched normoxic 
control pHi (figure 5.17). 
 
5.3.2.2 Effect of hypoxia with 20% O2, NH4Cl prepulse and NHE inhibition 
on myocardial pHi 
Perfusion with 20% O2 KHB plus NH4Cl and zoniporide infusion caused pHi to 
decrease from 7.1 ± 0.07 to 6.4 ± 0.06 (p<0.05) which returned to 7.1 ± 0.10 
after zoniporide was washed out for 15 mins (figure 5.) and was the same when 





Figure 5.17. (A) Representative stacked plot of 
31
P NMR spectra acquired from a hypoxic 
control (20% O2) heart.  (B) Single spectra from stacked plot. (C) Myocardial pHi (data are 
expressed as means ± standard deviation, n = 5). 

































Figure 5.18. (A) Representative stacked plot of 
31
P NMR spectra acquired from a hypoxic (20% 
O2) acidotic heart.  (B) Single spectra from stacked plot. (C) Myocardial pHi (data are expressed 
as means ± standard deviation, n = 5).*p<0.05 vs. time-matched normoxic control pHi. 
 
 
























5.3.2.3 Myocardial metabolite concentration 
5.3.2.3.1 Phosphorous metabolite concentration during normoxia and 
hypoxia with 20% O2 
Phosphorous metabolite concentrations for hearts perfused with 20% O2 KHB 
are displayed in figures 5.19-5.22. Compared to perfusion with 0% O2 KHB, 
20% O2 had less of an effect on metabolite concentration with the same time 
period; PCr decreased from 1.04 ± 0.09 to 0.36 ± 0.18, while Pi peak area 
increased from 0.68 ± 0.07 to 1.11 ± 0.20 and ATP decreased from 0.59 ± 0.08 
to 0.29 ± 0.22. Reoxygenation for 15 mins restored metabolite concentration in 
hypoxic (20% O2) hearts; PCr values returned to 1.12 ± 0.21, Pi to 0.46 ± 0.21 
and ATP to 0.40 ± 0.24. As with 0% O2, perfusing hearts with 20% O2 KHB also 
caused an increase in sugar phosphate concentration which peaked at 0.82 ± 
0.10 after 28 mins, however, returned towards 0 after reoxygenation for 19 
mins. 
5.3.2.3.2 Metabolite concentration during acidosis 
Similar to normoxic acidotic hearts, hypoxia with 20% O2 plus acidosis caused a 
decrease in PCr from 0.88 ± 0.15 to 0.16 ± 0.31, an increase in Pi from 0.50 ± 
0.21 to 1.61 ± 0.34 and a decrease in ATP from 0.70 ± 0.31 to 0.37 ± 0.18 
within 15 mins.  Phosphorus metabolite levels also returned towards basal 
values after NH4Cl and zoniporide had been washed out; however, PCr and 
ATP were still depressed compared to normoxic control values by the end of the 
experiment (PCr 0.68 ± 0.25, Pi 0.55 ± 0.45 and ATP 0.43 ± 0.25). As in acidotic 
hearts perfused with 0% O2 KHB, sugar phosphate levels were also 




Figure 5.19. PCr levels of hearts of hearts undergoing hypoxic (20% O2) or hypoxia (20% O2) + 
acidosis protocols. Grey shaded areas represent perfusion with hypoxic buffer. PCr peak areas 
from the first spectrum in each heart were normalised to 1.  Data are expressed as means ± 
standard deviation (n = 5). 
 
 
Figure 5.20. Pi levels of hearts undergoing hypoxic (20% O2) or hypoxia (20% O2) + acidosis 
protocols. Grey shaded areas represent perfusion with hypoxic buffer. P i peak areas are with 
respect to PCr peaks.  Data are expressed as means ± standard deviation (n = 5). 
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Figure 5.21. ATP levels of hearts undergoing hypoxic (20% O2) or hypoxia (20% O2) + acidosis 
protocols. Grey shaded areas represent perfusion with hypoxic buffer. ATP peak areas are with 




Figure 5.22. Sugar phosphate levels of hearts undergoing hypoxic (20% O2) or hypoxia (20% 
O2) + acidosis protocols. Grey shaded areas represent perfusion with hypoxic buffer. Peak 
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5.3.2.4 Cardiac Function 
5.3.2.4.1 Heart Rate 
Hypoxia with 20% O2 caused a gradual decrease in heart rate from 312.9 ± 9.0 
b.p.m. to 287.83 ± 57.8 b.p.m. after 6 mins and decreased further to 211.7 ± 
96.5 b.p.m. after 28 mins (figure 5.23). Reoxygenation led to the recovery of a 
regular sinus rhythm 311.9 ± 8.5 b.p.m. within 12 mins. Similar to normoxia plus 
acidosis, hypoxia with 20% O2 KHB plus acidosis caused a gradual decrease in 
heart rate, falling from 311.0 ± 3.7 to 269.6 ± 66.1 over 5 mins. Shortly after 
NH4Cl was washed from the hearts sinus rhythm was lost, however, 
reoxygenation and washout of zoniporide for 15 mins induced an increase in 
heart rate to 310.1 ± 5.1. 
 
 
 Figure 5.23. Heart rates (b.p.m.) of hearts undergoing hypoxic (20% O2) or hypoxia (20% O2) + 
acidosis protocols. Grey shaded areas represent perfusion with hypoxic buffer. Data are 
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5.3.2.4.2 Coronary Perfusion Pressure 
Hypoxia with 20% O2 caused a slight increase in perfusion pressure from 93.4 ± 
9.2 to 101.7 ± 15.6 mmHg by the end of the perfusion protocol and was similar 
to that in hearts perfused with 0% O2 KHB (figure 5.24). Hypoxia with 20% O2 
KHB plus acidosis also caused perfusion pressure to decrease from 115.0 ± 
17.1 to 105.6 ± 9.4 mmHg within 5 mins which then increased to 188.56 ± 44.17 
mmHg by the end of the acidosis period. Reoxygenation and zoniporide 
washout, however, caused a decrease to an end perfusion pressure of 152.3 ± 




Figure 5.24. Perfusion pressure (mmHg) of hearts undergoing hypoxic (20% O2) or hypoxia 
(20% O2) + acidosis protocols. Grey shaded areas represent perfusion with hypoxic buffer. Data 
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5.3.2.4.3 Left ventricular developed pressure (LVDP) 
Hypoxia with 20% O2 resulted in a decrease in LVDP from 115.4 ± 13.4 to 35.5 
± 12.5 mmHg after 25 mins which was similar to 0% O2; however, 
reoxygenation caused the LVDP to return to 103.3 ± 13.1 mmHg by the end of 
experiments (figure 5.25). Hypoxia with 20% O2 plus acidosis caused a rapid 
decrease in LVDP from 126.6 ± 10.4 to 15.8 ± 11.6 mmHg within 5 mins and 
was similar to normoxic acidosis hearts. Washout of NH4Cl further decreased 
LVDP to 1.2 ± 0.8 mmHg within 3 mins, however, reoxygenation led to its 
recovery to 90.2 ± 26.5 mmHg after by the end of experiments. 
 
 
Figure 5.25. LVDP (mmHg) of hearts undergoing hypoxic (20% O2) or hypoxia (20% O2) + 
acidosis protocols. Grey shaded areas represent perfusion with hypoxic buffer. Data are 
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5.3.2.4.4 Left ventricular end diastolic pressure (LVEDP) 
Perfusing hearts with 20% O2 KHB also led to an increase in LVEDP from 7.5 ± 
3.4 to 35.2 ± 12.9 mmHg which was similar to that in hearts perfused with 0% 
O2 KHB (figure 5.26). Reoxygenation, however, caused LVEDP to return to 11.5 
± 9.3 mmHg by the end of experiments. Hypoxia with 20% O2 plus acidosis 
caused an increase in LVEDP from 7.1 ± 2.6 to 44.1 ± 7.7 mmHg after 25 mins, 
again, similar to perfusion with 0% O2 KHB. Reoxygenation and washout of 
zoniporide initially caused a transient rise in LVEDP to 59.4 ± 17.8 mmHg, 
however, decreased to 47.3 ± 27.7 mmHg by the end of experiments. 
 
 
Figure 5.26. LVEDP (mmHg) of hearts undergoing hypoxic (20% O2) or hypoxia (20% O2) + 
acidosis protocols. Grey shaded areas represent perfusion with hypoxic buffer. Data are 
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5.3.2.4.5 Lactate release 
Hypoxia with 20% O2 KHB caused an increase in lactate release (figure 5.27), 
which was more gradual than occurred with perfusion with 0% O2 equilibrated 
buffer, reaching a maximum of 0.35 ± 0.03 nmol /mL /g dry wt after 20 mins of 
hypoxia. Lactate release from acidotic hearts perfused with 20% O2 KHB was 
similar to that of normoxic acidotic hearts (lactate release peaking after 3 mins 




Figure 5.27. Lactate concentration of perfusate samples from hearts undergoing hypoxic (20% 
O2) or hypoxia (20% O2) + acidosis protocols. Data are expressed as means ± standard 
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5.3.2.4.6 Glucose Consumption 
As in normoxic control hearts, perfusate glucose concentration remained stable 
from hearts perfused with 20% O2 KHB, ranging between 10.7 ± 1.3 and 11.6 ± 
0.7 mmol/L (figure 5.28). Induction of acidosis also had no effect on perfusate 
glucose concentration from hearts perfused with 20% O2 KHB, ranging from 





Figure 5.28. Glucose concentration of perfusate samples from hearts undergoing hypoxic (20% 
O2) or hypoxia (20% O2) + acidosis protocols. Data are expressed as means ± standard 
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5.3.2.4.7 Protein release 
Perfusion with 20% O2 did not induce cardiac protein release into the perfusate 
(ranging from 0.004 ± 0.009 to 0.008 ± 0.07 mg /mL /g dry wt) and was similar 
to that of normoxic hearts (figure 5.29). Unlike 0% O2, hypoxia with 20% O2 plus 
acidosis did not cause an increase in cardiac protein release (ranging from 
0.005 ± 0.01 to 02 ± 0.01 mg /mL /g dry wt). 
 
 
Figure 5.29. Protein concentration of perfusate samples from hearts undergoing hypoxic (20% 
O2) or hypoxia (20% O2) + acidosis protocols. Data are expressed as means ± standard 
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5.3.3 Effect of acidosis on 64Cu-ATSM hypoxia selectivity and 
pharmacokinetics  
In section 5.3.2.4 the effect of inducing less severe hypoxia (20% O2 compared 
to 0% which was used previously) in combination with acidosis on cardiac 
contractile function was described. As heart rate and LVDP began to recover 
once zoniporide/acid was washed from these hearts, it was determined that 
these groups would be added to 64Cu retention studies in place of 0% O2 
groups.   
 
5.3.3.1 64Cu retention from 64Cu-ATSM in acidic hearts 
Representative time-activity curves of 64Cu-ATSM injections and 64Cu retention 
with and without intracellular acidosis are shown in figure 5.30. During normoxic 
buffer perfusion, there was relatively little tissue retention of 64Cu from 64Cu-
ATSM at any point during the perfusion protocol. This was unaffected by 
induction of acidosis (figure 5.30A). Hypoxia caused a notable increase in 64Cu 
retention from 64Cu-ATSM; however, acidosis suppressed hypoxia dependent 




Figure 5.30. Representative time-activity curves from the triple detector system demonstrating 
64
Cu uptake from 
64
Cu-ATSM in (A) normoxic hearts and (B) hypoxic hearts. Each trace 
represents control hearts (no treatment; top) and heart undergoing acidosis (bottom). Black 
outlined boxes represent period of acidosis and grey shaded areas represent perfusion with 





The data from 5 replicate experiments are summarised in figure. 5.31. There 
was no significant difference in 64Cu retention between all three injections of 
64Cu-ATSM in normoxic control hearts (10.0 ± 2.5, 9.5 ± 2.1 and 8.9 ± 1.8 %), 
but during normoxic acidosis 64Cu retention significantly decreased from 9.3 ± 
2.7 % during the control period to 2.4 ± 1.6 % (figure 5.31 A; p<0.05), and 
returned to pre-acidotic values (12.7 ± 3.0 %) 15 mins after zoniporide/acid 
washout. 
Hypoxia significantly increased 64Cu retention from 11.0 ± 2.2 to 46.5 ± 12.0 % 
(p<0.05), which returned to 3.9 ± 4.6 % upon reoxygenation (Figure 5.31 B). 
Inducing acidosis, however, abolished 64Cu retention from 64Cu-ATSM during 





Figure 5.31. Effect of acidosis on 
64
Cu retention in normoxic and hypoxic isolated perfused rat 
hearts. Hearts were administered three bolus injections of 
64
Cu-ATSM. Data are expressed as 
the % of total activity injected (means ± standard deviation, n=5 per group). *p<0.05 vs. control 




















































































































































5.3.3.2 Pharmacokinetic analysis of time-activity curve data 
To determine whether acidosis changed the pharmacokinetics of 64Cu-ATSM 
washout time-activity curves of tracer washout were fitted with a bi-exponential 
function to obtain a fast clearance rate (FCR), a slow clearance rate (SCR), and 
their respective importance in governing overall washout (their amplitudes). 
Data is summarised in tables 5.1-5.2. The FCR, SCR or their amplitudes did not 
change during the normoxic perfusion protocol (figures 5.32-5.34). Acidosis had 
no effect on FCR, SCR or their amplitudes during normoxia. The FCR was 
always significantly higher than that of the SCR (p<0.05) during normoxia and 
this was unaffected by acidosis. 
During hypoxia, the FCR increased significantly over control values however, 
SCR remained the same in the non-acidosis group. Reoxygenation caused a 
decrease in FCR and a significant increase in SCR (p<0.05) compared to that 
of normoxic control values. Hypoxia in combination with acidosis, did not affect 
FCR or SCR or respective amplitudes. Reoxygenation and zoniporide washout 








Figure 5.32. FCR for each Cu –ATSM injection as determined by the bi-exponential analysis of 
64
Cu clearance from heart tissue based on time-activity curve data. Data are expressed as 
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Figure 5.33. SCR for each Cu –ATSM injection as determined by the bi-exponential analysis of 
64
Cu clearance from heart tissue based on time-activity curve data. Data are expressed as 
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Figure 5.34 Amplitudes of the FCR and SCR for all injections of 
64
Cu-ATSM. Data are 






































































































































Table 5.1. FCR and SCR values from figures 5.33 and 5.34. Data are expressed as rates of 
64




]; means ± standard deviation, n=5 per 
group). 
    Non-acidotic Acidotic 
  Injection FCR (kfc [min-1]) 
Normoxic 1: Normoxia   1.21 ± 0.04   1.50 ± 0.18 (pre-acidosis) 
hearts 2: Normoxia   1.29 ± 0.21   1.63 ± 0.37 (acidosis) 
 
3: Normoxia  1.32 ± 0.20  1.43 ± 0.11 (post-acidosis) 
     
     Hypoxic 1: Normoxia   1.44 ± 0.01   1.34 ± 0.01 (pre-acidosis) 
hearts 2: Hypoxia * 2.59 ± 0.42   1.41 ± 0.17 (acidosis) 
 
3: Reoxygenation   1.42 ± 0.08   0.91 ± 0.77 (post-acidosis) 
     
     
  
SCR (kfc [min-1]) 
Normoxic 1: Normoxia * 0.007 ± 0.001 0.006 ± 0.004 (pre-acidosis) 
hearts 2: Normoxia * 0.013 ± 0.003 0.027 ± 0.024 (acidosis) 
 
3: Normoxia * 0.012 ± 0.015 0.14 ± 0.005 (post-acidosis) 
     
     Hypoxic 1: Normoxia * 0.012 ± 0.003 0.010 ± 0.002 (pre-acidosis) 
hearts 2: Hypoxia  0.008 ± 0.005  0.016 ± 0.011 (acidosis) 
 
3: Reoxygenation * 0.049 ± 0.009 * 0.009 ± 0.003 (post-acidosis) 
   












Table 5.2. Amplitudes of FCR and SCR from figure 5.34. Data are expressed as amplitudes 
corresponding to the 
64
Cu FCR or SCR of each 
64
Cu-ATSM injection (means ± standard 
deviation, n=5 per group). 
    Non-acidotic Acidotic 
  Injection FCR amplitude (arbitrary units) 
Normoxic 1: Normoxia   0.81 ± 0.07   0.82 ± 0.04 (pre-acidosis) 
hearts 2: Normoxia   0.88 ± 0.06   0.79 ± 0.12 (acidosis) 
 
3: Normoxia   0.89 ± 0.04   0.76 ± 0.10 (post-acidosis) 
     
     Hypoxic 1: Normoxia   0.82 ± 0.07   0.84 ± 0.04 (pre-acidosis) 
hearts 2: Hypoxia   0.36 ± 0.02   0.81 ± 0.04 (acidosis) 
 
3: Reoxygenation   0.82 ± 0.08   0.79 ± 0.18 (post-acidosis) 
     
     
  
SCR amplitude (arbitrary units)
Normoxic 1: Normoxia * 0.13 ± 0.04 * 0.12 ± 0.02 (pre-acidosis) 
hearts 2: Normoxia * 0.10 ± 0.03 * 0.17 ± 0.14 (acidosis) 
 
3: Normoxia * 0.10 ± 0.03 * 0.16 ± 0.03 (post-acidosis) 
     
     Hypoxic 1: Normoxia * 0.13 ± 0.04 * 0.11 ± 0.003 (pre-acidosis) 
hearts 2: Hypoxia  0.49 ± 0.09  * 0.98 ± 0.06 (acidosis) 
 
3: Reoxygenation * 0.09 ± 0.06 * 0.29 ± 0.10 (post-acidosis) 
   
   *p < 0.05 vs. FCR amplitude 
 
 
5.3.4 Effect of perfusion with zoniporide in the absence of NH4Cl
  
As it was observed that found that hearts subjected to a combination of hypoxia 
and acidosis completely abolished the hypoxic dependent retention of 64Cu from 
64Cu-ATSM (figure 5.31), next the effect of zoniporide infusion in the absence of 
NH4Cl was investigated to determine if this effect was caused by acidosis or 




5.3.4.1 Cardiac contractile function 
Infusion of zoniporide did not affect heart rate in normoxic hearts, which 
remained stable between 302 ± 4.7 and 313 ± 12.3 b.p.m. (figure 5.35). Similar 
to hypoxic control hearts, hypoxia + zoniporide caused a decrease in heart rate, 
although its onset was more rapid and more severe (decreasing from 303 ± 
17.9 to 209 ± 69.9 b.p.m. within 7 mins).  
 
Figure 5.35. Heart rates (b.p.m) of normoxic and hypoxic hearts infused with zoniporide only. 
Grey shaded areas represent perfusion with hypoxic buffer. Data are expressed as means ± 
standard deviation (n = 5). 
 
Infusion with zoniporide caused an increase in coronary perfusion pressure in 
normoxic hearts from 71.3 ± 21.3 to 101.2 ± 24.1 mmHg after 25 mins. As soon 
as zoniporide was washed out this decreased immediately, reaching 76.5 ± 9.1 
mmHg by the end of the experimental protocol (figure 5.36). Similar to hypoxic 
hearts, hypoxia and zoniporide combined caused an increase in perfusion 
pressure from 88.7 ± 39.2 to 102.4 ± 48.8 mmHg , which did not recover upon 
reoxygenation. 


















































Figure 5.36. Coronary perfusion pressures (mmHg) of normoxic and hypoxic hearts infused with 
zoniporide only. Grey shaded areas represent perfusion with hypoxic buffer. Data are 
expressed as means ± standard deviation (n = 5). 
Zoniporide infusion had little effect on LVDP in normoxic hearts (98.8 ± 6.6 to 
109.8 ± 10.7 mmHg (figure 5.37). A combination of zoniporide and hypoxia 
induced a decrease in LVDP from 93.9 ± 31.0 to 65.9 ± 39.5 mmHg after 25 
mins which was similar to hypoxia alone. Reoxygenation and zoniporide 
washout caused this to recover to 113.7 ± 5.4 mmHg by the end of the 
experimental protocol. 
 
Figure 5.37. LVDP (mmHg) of normoxic and hypoxic hearts infused with zoniporide only. Grey 
shaded areas represent perfusion with hypoxic buffer. Data are expressed as means ± standard 
deviation (n = 5). 






































































































Zoniporide did not affect LVEDP in normoxic hearts which (4.9 ± 3.3 and 7.1 ± 
4.0 mmHg; figure 5.38). Hypoxia combined with zoniporide infusion caused a 
gradual increase in LVEDP from 8.41 ± 1.7 to 23.4 ± 21.7 mmHg after 25 mins 
which is similar to the effects of  hypoxia alone.    
 
Figure 5.38. LVEDP (mmHg) of normoxic and hypoxic hearts infused with zoniporide only. Grey 
shaded areas represent perfusion with hypoxic buffer. Data are expressed as means ± standard 
deviation (n = 5). 
 
5.3.4.2 64Cu retention from 64Cu-ATSM during zoniporide infusion alone 
Figure 5.39 displays the 64Cu retention from 64Cu-ATSM injections in hearts 
infused with zoniporide alone. In normoxic hearts, zoniporide had no effect upon 
64Cu retention (9.5 ± 2.1 % normoxia control vs. 14.42 ± 2.05 normoxia plus 
zoniporide). Furthermore, zoniporide alone had no effect on the hypoxia 
dependent retention of 64Cu from 64Cu-ATSM, which was significantly higher 
than normoxic control values (46.5 ± 12.0 % hypoxia vs. 50.7 ± 5.7 % hypoxia 
plus zoniporide; p<0.05). 
 




























































5.3.4.3 Pharmacokinetic analysis of time-activity curve data 
Pharmacokinetic data for normoxic and hypoxic hearts infused with zoniporide 
alone are summarised in tables 5.3 and 5.4. In normoxic hearts, zoniporide did 
not affect 64Cu FCR, SCR or their respective amplitudes across all three 64Cu-
ATSM injections and were similar to that of normoxic control hearts (figures 
5.40-5.42). Zoniporide also did not affect 64Cu FCR or SCR in hypoxic hearts, 
as 64Cu FCR significantly increased and SCR significantly decreased (p<0.05) 
compared to that of normoxic controls; similar to that of hearts perfused with 
hypoxic buffer alone. FCR and SCR amplitudes were also similar to that of 






Figure 5.39 Effect of zoniporide alone on 
64
Cu retention in normoxic and hypoxic isolated 
perfused rat hearts. Hearts were administered three bolus injections of 
64
Cu-ATSM. Data are 
expressed as the % of total activity injected (means ± standard deviation, n=5 per group). 




















































































































































Figure 5.40 FCR for each Cu–ATSM injection as determined by the bi-exponential analysis of 
64
Cu clearance from heart tissue based on time-activity curve data. Data are expressed as 
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Figure 5.41.  FCR for each Cu–ATSM injection as determined by the bi-exponential analysis of 
64
Cu clearance from heart tissue based on time-activity curve data. Data are expressed as 
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Figure 5.42. Amplitudes of the FCR and SCR for injections of 
64
Cu-ATSM in hearts infused with 

























































































































Table 5.3. FCR and SCR values from figures 5.40-5.41. Data are expressed as rates of 
64
Cu 




]; means ± standard deviation, n=5 per group). 
    Control Zoniporide 
  Injection FCR (kfc [min-1]) 
Normoxic 1: Normoxia   1.21 ± 0.04   1.50 ± 0.18 (pre-zoniporide) 
hearts 2: Normoxia   1.29 ± 0.21   0.73 ± 0.62 (zoniporide) 
 
3: Normoxia  1.32 ± 0.20  0.73 ± 0.60 (post-zoniporide) 
     
     Hypoxic 1: Normoxia   1.44 ± 0.01   1.35 ± 0.12 (pre-zoniporide) 
hearts 2: Hypoxia * 2.59 ± 0.42  * 1.99 ± 0.36 (zoniporide) 
 
3: Reoxygenation   1.42 ± 0.08  1.55 ± 0.18 (post-zoniporide) 
     
     
  
SCR (kfc [min-1]) 
Normoxic 1: Normoxia 0.007 ± 0.001 0.009 ± 0.001 (pre-zoniporide) 
hearts 2: Normoxia 0.014 ± 0.003 0.018 ± 0.004 (zoniporide) 
 
3: Normoxia 0.012 ± 0.015 0.016 ± 0.007 (post-zoniporide) 
     
     Hypoxic 1: Normoxia 0.012 ± 0.003 0.014 ± 0.003 (pre-zoniporide) 
hearts 2: Hypoxia  0.008 ± 0.005  0.012 ± 0.005 (zoniporide) 
 
3: Reoxygenation * 0.049 ± 0.009 * 0.044 ± 0.008 (post-zoniporide) 
   












Table 5.4. Amplitudes of FCR and SCR from figure 5.42. Data are expressed as amplitudes 
corresponding to the 
64
Cu FCR or SCR of each 
64
Cu-ATSM injection (means ± standard 
deviation, n=5 per group). 
    Control Zoniporide 
  Injection FCR amplitude (arbitrary units) 
Normoxic 1: Normoxia   0.81 ± 0.07   0.78 ± 0.008 (pre-zoniporide) 
hearts 2: Normoxia   0.88 ± 0.06   0.58 ± 0.07 (zoniporide) 
 
3: Normoxia   0.89 ± 0.04   0.76 ± 0.31 (post-zoniporide) 
     
     Hypoxic 1: Normoxia   0.82 ± 0.07   0.79 ± 0.06 (pre-zoniporide) 
hearts 2: Hypoxia   0.36 ± 0.02   0.34 ± 0.01 (zoniporide) 
 
3: Reoxygenation   0.82 ± 0.08   0.75 ± 0.05 (post-zoniporide) 
     
     
  
SCR amplitude (arbitrary units) 
Normoxic 1: Normoxia * 0.13 ± 0.04 * 0.12 ± 0.03 (pre-zoniporide) 
hearts 2: Normoxia * 0.10 ± 0.03 * 0.19 ± 0.04 (zoniporide) 
 
3: Normoxia * 0.10 ± 0.03 * 0.06 ± 0.03 (post-zoniporide) 
     
     Hypoxic 1: Normoxia * 0.13 ± 0.04 * 0.13 ± 0.03 (pre-zoniporide) 
hearts 2: Hypoxia  0.49 ± 0.09  * 0.50 ± 0.07 (zoniporide) 
 
3: Reoxygenation * 0.09 ± 0.06 * 0.10 ± 0.06 (post-zoniporide) 
   












5.4 Discussion and conclusions 
5.4.1 Effect of hypoxia on myocardial pHi and 
64Cu retention from 64Cu-
ATSM 
In chapter 3, the hypoxia-dependent retention of 64Cu from 64Cu-ATSM in 
isolated perfused rat hearts was demonstrated. Using 31P NMR spectroscopy, it 
was estabilished that induction of this degree of hypoxia, in a system where 
there is normal coronary flow, causes no significant change in intracellular pH.  
A transient but insignificant decrease in pHi from 7.12 to pH 7.03 was observed, 
which recovered to 7.1 by the end of the experiment. This is consistent with a 
previous study which demonstrated that perfusion with normoxic buffer only 
decreased rat heart pHi to pH 7.01
197.  Inducing hypoxia with a less severe 
model by perfusion with buffers equilibrated with 20% O2 did not affect cardiac 
pHi at all. Cave et al. used 
31P NMR spectroscopy to demonstrate that 
ischaemia caused pHi to decrease from 7.05 to 6.2-6.3 which was sustained 
while coronary flow was limited200.  In contrast, the current study demonstrates 
that the myocardium is hypoxic, but as coronary flow is maintained, the heart is 
still efficient at extruding H+ via NHE exchange and extruding lactate via MCT to 
prevent acidosis. In both this chapter and chapter 3, an increase in 64Cu 
retention from 64Cu-ATSM was observed during early hypoxia and a further 
increase during late hypoxia. As shown here, under these conditions the hearts 
were not acidotic, and it can be confirmed that acidosis is not a key determinant 





5.4.2 Effect of acidosis on 64Cu retention from 64Cu-ATSM 
The reverse situation was also investigated in these studies; whether acidosis 
itself increased 64Cu-ATSM dissociation and 64Cu trapping under either 
normoxic or hypoxic conditions. To induce acidosis hearts were infused with 
NH4Cl, during which pHi remained stable, but fell to 6.3-6.4 (p<0.05) when 
NH4Cl was washed from the heart in the presence of NHE inhibitor, zoniporide. 
The extent of this acidosis was not exacerbated by additional hypoxia.  Similar, 
but less severe intracellular acidosis of pH 6.7 has previously  been 
demonstrated with a similar protocol in isolated perfused ferret hearts using the 
NHE inhibitor 5-(N-ethyl-N-isopropyl)amiloride (EIPA) 201. 
It has previously been suggested that protonation of the Cu-ATSM complex 
would decrease its stability and increase copper dissociation119. An acidic 
environment should therefore increase 64Cu-ATSM dissociation and the 
retention of 64Cu. The observations of a decrease in 64Cu retention from 64Cu-
ATSM in acidotic hearts during normoxia, and that acidosis appeared to abolish 
hypoxia dependent 64Cu retention, were therefore very surprising. To ensure the 
decrease in 64Cu retention from 64Cu-ATSM was not due to interaction with 
zoniporide, these experiments were repeated in the absence of NH4Cl. 
Zoniporide alone had no effect on 64Cu retention during normoxia or hypoxia, 
confirming there was no interaction between zoniporide and 64Cu-ATSM which 
may have affected myocardial uptake or dissociation. The decrease in 64Cu 
retention observed was therefore due to acidosis itself.  
Using spectrophotometry, Petering demonstrated that the stability of Cu-KTS 
decreased with decreasing pH126.  He later demonstrated that decreasing the 
pH also decreased the reaction rate between various Cu-BTSC complexes and 
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GSH134. This implied that the initial reduction of Cu-BTSC complexes by thiols is 
hindered by decreasing pH; and that intracellular acidosis may decrease Cu-
ATSM dissociation.  
 
5.4.3 Effect of hypoxia and acidosis on contractile function 
Contractile function of normoxic control hearts remained stable throughout the 
perfusion protocol. Switching to hypoxic 0% O2 KHB caused a decrease in heart 
rate and LVDP and an increase in perfusion pressure and LVEDP within 5 mins. 
This is consistent with previous reports174,175. During hypoxia, the heart 
generates ATP via anaerobic glycolysis which is not as efficient at generating 
ATP as aerobic metabolism; therefore less ATP is available to sustain cardiac 
contractility which results in a fall in heart rate and LVDP. Increased intracellular 
Ca2+ during hypoxia prevents complete ventricular relaxation and consequently 
increases LVEDP and perfusion pressure176. 
Acidosis also adversely affected contractile function; decreases in LVDP and 
increases in LVEDP and coronary perfusion pressure were observed in these 
hearts. Heart rate declined as a result of acidosis and was not measureable for 
part of the protocol due to ventricular fibrillation. A similar study investigating the 
effects of NH4Cl infusion and NHE-1 inhibitor cariporide reported similar 
changes to contractile function in isolated perfused rat hearts202. In particular, 
LVDP depression coincided with the onset of acidosis. While NHE inhibition is 
associated with a loss of Ca2+ uptake via NCX, acidosis-mediated loss of 
contractile function is not due to the decrease in Ca2+ concentration, but a 
decrease in contractile protein responsiveness to Ca2+ 40. High concentrations 
of H+ are known to compete with Ca2+ for the binding site of troponin C27,41.  
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It was also observed that contractile function failed to recover after zoniporide 
(and therefore acid) was washed from the heart in the 0% O2 group. It was 
therefore apparent that hearts treated with this extreme degree of hypoxia were 
not viable with the combined insult of acidosis and that this protocol was not 
suitable for the 64Cu-ATSM experiments, where the aim was to generate 
hypoxically compromised but viable myocardium. A revised less extreme 
hypoxic injury was therefore devised in which hearts were perfused with KHB 
gassed with 20% O2. This degree of hypoxia caused less of a deficit in 
contractile function which recovered upon reoxygenation and acid washout, 
which was a more suitable model upon which to examine the effect of acidosis 
on 64Cu-ATSM pharmacokinetics.  
 
5.4.4 Effect of hypoxia and acidosis on lactate release, glucose 
consumption and viability 
Consistent with the results in chapter 3, lactate was only released into the 
perfusate in hearts perfused with hypoxic (0% or 20% O2) buffer in the absence 
of acidosis. There was no lactate release from hypoxic hearts during acidosis, 
implying that these hearts were not hypoxic. As it was also observed that 
acidosis decreases myocardial contractility the energy demand of these hearts 
would have been lower; therefore decreasing oxygen consumption and 
becoming less hypoxic. 
 The amount of glucose extracted by the heart during hypoxia is negligible 
compared to the high concentration in KHB (11mM), therefore changes in first 




There was no myocardial protein released from normoxic, hypoxic (0% or 20%) 
or normoxic acidotic hearts, confirming that these protocols did not compromise 
myocardial viability, as opposed to hearts exposed to the acidosis protocol and 
0% O2 buffer perfusion, which did. This supports the contractile data which 
demonstrated that hypoxia with 0% O2 plus acidosis caused an irreversible loss 
of contractility.  
 
5.4.5 Effect of hypoxia on myocardial metabolism 
Decreases in both PCr and ATP concentrations and increases in Pi 
concentrations during hypoxia and acidosis protocols were observed. During 
hypoxia and ischaemia, ATP hydrolysis is not matched by ATP production, 
leading to increases in net ATP consumption and increases in intracellular Pi 
and H+ release27. PCr is consumed in the regeneration of ATP until it is also 
depleted. The regeneration of ATP by PCr also utilises H+ such that PCr and 
creatine kinase (CK) play a role in maintaining ATP concentration95. 
Hypoxia also induced an increase in sugar phosphate concentration in hypoxia 
protocols. As described in chapter 1, glycolysis converts glucose to ATP 
through a number of enzymatic processes, some of which produce sugar 
phosphate compounds such as glucose-6-phosphate. As glucose is delivered to 
the cell it is phosphorylated to glucose-6-phosphate, fructose-6-phosphate and 
fructose-1,6-diphosphate. As the oxygen reserve is used up, substrates such as 
NADH accumulate as they can no longer be utilised by the ETC and inhibit 
further glycolysis95. In addition, fructose-1,6-diphosphate accumulates and 
inhibits phosphofructokinase; the main rate limiting enzyme in glycolysis, 
resulting in an accumulation of glucose-6-phosphate and fructose-6-phosphate 
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as glucose is still delivered and entering the glycolytic pathway27. The frequency 
of the sugar phosphate peak is in close range of the Pi peak and was obscured 
by the larger increase of Pi observed during the hypoxia and acidosis protocols, 
hence the sugar phosphate peak was only measureable in hypoxic hearts in the 
absence of acidosis where the concentration of Pi was lower.  
While it may be possible that acidosis decreases tracer retention by inhibiting 
thiol induced Cu-BTSC reduction, it is more likely that tracer retention 
decreased in these acidotic hearts because they were no longer hypoxic. It was 
demonstrated that acidosis had a profound inhibitory effect on cardiac 
contractility. As myocardial contractility decreases, less energy is required and 
oxygen consumption decreases, such that the residual aerobic glycolysis that 
the heart is capable of can support myocardial metabolism. A lack of lactate 
released from the hearts during hypoxia as a result of acidosis was also 
observed, which supports this hypothesis. It is likely that acidosis has an O2 
sparing effect in both the normoxic and hypoxic heart which decreases 64Cu 
retention from 64Cu-ATSM. A decrease in background 64Cu retention in 
normoxic hearts during acidosis was also observed. KHB is well known to have 
a lower oxygen-carrying capacity than blood, even under normoxic conditions 
where the buffer is gassed with 95% O2/ 5% CO2, isolated hearts perfused with 
KHB are almost maximally vasodilated, and is possible that they may be slightly 
hypoxic, particularly in the endocardium, where energy (and oxygen) demands 
are highest140. This would explain the small background uptake of 64Cu-ATSM, 
which reduces with acidosis (and therefore decreased hypoxia severity). 
Although the data collected thus far can therefore not absolutely confirm the 
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effect of acidosis on 64Cu retention from 64Cu-ATSM, it does support the 











































6.1 Summary of main conclusions 
The proposed mechanism governing Cu-ATSM hypoxia selectivity involves the 
reduction of Cu(II)-ATSM to a less stable Cu(I)-ATSM- species, which 
dissociates in the absence of oxygen to release its copper core. It is therefore 
possible that Cu-ATSM hypoxia selectivity would be altered in environments 
which encourage reduction and/ or dissociation. The aim of this thesis was to 
identify the importance of two key parameters known to change during 
ischaemia on the hypoxia selectivity of Cu-ATSM; thiol concentration and 
acidosis.  
Petering originally suggested that Cu-BTSC complexes were reduced by 
intracellular thiols such as GSH, and that changes in GSH concentration would 
impact reduction, subsequent dissociation and the hypoxia selectivity of these 
complexes134. Ischaemia can cause decreases in myocardial GSH; since GSH 
concentration may affect the rate of Cu-ATSM reduction, this would complicate 
the interpretation of Cu-ATSM images of the ischaemic myocardium. Through 
depletion and augmentation of GSH in isolated perfused rat hearts, it was 
demonstrated that large changes in thiol concentration do not affect background 
64Cu retention from 64Cu-ATSM injections, nor do they impact upon the degree 
of hypoxia selective 64Cu retention in the heart, demonstrating that thiol 
concentration is not a rate limiting step for Cu-ATSM reduction. It cannot 
confirmed, however, that thiols such as GSH are not essential for Cu-ATSM 
reduction. Even in the thiol depleted hearts, where concentrations (3-4 nmol/mg 
protein) were far lower than that observed in ischaemic myocardial tissue (6-7 
nmol/mg protein)157,203, thiol concentrations were still in the mM range,  whilst 
64Cu-ATSM was present in fM concentrations. The amount of intracellular thiol 
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present will always be in vast excess of the radiotracer concentration, and it 
appears that changes in thiol concentration within the physiological or even 
pathophysiological range do not impact upon the activity of Cu-ATSM as a 
hypoxia selective PET tracer in the heart. 
Interestingly, supraphysiological thiol augmentation with NAC decreased 
hypoxia dependent retention of 64Cu from 64Cu-ATSM during late hypoxia in the 
current isolated perfused heart model. As a precursor for GSH synthesis, NAC 
is known to increase intracellular ROS scavenging capacity149. It is therefore 
possible that in these hearts, prolonged perfusion with NAC scavenged some 
portion of intracellularly generated ROS, resulting in a loss of maximal tracer 
trapping capacity. Hypoxia is often associated with ROS generation as a result 
of the accumulation and leakage of electrons from the mitochondrial electron 
transport chain. ROS have also been suggested to play a role in the reduction 
of Cu-ATSM132,133,204, although it has not yet been explored empirically. Further 
studies need to be carried out in order to clarify if Cu-ATSM and other Cu-BTSC 
complexes are sensitive to increased ROS generation before they can be used 
to image increased ROS generation and oxidative stress. 
It was also demonstrated the retention of 64Cu from 64Cu-ATSM in hypoxic 
BAEC. This is the first time that the hypoxia selectivity of Cu-ATSM has been 
investigated in vascular endothelial cells and supports its use as a hypoxia avid 
probe. Thiol depletion did not affect hypoxia dependent retention in BAEC which 
supports the data obtained from thiol depleted hearts; however, NAC 
supplementation further increased 64Cu retention in hypoxic cells. This conflicts 
with the isolated perfused heart model, where NAC supplementation decreased 
64Cu retention from 64Cu-ATSM during hypoxia. In other BAEC model, however, 
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64Cu-ATSM was incubated with the cells for 1 hr. This does not represent the 1st 
pass extraction of tracer which occurs in isolated perfused hearts. As BAEC had 
a longer radiotracer incubation time, reaction between excess intracellular thiol 
and 64Cu-ATSM was potentially more likely, which may explain the increased 
64Cu-ATSM reduction and 64Cu retention observed. The thiol concentration of 
hypoxic BAEC supplemented with NAC for three hours were also 3 fold higher 
than that of hypoxic, thiol augmented hearts. Hypoxic BAEC supplemented with 
NAC for 2 hours only contained a thiol concentration of 22-27 nmol/ mg protein, 
which although was more than BAEC subject to hypoxia alone, was less than 
half that of NAC supplemented hypoxic hearts. Both these groups of BAEC still 
retained significantly more 64Cu from 64Cu-ATSM than hypoxic BAEC alone, 
confirming that thiols promote Cu retention from Cu-ATSM and therefore their 
presence may be essential in Cu-ATSM reduction. 
It has previously been suggested that the dissociation of the Cu(I)-ATSM- 
species is dependent on protonation, and may therefore be accelerated by 
acidosis119,120. Again, since the ischaemic heart is known to be acidotic, it was 
possible that this would impact upon the hypoxia selectivity of Cu-ATSM5,118.  
Although the retention of 64Cu from 64Cu-ATSM in hypoxic isolated perfused 
hearts was demonstrated,  it was also shown by 31P NMR spectroscopy that 
these hearts were not acidotic. Since these hearts were perfused at a constant 
flow rate, any protons generated during hypoxia were washed out, and a 
physiological pH was maintained. This confirms that the hypoxia selectivity of 
64Cu-ATSM is not dependant on acidosis. It was, however, surprising to see that 
pharmacologically induced acidosis decreased 64Cu retention in both normoxic 
and hypoxic hearts. It is apparent that acidosis causes a decline in contractile 
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function, which had an oxygen sparing effect, which decreased the degree of 
hypoxia, such that 64Cu from 64Cu-ATSM was no longer retained. The lack of 
lactate released into the perfusate in these hearts when they were made 
hypoxic supports this suggestion. The protons in an acidotic myocyte compete 
with Ca2+ for the binding site of troponin c in contractile proteins, which results 
in decreased contractility, even in a normoxic heart41. In EMT6 tumour cells 
equilibrated with different pO2, it has been demonstrated that  
64Cu retention 
from 64Cu-ATSM falls rapidly between 0 and 0.1% O2, therefore Cu-ATSM may 
only be useful in detecting extremely low levels of hypoxia110. In isolated 
perfused hearts, perfusion with 20% O2 alone increased 
64Cu-retention from 
64Cu-ATSM, therefore these hearts were sufficiently hypoxic for radiotracer 
retention. When acidosis was induced and myocardial contractility and oxygen 
demand decreased, it is proposed that myocardial oxygen concentrations 












6.2 Recommendations for future work 
Following the results described in this thesis, further investigation is required to 
understand the mechanisms of Cu-ATSM hypoxia selectivity and its use as a 
cardiovascular hypoxia imaging agent. To achieve this it is recommend that the 
following are investigated: 
 The effect of decreased contractility on Cu retention from Cu-ATSM  
 The effect of zoniporide alone on pHi 
 The effect of acidosis on thiol mediated Cu-ATSM reduction  
 The role of ROS in Cu-ATSM hypoxia selectivity 
 The hypoxia selectivities of other Cu-BTSC complexes 
To fully understand the effect of acidosis on 64Cu-ATSM hypoxia selectivity the 
current results should be compared to those obtained from non-acidotic hearts 
with similar deficits in contractile function. An arrested heart model is therefore 
required. This can be achieved by perfusing the heart with a hyperkalaemic 
perfusion buffer, which reduces the transmembrane potential and maintains the 
heart in a non-contracting, depolarised state205. As such, cardiac contractility 
(and therefore oxygen consumption) could be normalised between all groups, to 
allow the investigation of the effect of tissue acidosis alone on Cu-ATSM 
pharmacokinetics and hypoxia selectivity.  A suggestion would be to confirm 
and evaluate acidosis in each experimental model using 31P NMR spectroscopy 
as has been done here. As zoniporide inhibits the NHE, it is possible that 
perfusion with zoniporide alone also decreases pHi. In this model it was unlikely 
as hearts were perfused with a bicarbonate buffer during NHE inhibition, which 
buffered pHi. Again, 
31P NMR spectroscopy should be used to confirm 
zoniporide does not affect pHi. 
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Alternatively it is possible that the decrease in 64Cu retention from 64Cu-ATSM 
observed during acidosis may result from decreased reduction rates of Cu-
ATSM by thiols. It has previously been reported that thiol mediated Cu-KTS 
reduction progressively slows with decreasing pH, although Cu-ATSM was not 
included in that study134. As thiols may be an essential reductant, acidosis may 
decrease Cu-ATSM reduction and subsequent dissociation of the complex and 
radiocopper release. Although thiol concentration did not affect 64Cu retention in 
isolated perfused hearts, increases in 64Cu retention as a result of thiol 
augmentation were not observed in isolated BAEC. A combination of thiol 
augmentation and acidosis in BAEC could therefore provide a model in which 
the effect of acidosis on thiol mediated 64Cu-ATSM reduction could be 
investigated. 
As the hypoxia selectivities of Cu-BTSC are governed by redox potential, it is 
possible that Cu-ATSM or its analogs could be utilised as markers of oxidative 
stress. Although some studies have used 62Cu-ATSM as a marker of oxidative 
stress133,204, to date no studies have been carried out to investigate the direct 
effect of ROS generation on Cu-ATSM reduction or Cu retention. It would 
therefore be interesting to determine the importance of ROS in Cu-ATSM 
reduction. 
Finally, the hypoxia selectivities of other Cu-BTSC complexes must be 
determined. Cu-ATSM only detects extremely low levels of hypoxia which may 
not be relevant in a pathophysiological setting for cardiology5. The main 
purpose of developing a radiotracer to image the hypoxic myocardium is to 
diagnose ischaemia earlier on to allow for the earliest possible intervention. As 
the myocardium becomes acidotic soon after the onset of ischaemia and 
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possibly decreases myocardial oxygen demand, other Cu-BTSC complexes 
which detect less severe levels of hypoxia may be better suited in imaging the 
ischaemic myocardium5. A range of other 64Cu-BTSC complexes with different 
redox potentials are currently being evaluated for their sensitivity at less 
extreme levels of cardiac hypoxia. This is being performed using a gas mixer to 
titrate buffer pO2 to more pathophysiologically relevant levels before the 
64Cu-
BTSC complexes are administered. It is hoped that this approach may identify 
other Cu-BTSC complexes in this family which may be better suited to 
delineating hypoxic myocardium in the setting of chronic ischaemic heart 
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